Nanoparticles comprising amphiphilic polymers and lipids for the targeted delivery of antigens

Abstract

The present application relates to nanoparticles comprising (a) an amphiphilic polymer; (b) a first lipid comprising a polar head group and a non-polar tail group; and (c) a peptide comprising a T cell epitope. Also disclosed are populations of said nanoparticles, processes for manufacturing said nanoparticles, precursors for manufacturing said nanoparticles, pharmaceutical compositions of said nanoparticles, and methods of treating a disease or disorder comprising administering said nanoparticles to a subject.

Description

[0001] This application claims the benefit of priority to U.S. Serial No. 63 / 620,436, filed January 12, 2024, and to U.S. Serial No. 63 / 620,442, filed January 12, 2024, each of which is incorporated herein by reference in its entirety.

[0002] This application contains a computer readable Sequence Listing which has been submitted in XML file format with this application, the entire content of which is incorporated by reference herein in its entirety. The Sequence Listing XML file submitted with this application is entitled “14779-005-228_SEQLISTING.xml”, was created on January 8, 2025, and is 66,359 bytes in size.. 1. FIELD

[0003] The present invention provides nanoparticles for use in the prevention and treatment of autoimmune diseases, allergies or other chronic inflammatory conditions, and for generation of regulatory T cells. In particular, the present invention relates to nanoparticles comprising a micelle comprising an amphiphilic polymer, a first lipid comprising a polar head group and a non-polar tail group; and a peptide comprising a T cell epitope. The present invention also relates to populations of the nanoparticles and processes for manufacturing the nanoparticles. 2. BACKGROUND

[0004] Autoimmune diseases represent a substantial burden for patients and healthcare systems. Current therapies rely mostly on immunosuppressive drugs with considerable side effects. Autoantigen-specific immunotherapies that exclusively target disease-specific immune pathologies leaving the general immune status untouched represent an unmet medical need.

[0005] Immune tolerance to self-antigens is maintained by multiple mechanisms that control potentially pathogenic autoreactive lymphocytes, including deletion, clonal anergy or suppression by regulatory T cells. Autoimmune disease may thus result from insufficient control of autoreactive lymphocytes, and a major goal of immunotherapy for autoimmune diseases is the induction of tolerance to autoantigens by restoring regulation. A particularly promising way to restore selftolerance seems to be the manipulation of autoantigen-specific CD4+CD25+FOXP3+ regulatory T cells. The adoptive transfer of these cells can prevent autoimmune or inflammatory conditions.

[0006] The liver plays a central role in the suppression of unwanted immune responses against blood-borne antigens, e.g. food antigens, entering the circulation. This fundamental mechanism of the liver can be employed to specifically downregulate detrimental immune responses against external protein antigens or autoantigens. Antigenic peptides derived from such proteins, when coupled to nano-sized carriers and administered intravenously, mimic food antigens triggering uptake by specific liver cells, the liver sinusoidal endothelial cells (LSECs), followed by a tolerogenic immune response. Peptide-specific immune tolerance can thus be induced for defined immune disease-causing antigens, leading to the amelioration or even eradication of detrimental immune reactions. This approach can thus be used to treat ongoing diseases and may also be used to prevent the respective diseases in a preventive setting.

[0007] For example, ectopic expression of a neuroantigen in the liver can prevent autoimmune neuroinflammation in mice with experimental autoimmune encephalomyelitis (EAE), an animal model for multiple sclerosis (MS). This finding can be explained by the capacity of the liver to generate neuroantigen-specific regulatory T cells (Tregs) that have a profound ability to control and suppress autoimmune responses. LSECs play a crucial role for achieving this effect. LSECs express MHC / HLA class I and class II molecules on their surface and thus have the capacity to present peptides to both, CD8+ (via cross-presentation) and CD4+ T cells, respectively. Peptide-antigen presentation by LSECs converts naive and T effector cells to Tregs in an antigen-specific way in vitro. This is apparently the physiological mechanism by which LSECs can establish tolerance against blood-borne antigens.

[0008] Nanoparticles conjugated with a disease-specific antigenic peptide to the particle surface, like blood-borne antigens, target the liver after intravenous injection. Upon uptake by LSECs, presumably by pinocytosis, the nanoparticles accumulate in the endosomal compartment where the peptide antigens are released from the surface of the particles. This leads to the presentation of those antigenic peptides at the LSEC surface, mediated by MHC / HLA molecules. There is evidence that the subsequent generation of Tregs confers immune tolerance specific for the respective autoantigen based on its antigenic peptide epitopes.

[0009] In certain medical applications it is important that the nanoparticles can be produced with a very high degree of chemical and physical purity.

[0010] There still is a need in the art for improved nanoparticles for treating and preventing a disease wherein suppression of a specific immune response is beneficial, e.g. in autoimmune diseases, in allergies, in transplantation, in the suppression of anti-drug-antibodies (ADA) against therapeutics or gene vectors, or in a disease wherein inflammation is excessive, chronic or adverse, and wherein said pharmaceutical composition is suitable for use in human subjects. 3. SUMMARY

[0011] Provided herein is a nanoparticle comprising: (a) an amphiphilic polymer; (b) a first lipid comprising a polar head group and a non-polar tail group; and (c) a peptide comprising a T cell epitope.

[0012] Also provided herein is a nanoparticle comprising: (a) an amphiphilic polymer; (b) a first lipid comprising a polar head group and a non-polar tail group; (c) a second lipid capable of enhancing the stability of the nanoparticle; and (d) a peptide comprising a T cell epitope.

[0013] Also provided herein is a nanoparticle comprising: (a) an amphiphilic polymer; (b) a first lipid comprising a polar head group and a non-polar tail group; (c) a third lipid capable of being conjugated to a peptide comprising a T cell epitope; and (d) a peptide comprising a T cell epitope.

[0014] Also provided herein is a nanoparticle comprising: (a) an amphiphilic polymer; (b) a first lipid comprising a polar head group and a non-polar tail group; (c) a second lipid capable of enhancing the stability of the nanoparticle; (d) a third lipid capable of being conjugated to a peptide comprising a T cell epitope; and (e) a peptide comprising a T cell epitope.

[0015] Also provided herein is a nanoparticle comprising: (a) an amphiphilic polymer; (b) a first lipid comprising a polar head group and a non-polar tail group; and (c) a lipid-peptide conjugate, wherein the peptide is covalently linked the lipid, and the peptide comprises a T cell epitope.

[0016] Also provided herein is a nanoparticle comprising: (a) an amphiphilic polymer; (b) a first lipid comprising a polar head group and a non-polar tail group; (c) a second lipid capable of enhancing the stability of the nanoparticle; and (d) a lipid-peptide conjugate, wherein the peptide is covalently linked the lipid, and the peptide comprises a T cell epitope.

[0017] Also provided herein is a nanoparticle comprising: (a) an amphiphilic polymer; (b) a first lipid comprising a polar head group and a non-polar tail group; and (c) a second lipid capable of enhancing the stability of the nanoparticle.

[0018] Also provided herein is a nanoparticle comprising: (a) an amphiphilic polymer; (b) a first lipid comprising a polar head group and a non-polar tail group; (c) a second lipid capable of enhancing the stability of the nanoparticle; and (d) a third lipid capable of being conjugated to a peptide comprising a T cell epitope.

[0019] In certain embodiments, the nanoparticle provided herein does not comprise a solid inorganic core.

[0020] In certain embodiments of the nanoparticle provided herein, the first lipid comprises a Cio to C26 tail group. In certain embodiments, the first lipid comprises a C10 to C26 alkyl or alkenyl tail group. In certain embodiments, the first lipid comprises a Ci6 to C20 alkyl or alkenyl tail group. In certain embodiments, the first lipid comprises a Cis alkyl or alkenyl tail group. In certain embodiments, the first lipid comprises an octadecanoyloxy tail group.

[0021] In certain embodiments of the nanoparticle provided herein, the first lipid is a phospholipid comprising a polar head group and a non-polar tail group. In certain embodiments, the first lipid comprises a polar head group lacking an -NH2, -NH3+, or -SH moiety capable of being conjugated to the peptide. In certain embodiments, the polar head group of the first lipid comprises a tetraalkylammonium moiety. In certain embodiments, the first lipid is a phospholipid of Formula (I): (I), wherein, R1 is a group that lacks an -NH2, -NH3+, or -SH moiety capable of being conjugated to the peptide; and R2 and R3 are each independently a C10 to C26 alkyl or alkenyl group. In certain embodiments, R1 comprises a tetraalkylammonium moiety. In certain embodiments, R1 is choline, ethanolamine, serine, inositol or glycerol, or a group derived therefrom lacking an -NH2, -NH3+, or -SH moiety.

[0022] In certain embodiments of the nanoparticle provided herein, the first lipid is a phosphatidylcholine, a phosphatidylinositol, a phosphatidylethanolamine, a phosphatidylserine, or a phosphatidylglycerol lacking an -NH2, -NH3+, or -SH moiety. In certain embodiments, the first lipid is selected from the group consisting of l,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dilinoleoyl-sn-glycero-3 -phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC), l,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), l,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC), 1 -palmitoyl-2-oleoyl-sn-glycero-3 -phosphocholine (POPC), 1,2-di-O-octadecenyl-sn-glycero-3 -phosphocholine (18:0 Diether PC), l-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC), l-hexadecyl-sn-glycero-3-phosphocholine (Cl6 Lyso PC), 1,2-dilinolenoyl-sn-glycero-3-phosphocholine, 1,2-diarachidonoyl-sn-glycero-3-phosphocholine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine, l-stearoyl-2-oleoyl-phosphatidylcholine (SOPC), 1,2-dielaidoyl-sn-glycero-3-phosphocholine (18:1 A9-Trans-PC), l,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), dimyristoyl phosphatidylserine (DMPS), diarachidoyl phosphatidylserine (DAPS), dipalmitoyl phosphatidylserine (DPPS), distearoylphosphatidylserine (DSPS), dioleoylphosphatidylserine (DOPS), dilauroyl-phosphatidylinositol (DLPI), diarachidoylphosphatidylinositol (DAPI), dimyristoylphosphatidylinositol (DMPI), dipalmitoylphosphatidylinositol (DPPI), distearoylphosphatidylinositol (DSPI), dioleoylphosphatidy linositol (DOPI), l,2-dimyristoyl-sn-glycero-3-phosphoglycerol (DMPG), 1,2-dipalmitoyl-sn-glycero-3 -phosphoglycerol (DPPG), 1,2-distearoyl-sn-glycero-3 -phosphoglycerol (DSPG), and 1,2-dioleoyl-sn-glycero-3-phosphoglycerol (DOPG), or mixtures thereof. In certain embodiments, the first lipid is l,2-distearoyl-s«-glycero-3-phosphocholine (DSPC).

[0023] In certain embodiments of the nanoparticle provided herein, the first lipid is a tetraalkylammonium compound. In certain embodiments, the tetraalkylammonium compound comprises one or two Cio to C26 alkyl or alkenyl tail groups. In certain embodiments, the tetraalkylammonium compound comprises one or two Ci6 to C20 alkyl or alkenyl tail groups. In certain embodiments, the first lipid is l,2-dioleoyl-3-trimethylammonium propane (DOTAP) or dimethyldioctadecylammonium (DDAB).

[0024] In certain embodiments of the nanoparticle provided herein, the first lipid is a fatty acid compound. In certain embodiments, the fatty acid comprises a Cio to C26 hydrocarbyl tail group. In certain embodiments, the fatty acid comprises a Ci6 to C20 hydrocarbyl tail group. In certain embodiments, the fatty acid is selected from the group consisting of decanoic acid (capric acid), undecanoic acid (undecylic acid), dodecanoic acid (lauric acid), tridecanoic acid (tridecylic acid), tetradecanoic acid (myristic acid), pentadecanoic acid, hexadecanoic acid (palmitic acid), heptadecanoic acid (margaric acid), octadecanoic acid (stearic acid), nonadecanoic acid (nonadecylic acid), eicosanoic acid (arachidic acid, icosanoic acid), heneicosanoic acid (heneicosylic acid), docosanoic acid (behenic acid), tricosanoic acid, tetracosanoic acid (lignoceric acid), pentacosanoic acid, pentacosanoic acid (cerotic acid), and (Z)-octadec-9-en-17-ynoic acid (oleic acid). In certain embodiments, the first lipid is hexadecanoic acid (palmitic acid), heptadecanoic acid (margaric acid), octadecanoic acid (stearic acid), nonadecanoic acid (nonadecylic acid), eicosanoic acid (arachidic acid, icosanoic acid), or (Z)-octadec-9-en-17-ynoic acid (oleic acid).

[0025] In certain embodiments of the nanoparticle provided herein, the first lipid is a structural lipid.

[0026] In certain embodiments of the nanoparticle provided herein, the second lipid is a fused polycyclic hydrocarbon, optionally substituted with one or more exocyclic oxygen, nitrogen, or sulfur-containing moieties. In certain embodiments, the second lipid is a sterol or a hopanoid.

[0027] In certain embodiments of the nanoparticle provided herein, the second lipid is a sterol of Formula (II): (II), or a stereoisomer or mixture of stereoisomers thereof; wherein R4, R5, R6, R7, and R8 are each independently H or a C1-3 alkyl group; R9 is a hydrocarbyl group optionally substituted with an -OH moiety; and the dashed bonds are each independently single or double bonds. In certain embodiments, the second lipid is a sterol of Formula (Ila): (Ha), or a stereoisomer or mixture of stereoisomers thereof; wherein R6 and R8 are each independently H or a Ci-3 alkyl group; R9 is a hydrocarbyl group optionally substituted with an -OH moiety; and the dashed bonds are each independently single or double bonds. In certain embodiments, the second lipid is a sterol of Formula (lib): (lib), or a stereoisomer or mixture or stereoisomers thereof; wherein R6 and R8 are each independently H or a Ci-3 alkyl group; and R9 is a hydrocarbyl group optionally substituted with an -OH moiety. In certain embodiments, the second lipid is a sterol of Formula (lie): (lie), wherein R6 and R8 are each independently H or a C1-3 alkyl group; and R9 is a hydrocarbyl group optionally substituted with an -OH moiety. In certain embodiments, R6 and R8 are each independently H or a methyl group. In certain embodiments, R9 is a C3-C15 alkyl or alkenyl group optionally substituted with an -OH moiety. In certain embodiments, R9 is a C7-C11 alkyl or alkenyl group. In certain embodiments, the second lipid is cholesterol, cycloartenol, sitosterol, stigmasterol, ergosterol, lanosterol, campesterol, fecosterol, brassicasterol, tomatidine, tomatine, ursolic acid and alpha-tocopherol. In certain embodiments, the second lipid is cholesterol.

[0028] In certain embodiments of the nanoparticle provided herein, the second lipid is a hopanoid of Formula (III): (III), or a stereoisomer or mixture of stereoisomers thereof; wherein R11, R12, R13, R14, R15, R16, and R17 are each independently H or a C1-3 alkyl group; R10 is a hydrocarbyl group optionally substituted with one or more oxygen, nitrogen, or sulfur-containing moieties. In certain embodiments, the second lipid is a hopanoid of Formula (Illa): (Hla), wherein R11, R12, R13, R14, R15, R16, and R17 are each independently H or a C1-3 alkyl group; R10 is a hydrocarbyl group optionally substituted with one or more oxygen, nitrogen, or sulfur-containing moieties.

[0029] In certain embodiments of the nanoparticle provided herein, the second lipid is a cohesive lipid.

[0030] In certain embodiments of the nanoparticle provided herein, the third lipid comprises an oxygen, nitrogen, or sulfur-containing moiety capable of being conjugated to the peptide. In certain embodiments, the third lipid comprises an -COOH, -OH, -NH2, -NH3, or -SH moiety. In certain embodiments, the third lipid comprises a polar head group and a non-polar tail group.

[0031] In certain embodiments of the nanoparticle provided herein, the third lipid is a phospholipid. In certain embodiments, the third lipid is a phospholipid of Formula (IV): O         O P Ri 9 O O A. O ry° 0 (IV), wherein R18 is a group comprising an oxygen, nitrogen, or sulfur-containing moiety capable of being conjugated to the peptide; and R19 and R20 are each independently a hydrocarbyl group. In certain embodiments, R18 is a group comprising an -COOH, -OH, -NH2, -NH3, or -SH moiety capable of being conjugated to the peptide. In certain embodiments, R19 and R20 are each independently a C10 to C26 alkyl or alkenyl group. In certain embodiments, R19 and R20 are each independently a Ci6 to C20 alkyl or alkenyl group. In certain embodiments, the third lipid is a phosphatidylinositol, a phosphatidylethanolamine, a phosphatidylserine, or a phosphatidylglycerol. In certain embodiments, the third lipid is l,2-distearoyl-s«-glycero-3-phosphoinositol (DSPI), 1,2-Distearoyl-5 / 7-glycero-3-phosphoethanolamine (DSPE), l,2-distearoyl-s77-glycero-3-phospho-L-serine, or 1,2-distearoyl-sn-glycero-3-phosphoglycerol (DSPG).

[0032] In certain embodiments of the nanoparticle provided herein, the third lipid is a fused polycyclic hydrocarbon substituted with an exocyclic oxygen, nitrogen, or sulfur-containing moiety capable of being conjugated to the peptide.

[0033] In certain embodiments of the nanoparticle provided herein, the third lipid is a sterol. In certain embodiments, the third lipid is a sterol of Formula (V): R' (V), or a stereoisomer or mixture of stereoisomers thereof; wherein R21, R22, R23, R24, and R25 are each independently H or a C1-3 alkyl group; R26 is a hydrocarbyl group optionally substituted with an -OH moiety; and the dashed bonds are each independently single or double bonds. In certain embodiments, the third lipid is a sterol of Formula (Va): R2XcjX / r a  b j (Va), or a stereoisomer or mixture of stereoisomers thereof; wherein R23 and R24 are each independently H or a C1-3 alkyl group; R26 is a hydrocarbyl group optionally substituted with an -OH moiety; and the dashed bonds are each independently single or double bonds. In certain embodiments, the third lipid is a sterol of Formula (Vb): (Vb), or a stereoisomer or mixture of stereoisomers thereof; wherein R23 and R24 are each independently H or a Ci-3 alkyl group; and R26 is a hydrocarbyl group optionally substituted with an -OH moiety.

[0034] In certain embodiments, the third lipid is a sterol of Formula (Vc): R^ / r26 XaXb a (Vc), wherein R23 and R24 are each independently H or a C1-3 alkyl group; and R26 is a hydrocarbyl group optionally substituted with an -OH moiety. In certain embodiments, R23 and R24 are each independently H or a methyl group. In certain embodiments, R26 is a C3-C15 alkyl or alkenyl group optionally substituted with an -OH moiety. In certain embodiments, R26 is a C7-C11 alkyl or alkenyl group. In certain embodiments, the third lipid is selected from the group consisting of cholesterol, cycloartenol, sitosterol, stigmasterol, ergosterol, lanosterol, campesterol, fecosterol, brassicasterol, tomatidine, tomatine, ursolic acid and alpha-tocopherol. In certain embodiments, the third lipid is cholesterol.

[0035] In certain embodiments of the nanoparticle provided herein, wherein the third lipid is a hopanoid. In certain embodiments, the third lipid is a hopanoid of Formula (VI): (VI), or a stereoisomer or mixture of stereoisomers thereof; wherein R27 is a group comprising an oxygen, nitrogen, or sulfur-containing moiety capable of being conjugated to the peptide; and R28, R29, R30, R31, R32, R33, and R34 are each independently H or a C1-3 alkyl group. In certain embodiments, the third lipid is a hopanoid of Formula (Via): (Via), wherein R27 is a group comprising an oxygen, nitrogen, or sulfur-containing moiety capable of being conjugated to the peptide; and R28, R29, R30, R31, R32, R33, and R34 are each independently H or a C1-3 alkyl group.

[0036] In certain embodiments of the nanoparticle provided herein, the third lipid is a fatty acid compound. In certain embodiments, the fatty acid comprises a C10 to C26 hydrocarbyl tail group. In certain embodiments, the fatty acid comprises a Ci6 to C20 hydrocarbyl tail group. In certain embodiments, the fatty acid is selected from the group consisting of decanoic acid (capric acid), undecanoic acid (undecylic acid), dodecanoic acid (lauric acid), tridecanoic acid (tridecylic acid), tetradecanoic acid (myristic acid), pentadecanoic acid, hexadecanoic acid (palmitic acid), heptadecanoic acid (margaric acid), octadecanoic acid (stearic acid), nonadecanoic acid (nonadecylic acid), eicosanoic acid (arachidic acid, icosanoic acid), heneicosanoic acid (heneicosylic acid), docosanoic acid (behenic acid), tricosanoic acid, tetracosanoic acid (lignoceric acid), pentacosanoic acid, pentacosanoic acid (cerotic acid), and (Z)-octadec-9-en-17-ynoic acid (oleic acid). In certain embodiments, the fatty acid is hexadecanoic acid (palmitic acid), heptadecanoic acid (margaric acid), octadecanoic acid (stearic acid), nonadecanoic acid (nonadecylic acid), eicosanoic acid (arachidic acid, icosanoic acid), or (Z)-octadec-9-en-17-ynoic acid (oleic acid).

[0037] In certain embodiments of the nanoparticle provided herein, the third lipid is an anchor lipid.

[0038] In certain embodiments of the nanoparticle provided herein, the lipid of the lipid-peptide conjugate comprises a polar head group and a non-polar tail group. In certain embodiments, the polar head group comprises an oxygen, nitrogen, or sulfur-containing moiety covalently linked to the peptide. In certain embodiments of the nanoparticle provided herein, the lipid of the lipidpeptide conjugate is a phospholipid, a fatty acid, a sterol, or a hopanoid.

[0039] In certain embodiments of the nanoparticle provided herein, the lipid-peptide conjugate is a phospholipid-peptide conjugate of Formula (VII): O          O O (VII), wherein L is a linker comprising an oxygen, nitrogen, or sulfur-containing moiety; R35 is the peptide; and R36 and R37 are each independently a hydrocarbyl group. In certain embodiments, R36 and R37 are each independently a Cio to C26 alkyl or alkenyl group. In certain embodiments, R36 and R37 are each independently a Cie to C20 alkyl or alkenyl group. In certain embodiments, L is ethanolamine, serine, inositol, or glycerol, or a group derived from ethanolamine, serine, inositol, or glycerol. In certain embodiments, the lipid-peptide conjugate comprises the peptide covalently linked to a phospholipid selected from the group consisting of phosphatidylethanolamine, phosphatidylglycerol, phosphatidylserine, phosphatidylate, or phosphatidylinositol.

[0040] In certain embodiments of the nanoparticle provided herein, the lipid-peptide conjugate is a fatty acid-peptide conjugate of formula R39-C(O)-R38, wherein R38 is the peptide and R39 is a hydrocarbyl group. In certain embodiments, R39 is a Cio to C26 alkyl or alkenyl group. In certain embodiments, R39 is a Cie to C20 alkyl or alkenyl group.

[0041] In certain embodiments of the nanoparticle provided herein, the lipid-peptide conjugate is a sterol-peptide conjugate of Formula (VIII): (VIII), or a stereoisomer or mixture of stereoisomers thereof; wherein R40 is the peptide; R41, R42, R43, R44, and R45 are each independently H or a C1-3 alkyl group; R46 is a hydrocarbyl group optionally substituted with an -OH moiety; and the dashed bonds are each independently single or double bonds. In certain embodiments, the lipid-peptide conjugate is a sterol-peptide conjugate of Formula (Villa): 46 (Villa), or a stereoisomer or mixture of stereoisomers thereof; wherein R40 is the peptide; R43 and R44 are each independently H or a C1-3 alkyl group; R46 is a hydrocarbyl group optionally substituted with an -OH moiety; and the dashed bonds are each independently single or double bonds. In certain embodiments, the lipid-peptide conjugate is a sterol-peptide conjugate of Formula (VHIb): 46 (VHIb), or a stereoisomer or mixture of stereoisomers thereof; wherein R40 is the peptide; R43 and R44 are each independently H or a C1-3 alkyl group; and R46 is a hydrocarbyl group optionally substituted with an -OH moiety. In certain embodiments, the lipid-peptide conjugate is a sterol-peptide conjugate of Formula (VIIIc): ^46 (vine), wherein R40 is the peptide; R43 and R44 are each independently H or a C1-3 alkyl group; and R46 is a hydrocarbyl group optionally substituted with an -OH moiety. In certain embodiments, R43 and R44 are each independently H or a methyl group. In certain embodiments, R46 is a C3-C15 alkyl or alkenyl group optionally substituted with an -OH moiety. In certain embodiments, R46 is a C7-C11 alkyl or alkenyl group. In certain embodiments, the lipid-peptide conjugate comprises the peptide covalently linked to a sterol selected from the group consisting of cholesterol, cycloartenol, sitosterol, stigmasterol, ergosterol, lanosterol, campesterol, fecosterol, brassicasterol, tomatidine, tomatine, ursolic acid and alpha-tocopherol. In certain embodiments, the lipid-peptide conjugate comprises the peptide covalently linked to cholesterol.

[0042] In certain embodiments of the nanoparticle provided herein, the lipid-peptide conjugate is a hopanoid-peptide conjugate of Formula (IX): (IX), or a stereoisomer or mixture of stereoisomers thereof; wherein R47 is the peptide; R48, R49, R50, R51, R52, R53, and R54 are each independently H or a C1-3 alkyl group; L is a linker comprising an oxygen, nitrogen, or sulfur-containing moiety covalently linked to the peptide. In certain embodiments, the lipid-peptide conjugate is a hopanoid-peptide conjugate of Formula (IXa): (IXa), or a stereoisomer or mixture of stereoisomers thereof; wherein R47 is the peptide; R48, R49, R50, R51, R52, R53, and R54 are each independently H or a C1-3 alkyl group; L is a linker comprising an oxygen, nitrogen, or sulfur-containing moiety covalently linked to the peptide.

[0043] In certain embodiments of the nanoparticle provided herein, the nanoparticle comprises only one type of lipid. In certain embodiments, the nanoparticle comprises only one type of the first lipid. In certain embodiments, the nanoparticle comprises only two types of lipids. In certain embodiments, the nanoparticle comprises only one type of the first lipid and only one type of the second lipid. In certain embodiments, the nanoparticle comprises only one type of the first lipid and only one type of the third lipid. In certain embodiments, the nanoparticle comprises only one type of the first lipid and only one type of the lipid-peptide conjugate. In certain embodiments, the nanoparticle comprises only three types of lipids. In certain embodiments, the nanoparticles comprises only one type of the first lipid, only one type of the second lipid, and only one type of the third lipid. In certain embodiments, the nanoparticle comprises only one type of the first lipid, only one type of the second lipid, and only one type of the lipid-peptide conjugate. In certain embodiments, the nanoparticle comprises a phosphatidylcholine and a sterol. In certain embodiments, the nanoparticle comprises DSPC and cholesterol.

[0044] In certain embodiments of the nanoparticle provided herein, the peptide is covalently linked to the amphiphilic polymer. In certain embodiments, the peptide is non-covalently associated with the amphiphilic polymer, and / or the first lipid, and / or the second lipid, and / or the third lipid. In certain embodiments, the peptide is covalently linked to the third lipid.

[0045] In certain embodiments of the nanoparticle provided herein, the peptide comprises an MHC Class I or MHC Class II epitope. In certain embodiments, the MHC Class I or MHC Class II epitope is a human MHC Class I or MHC Class II epitope. In certain embodiments, the peptide has an amino acid sequence comprising between 6 and 60 amino acids, optionally between 9 and 60 amino acids. In certain embodiments, the peptide has an amino acid sequence comprising between 10 and 20 amino acids. In certain embodiments, the nanoparticle comprises only one type of peptide (e.g. peptides having the same amino acid sequence). In certain embodiments, only one type of peptide (e.g. peptides having the same amino acid sequence) is associated with the nanoparticle. In certain embodiments, only one type of peptide (e.g. peptides having the same amino acid sequence) is covalently linked to the nanoparticle.

[0046] In certain embodiments of the nanoparticle provided herein, wherein the amphiphilic polymer is an alternating copolymer of maleic anhydride and at least one alkene. In certain embodiments, the number average molecular weight (Mn) of the amphiphilic polymer is between about 1,000 g / mol and 20,000 g / mol, between about 2,500 g / mol and 20,000 g / mol, between about 1,000 g / mol and 10,000 g / mol, between about 2,500 g / mol and 10,000 g / mol, between about 1,000 g / mol and 6,000 g / mol, between about 2,500 g / mol and 6,000 g / mol, between about 1,000 g / mol and 4,000 g / mol, or between about 2,500 g / mol and 4,000 g / mol. In certain embodiments, the number average molecular weight (Mn) of the amphiphilic polymer is between about 1,000 g / mol and 6,000 g / mol. In certain embodiments, the number average molecular weight (Mn) of the amphiphilic polymer is between about 2,500 g / mol and 4,000 g / mol. In certain embodiments, the amphiphilic polymer comprises the following building block: wherein R is a hydrocarbyl group or a substituted hydrocarbyl group. In certain embodiments, R is a C4 to C30 alkyl group. In certain embodiments, R is a C?to C19 alkyl group. In certain embodiments, R is a C15 alkyl group. In certain embodiments, the amphiphilic polymer is selected from the group consisting of poly(maleic acid-a / t-1-octadecene), poly(maleic acid-a / t-1 -tetradecene) and poly(maleic acid-a / t-1-dodecene). In certain embodiments, the amphiphilic polymer is poly(maleic acid-a / t-1-octadecene).

[0047] In certain embodiments, the nanoparticle provided herein comprises between about 10 and 40 mol of the building block per mol of the first lipid. In certain embodiments, the nanoparticle comprises between about 15 and 35 mol of the building block per mol of the first lipid. In certain embodiments, the nanoparticle comprises between about 20 and 25 mol of the building block per mol of the first lipid. In certain embodiments, the nanoparticle comprises about 20, about 21, about 22, about 23, about 24, or about 25 mol of the building block per mol of the first lipid.

[0048] In certain embodiments, the nanoparticle provided herein comprises the first lipid and the amphiphilic polymer in a ratio of between about 0.01:1 (w / w) and 1:1 (w / w), between about 0.05:1 (w / w) and 1:1 (w / w), between about 0.01:1 (w / w) and 0.5:1 (w / w), between about 0.05:1 (w / w) and 0.5:1 (w / w), between about 0.01:1 (w / w) and 0.4:1 (w / w), between about 0.05:1 (w / w) and 0.4:1 (w / w), between about 0.01:1 (w / w) and 0.3:1 (w / w), between about 0.05:1 (w / w) and 0.3:1 (w / w), between about 0.01:1 (w / w) and 0.2:1 (w / w), between about 0.05:1 (w / w) and 0.2:1 (w / w), between about 0.01:1 (w / w) and 0.15:1 (w / w), or between about 0.05:1 (w / w) and 0.15:1 (w / w) first lipid to amphiphilic polymer. In certain embodiments, the nanoparticle comprises the first lipid and the amphiphilic polymer in a ratio of between about 0.01:1 (w / w) and 0.2:1 (w / w), between about 0.05:1 (w / w) and 0.2:1 (w / w), between about 0.01:1 (w / w) and 0.15:1 (w / w), or between about 0.05:1 (w / w) and 0.15:1 (w / w) first lipid to amphiphilic polymer. In certain embodiments, the nanoparticle comprises the first lipid and the amphiphilic polymer in a ratio of between about 0.05:1 (w / w) and 0.15:1 (w / w) first lipid to amphiphilic polymer. In certain embodiments, the nanoparticle comprises the first lipid and the amphiphilic polymer in a ratio of about 0.01:1 (w / w), about 0.02:1 (w / w), about 0.03:1 (w / w), about 0.04:1 (w / w), about 0.05:1 (w / w), about 0.06:1 (w / w), about 0.07:1 (w / w), about 0.08:1 (w / w), about 0.09:1 (w / w), about 0.10:1 (w / w), about 0.11:1 (w / w), about 0.12:1 (w / w), about 0.13:1 (w / w), about 0.14:1 (w / w), about 0.15:1 (w / w), about 0.16:1 (w / w), about 0.17:1 (w / w), about 0.18:1 (w / w), about 0.19:1 (w / w), or about 0.20:1 (w / w) first lipid to amphiphilic polymer. In certain embodiments, the nanoparticle comprises the first lipid and the amphiphilic polymer in a ratio of about 0.09:1 (w / w) or about 0.10:1 (w / w) first lipid to amphiphilic polymer.

[0049] In certain embodiments, the nanoparticle provided herein comprises the first lipid and the amphiphilic polymer in a ratio of about 0.05:1 (mol / mol) and 1:1 (mol / mol), between about 0.1:1 (mol / mol) and 1:1 (mol / mol), between about 0.05:1 (mol / mol) and 0.9:1 (mol / mol), between about 0.1:1 (mol / mol) and 0.9:1 (mol / mol), between about 0.05:1 (mol / mol) and 0.8:1 (mol / mol), between about 0.1:1 (mol / mol) and 0.8:1 (mol / mol), between about 0.05:1 (mol / mol) and 0.7:1 (mol / mol), between about 0.1:1 (mol / mol) and 0.7:1 (mol / mol), between about 0.05:1 (mol / mol) and 0.6:1 (mol / mol), between about 0.1:1 (mol / mol) and 0.6:1 (mol / mol), between about 0.05:1 (mol / mol) and 0.5:1 (mol / mol), between about 0.1:1 (mol / mol) and 0.5:1 (mol / mol), between about 0.2:1 (mol / mol) and 0.5:1 (mol / mol), between about 0.3:1 (mol / mol) and 0.5:1 (mol / mol), or between about 0.3:1 (mol / mol) and 0.4:1 (mol / mol) first lipid to amphiphilic polymer. In certain embodiments, the nanoparticle comprises the first lipid and the amphiphilic polymer in a ratio of between about 0.3:1 (mol / mol) and 0.7:1 (mol / mol) first lipid to amphiphilic polymer. In certain embodiments, the nanoparticle comprises the first lipid and the amphiphilic polymer in a ratio of about 0.25:1 (mol / mol), 0.26:1 (mol / mol), 0.27:1 (mol / mol), 0.28:1 (mol / mol), 0.30:1 (mol / mol), 0.31:1 (mol / mol), 0.32:1 (mol / mol), 0.33:1 (mol / mol), 0.34:1 (mol / mol), 0.35:1 (mol / mol), 0.36:1 (mol / mol), 0.37:1 (mol / mol), 0.38:1 (mol / mol), 0.39:1 (mol / mol), 0.40:1 (mol / mol), 0.41:1 (mol / mol), 0.42:1 (mol / mol), 0.43:1 (mol / mol), 0.44:1 (mol / mol), or 0.45:1 (mol / mol) first lipid to amphiphilic polymer. In certain embodiments, the nanoparticle comprises the first lipid and the amphiphilic polymer in a ratio of about 0.35:1 (mol / mol) first lipid to amphiphilic polymer. In certain embodiments, the nanoparticle comprises the first lipid and the amphiphilic polymer in a ratio of about 0.4:1 (mol / mol) first lipid to amphiphilic polymer. In certain embodiments, the nanoparticle comprises the first lipid and the amphiphilic polymer in a ratio of about 0.6:1 (mol / mol) first lipid to amphiphilic polymer.

[0050] In certain embodiments, the nanoparticle provided herein comprises the amphiphilic polymer in an amount of about 50-85%, about 55-65%, about 65-75%, about 75-85%, or about 8595% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle comprises: (i) the amphiphilic polymer in an amount of about 50-95% by weight of the total weight of the nanoparticle; and (ii) the first lipid in an amount of about 4-10% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; and (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle comprises: (i) the amphiphilic polymer in an amount of about 65-75% by weight of the total weight of the nanoparticle; and (ii) the first lipid in an amount of about 5-7% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle comprises: (i) the amphiphilic polymer in an amount of about 75-85% by weight of the total weight of the nanoparticle; (ii) and the first lipid in an amount of about 6-8% by weight of the total weight of the nanoparticle.

[0051] In certain embodiments, the nanoparticle provided herein comprises the second lipid in an amount of about 20-50% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle comprises the second lipid in an amount of about 20-35% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle comprises the second lipid in an amount of about 22-32% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle comprises the second lipid in an amount of about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, or about 32% by weight of the total weight of the nanoparticle.

[0052] In certain embodiments, the nanoparticle provided herein comprises a combined amount of the first lipid and the amphiphilic polymer of between about 2:1 to about 3:1 by weight (w / w) to relative to the amount of the second lipid. In certain embodiments, the nanoparticle comprises a combined amount of the first lipid and the amphiphilic polymer of about 7:3 by weight (w / w) to relative to the amount of the second lipid.

[0053] In certain embodiments, the nanoparticle provided herein comprises the third lipid in an amount of about 1 -3 mol% of all components of the nanoparticle. In certain embodiments, the nanoparticle comprises the third lipid in amount of about 2 mol% of all components of the nanoparticle.

[0054] In certain embodiments, the nanoparticle provided herein comprises the second lipid and the third lipid in amounts that combined are about 20-50% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle comprises the second lipid and the third lipid in amounts that combined are about 20-35% by weight of the total weight of the nanoparticle.

[0055] In certain embodiments, the nanoparticle provided herein comprises the lipid-peptide conjugate in an amount of about 5-20%, 8-16%, or 10-15% by weight of the total weight of the nanoparticle.

[0056] In certain embodiments, the nanoparticle provided herein comprises the lipid-peptide conjugate in an amount of about 1-3 mol% of all components of the nanoparticle. In certain embodiments, the nanoparticle comprises the lipid-peptide conjugate in an amount of about 2 mol% of all components of the nanoparticle.

[0057] In certain embodiments, the nanoparticle provided herein comprises the peptide in an amount of about 5-15% or 8-12% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle comprises the peptide in an amount of about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle comprises the peptide in an amount of about 10% by weight of the total weight of the nanoparticle.

[0058] In certain embodiments, the nanoparticle provided herein comprises the peptide in an amount of about 1 -3 mol% of all components of the nanoparticle. In certain embodiments, the nanoparticle comprises the peptide in an amount of about 2 mol% of all components of the nanoparticle.

[0059] In certain embodiments, the nanoparticle provided herein comprises the peptide and the amphiphilic polymer in a ratio of between about 0.03:1 (w / w) and 0.25:1 (w / w) of peptide to amphiphilic polymer.

[0060] In certain embodiments, the nanoparticle provided herein comprises the peptide and the amphiphilic polymer in a ratio of between about 0.03:1 (mol / mol) and 0.25:1 (mol / mol) of peptide to amphiphilic polymer.

[0061] In certain embodiments, the nanoparticle provided herein has a hydrodynamic diameter in the range of 10 to 100 nm as determined by DLS. In certain embodiments, the nanoparticle has a hydrodynamic diameter in the range of 10 to 60 nm as determined by DLS. In certain embodiments, the nanoparticle has a hydrodynamic diameter in the range of 10 to 50 nm as determined by DLS. In certain embodiments, the nanoparticle has a hydrodynamic diameter in the range of 10 to 40 nm as determined by DLS. In certain embodiments, the nanoparticle has a hydrodynamic diameter in the range of 10 to 30 nm as determined by DLS.

[0062] In certain embodiments, the nanoparticle provided herein is stable for at least 1 hour, at least 2 hours, at least 3 hours, at least 4 hours, at least 5 hours, at least 6 hours, at least 12 hours, at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, or at least 12 days at 25 °C in 25 mM sodium acetate buffer at pH about 5 as determined by Dynamic Light Scattering (DLS).

[0063] In certain embodiments, the nanoparticle provided herein is stable for at least 1 hour, at least 2 hours, at least 3 hours, at least 4 hours, at least 5 hours, at least 6 hours, at least 12 hours, at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, or at least 12 days at 25 °C in 25 mM MES buffer at pH about 6 as determined by Dynamic Light Scattering (DLS).

[0064] In certain embodiments, the nanoparticle provided herein is stable for at least 1 hour, at least 2 hours, at least 3 hours, at least 4 hours, at least 5 hours, at least 6 hours, at least 12 hours, at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, or at least 12 days at 25 °C in 0. lx PBS buffer at pH about 7 as determined by Dynamic Light Scattering (DLS).

[0065] In certain embodiments, the nanoparticle provided herein is stable for at least 1 hour, at least 2 hours, at least 3 hours, at least 4 hours, at least 5 hours, at least 6 hours, at least 12 hours, at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, or at least 12 days at 25 °C in 25 mM HEPES buffer at pH about 8 as determined by Dynamic Light Scattering (DLS).

[0066] In certain embodiments, the nanoparticle provided herein is stable for at least 1 hour, at least 2 hours, at least 3 hours, at least 4 hours, at least 5 hours, at least 6 hours, at least 12 hours, at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, or at least 12 days at 25 °C in 25 mM SBB buffer at pH about 9 as determined by Dynamic Light Scattering (DLS).

[0067] In certain embodiments, the nanoparticle provided herein is stable to Stress Test Assay as determined by DLS.

[0068] In certain embodiments, the nanoparticle provided herein is suitable for administration to a subject, and capable of tolerizing the subject to the peptide(s) associated with or conjugated to the nanoparticle. In certain embodiments, the nanoparticle is suitable for administration to a subject, and capable of suppressing a specific immune response in the subject. In certain embodiments, the nanoparticle is suitable for administration to a subject, and capable of treating or preventing a disease or disorder in the subject. In certain embodiments, the nanoparticle is suitable for transferring peptides to liver sinusoidal endothelial cells of a subject in vivo.

[0069] Also provided herein is a population of nanoparticles provided herein, wherein the population is characterized by a D90 of below 100 nm as determined by DLS.

[0070] Also provided herein is a population of nanoparticles provided herein, wherein at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of the nanoparticles in the population have a hydrodynamic diameter in the range of 10 to 100 nm as determined by DLS. In certain embodiments, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of the nanoparticles in the population have a hydrodynamic diameter in the range of 10 to 60 nm as determined by DLS. In certain embodiments, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of the nanoparticles in the population have a hydrodynamic diameter in the range of 10 to 50 nm as determined by DLS. In certain embodiments, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of the nanoparticles in the population have a hydrodynamic diameter in the range of 10 to 40 nm as determined by DLS. In certain embodiments, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of the nanoparticles in the population have a hydrodynamic diameter in the range of 10 to 30 nm as determined by DLS.

[0071] Also provided herein is a population of nanoparticles provided herein, wherein the population of nanoparticles has an intensity weighted mean hydrodynamic size of the ensemble collection of particles (“Z average”) of about 10 to 100 nm as determined by DLS. In certain embodiments, the population of nanoparticles has a Z average of about 10 to 60 nm as determined by DLS. In certain embodiments, the population of nanoparticles has a Z average of about 10 to 50 nm as determined by DLS. In certain embodiments, the population of nanoparticles has a Z average of about 10 to 40 nm as determined by DLS. In certain embodiments, the population of nanoparticles has a Z average of about 10 to 30 nm as determined by DLS.

[0072] Also provided herein is a population of nanoparticles provided herein, wherein the population of nanoparticles has a polydispersity index of less than 0.40, less than 0.35, or less than 0.30, as determined by DLS. In certain embodiments, the population of nanoparticles has a polydispersity index of less than 0.30, as determined by DLS.

[0073] Also provided herein is a population of nanoparticles provided herein, wherein the average hydrodynamic diameter of the nanoparticles changes by no more than about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, or about 20% as determined by Dynamic Light Scattering (DLS) after storing the population for at least 1 hour, at least 2 hours, at least 3 hours, at least 4 hours, at least 5 hours, at least 6 hours, at least 12 hours, at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, or at least 12 days at 25 °C in 25 mM sodium acetate buffer at pH about 5.

[0074] Also provided herein is a population of nanoparticles provided herein, wherein the average hydrodynamic diameter of the nanoparticles changes by no more than about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, or about 20% as determined by Dynamic Light Scattering (DLS) after storing the population for at least 1 hour, at least 2 hours, at least 3 hours, at least 4 hours, at least 5 hours, at least 6 hours, at least 12 hours, at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, or at least 12 days at 25 °C in 25 mM MES buffer at pH about 6.

[0075] Also provided herein is a population of nanoparticles provided herein, wherein the average hydrodynamic diameter of the nanoparticles changes by no more than about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, or about 20% as determined by Dynamic Light Scattering (DLS) after storing the population for at least 1 hour, at least 2 hours, at least 3 hours, at least 4 hours, at least 5 hours, at least 6 hours, at least 12 hours, at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, or at least 12 days at 25 °C in 0. lx PBS buffer at pH about 7.

[0076] Also provided herein is a population of nanoparticles provided herein, wherein the average hydrodynamic diameter of the nanoparticles changes by no more than about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, or about 20% as determined by Dynamic Light Scattering (DLS) after storing the population for at least 1 hour, at least 2 hours, at least 3 hours, at least 4 hours, at least 5 hours, at least 6 hours, at least 12 hours, at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, or at least 12 days at 25 °C in 25 mM HEPES buffer at pH about 8.

[0077] Also provided herein is a population of nanoparticles provided herein, wherein the average hydrodynamic diameter of the nanoparticles changes by no more than about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, or about 20% as determined by Dynamic Light Scattering (DLS) after storing the population for at least 1 hour, at least 2 hours, at least 3 hours, at least 4 hours, at least 5 hours, at least 6 hours, at least 12 hours, at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, or at least 12 days at 25 °C in 25 mM SBB buffer at pH about 9.

[0078] Also provided herein is a population of nanoparticles provided herein, wherein the average hydrodynamic diameter of the nanoparticles changes by no more than about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, or about 20% as determined by Dynamic Light Scattering (DLS) after subjecting the population to the Stress Test Assay.

[0079] Also provided herein is a population of nanoparticles provided herein, wherein the poly dispersity index of the population changes by no more than about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, or about 40% as determined by Dynamic Light Scattering (DLS) after storing the population for at least 1 hour, at least 2 hours, at least 3 hours, at least 4 hours, at least 5 hours, at least 6 hours, at least 12 hours, at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, or at least 12 days at 25 °C in 25 mM sodium acetate buffer at pH about 5.

[0080] Also provided herein is a population of nanoparticles provided herein, wherein the poly dispersity index of the population changes by no more than 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, or about 40% as determined by Dynamic Light Scattering (DLS) after storing the population for at least 1 hour, at least 2 hours, at least 3 hours, at least 4 hours, at least 5 hours, at least 6 hours, at least 12 hours, at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, or at least 12 days at 25 °C in 25 mM MES buffer at pH about 6.

[0081] Also provided herein is a population of nanoparticles provided herein, wherein the poly dispersity index of the population changes by no more than 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, or about 40% as determined by Dynamic Light Scattering (DLS) after storing the population for at least 1 hour, at least 2 hours, at least 3 hours, at least 4 hours, at least 5 hours, at least 6 hours, at least 12 hours, at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, or at least 12 days at 25 °C in 0. lx PBS buffer at pH about 7.

[0082] Also provided herein is a population of nanoparticles provided herein, wherein the poly dispersity index of the population changes by no more than 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, or about 40% as determined by Dynamic Light Scattering (DLS) after storing the population for at least 1 hour, at least 2 hours, at least 3 hours, at least 4 hours, at least 5 hours, at least 6 hours, at least 12 hours, at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, or at least 12 days at 25 °C in 25 mM HEPES buffer at pH about 8.

[0083] Also provided herein is a population of nanoparticles provided herein, wherein the poly dispersity index of the population changes by no more than 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, or about 40% as determined by Dynamic Light Scattering (DLS) after storing the population for at least 1 hour, at least 2 hours, at least 3 hours, at least 4 hours, at least 5 hours, at least 6 hours, at least 12 hours, at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, or at least 12 days at 25 °C in 25 mM SBB buffer at pH about 9.

[0084] Also provided herein is a population of nanoparticles provided herein, wherein the poly dispersity index of the population changes by no more than 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, or about 40% as determined by Dynamic Light Scattering (DLS) after subjecting the population to the Stress Test Assay.

[0085] In certain embodiments of a population of nanoparticles provided herein, the population is suitable for administration to a subject, and capable of tolerizing the subject to the peptide(s) associated with or conjugated to the nanoparticles of the population. In certain embodiments, the population is suitable for administration to a subject, and capable of suppressing a specific immune response in the subject. In certain embodiments, the population is suitable for administration to a subject, and capable of treating or preventing a disease or disorder in the subject. In certain embodiments, the population is suitable for transferring peptides to liver sinusoidal endothelial cells of a subject in vivo.

[0086] Also provided herein is a process for manufacturing nanoparticles or a population of nanoparticles, said process comprising: (a) combining the amphiphilic polymer and the first lipid in an organic solvent; and (b) mixing the combination from step a with an aqueous solution, thereby forming precursor particles; and (c) reacting the precursor particles with the peptides, thereby forming the nanoparticles. In certain embodiments, step a comprises combining the amphiphilic polymer, the first lipid, and the second lipid in an organic solvent. In certain embodiments, step a comprises combining the amphiphilic polymer, the first lipid, and the third lipid in an organic solvent. In certain embodiments, step a comprises combining the amphiphilic polymer, the first lipid, the second lipid, and the third lipid in an organic solvent.

[0087] Also provided herein is a process for manufacturing nanoparticles or a population of nanoparticles, said process comprising: (a) combining the amphiphilic polymer, the first lipid, and the lipid-peptide conjugate in an organic solvent; and (b) mixing the combination from step a with an aqueous solution, thereby forming the nanoparticles. In certain embodiments, step a comprises combining the amphiphilic polymer, the first lipid, the lipid-peptide conjugate, and the second lipid in an organic solvent.

[0088] Also provided herein is a process for manufacturing nanoparticles or a population of nanoparticles, said process comprising: (a) combining the amphiphilic polymer, the first lipid, and the second lipid in an organic solvent; and (b) mixing the combination from step a with an aqueous solution, thereby forming the nanoparticles. In certain embodiments, step a comprises combining the amphiphilic polymer, the first lipid, the second lipid, and the third lipid in an organic solvent.

[0089] In certain embodiments of the process provided herein, the organic solvent is a protic organic solvent or ethereal solvent. In certain embodiments, the organic solvent is ethanol, tetrahydrofuran, or a mixture thereof.

[0090] In certain embodiments of the process provided herein, the combination in step a comprises the first lipid and the amphiphilic polymer in a ratio of between about 0.05:1 (w / w) and 0.15:1 (w / w) first lipid to amphiphilic polymer. In certain embodiments, the combination in step a comprises the first lipid and the amphiphilic polymer in a ratio of about 0.09:1 (w / w) or about 0.10:1 (w / w) first lipid to amphiphilic polymer.

[0091] In certain embodiments of the process provided herein, the combination in step a comprises the first lipid and the amphiphilic polymer in a ratio of between about 0.3:1 (mol / mol) and 0.7:1 (mol / mol) first lipid to amphiphilic polymer. In certain embodiments, the combination in step a comprises the first lipid and the amphiphilic polymer in a ratio of about 0.35:1, about 0.4:1, or about 0.6:1 (mol / mol) first lipid to amphiphilic polymer.

[0092] In certain embodiments of the process provided herein, the combination in step a comprises the second lipid in an amount of about 20-50% by weight of all components in step a. In certain embodiments, the combination in step a comprises the second lipid in an amount of about 20-35% by weight of all components in step a. In certain embodiments, the combination in step a comprises the second lipid in an amount of about 25-35% by weight of all components in step a. In certain embodiments, the combination in step a comprises the second lipid in an amount of about 30% by weight of all components in step a.

[0093] In certain embodiments of the process provided herein, the aqueous solution is a buffered aqueous solution capable of maintaining the pH in step b between about pH 6 and pH 7.6. In certain embodiments, the aqueous solution is a buffered aqueous solution capable of maintaining the pH in step b at about pH 7.

[0094] In certain embodiments of the process provided herein, the aqueous solution is a phosphate-buffered saline (PBS) solution.

[0095] In certain embodiments of the process provided herein, the combination from step a and the aqueous solution are mixed at a ratio of about 1:1 to about 1:20 (vol:vol) in step b. In certain embodiments, the combination from step a and the aqueous solution are mixed at a ratio of about 1:4 to about 1:10 (vol:vol) in step b. In certain embodiments, the combination from step a and the aqueous solution are mixed at a ratio of about 1:10 (vol: vol) in step b.

[0096] In certain embodiments of the process provided herein, the combination from step a is not preheated prior to mixing in step b (i.e. the combination from step a is used at room temperature). In certain embodiments, the combination from step a is preheated at a temperature of at least 30 °C or at least 40 °C prior to mixing in step b. In certain embodiments, the combination from step a is preheated at a temperature of about 40-80 °C prior to mixing in step b. In certain embodiments, the combination from step a and the aqueous solution are mixed at room temperature in step b. In certain embodiments, the combination from step a and the aqueous solution are preheated at a temperature of about 40-80 °C prior to mixing in step b. In certain embodiments, the combination from step a and the aqueous solution are mixed at a temperature of about 40-80 °C in step b.

[0097] In certain embodiments of the process provided herein, the combination from step a and the aqueous solution are mixed at a pH of between about 6 and about 7.6 in step b. In certain embodiments, the combination from step a and the aqueous solution are mixed at a pH of about 7 in step b.

[0098] In certain embodiments of the process provided herein, steps b and c are conducted in one pot.

[0099] In certain embodiments of the process provided herein, step b further comprises purifying the precursor particles prior to step c.

[00100] In certain embodiments of the process provided herein, the precursor particles are reacted with the peptides in O.lxPBS.

[00101] In certain embodiments of the process provided herein, step c comprises reacting the precursor particles with the peptides at a pH of about 7 to 8.

[00102] In certain embodiments of the process of provided herein, step c comprises reacting the precursor particles with the peptides at a temperature of about 0 to 30 °C.

[00103] Also provided herein is a nanoparticle or population of nanoparticles produced by a process described herein. 4. BRIEF DESCRIPTION OF THE DRAWINGS

[00104] Figure 1 depicts the microfluidic mixing method for making precursor nanoparticles as in Example 1.

[00105] Figure 2 depicts a generalized synthesis of peptide-coupled nanoparticles beginning with formation of precursor nanoparticles as in Example 1 followed by coupling of peptides to the precursor nanoparticles as in Example 2.

[00106] Figure 3 depicts a generalized synthesis of peptide-coupled nanoparticles in one step starting from amphiphilic polymer (“TPP”), lipids (e.g. DSPC), and lipid-peptide conjugate.

[00107] Figure 4 depicts the organ distribution of Cy5-labelled nanoparticles following administration to C57BL / 6 mice.

[00108] Figure 5 depicts targeted delivery of Cy5-labelled nanoparticles within the liver.

[00109] Figure 6 shows that the proportion of Cy5 signal arising from different liver cell types following administration of Cy5-labelled nanoparticles (DC: dendritic cell; KC: Kupffer cell; MoMF: monocyte-derived macrophage; PMN: polymorphonuclear leukocyte).

[00110] Figure 7 depicts how nanoparticles functionalized with gluten derived peptides can stimulate T cell clones to produce IFNy.

[00111] Figure 8 depicts the results of a IFN-y ELISpotPLUS assay applied to samples of peripheral blood mononuclear cells (PBMC) treated with nanoparticles coupled to soluble gliadin peptide (SEQ ID NO. 1). From left to right at each concentration: gliadin peptide; Control; Sample 1; Sample 2.

[00112] Figure 9 depicts change in clinical score + SEM over time for BL / 6 mice administered treatment intravenously on D-l.

[00113] Figure 10 depicts change in clinical score + SEM over time for BL / 6 mice administered treatment intravenously on the first day of disease. 5. DETAILED DESCRIPTION

[00114] Provided herein are nanoparticles according to Section 5.2, populations of nanoparticles according to Section 5.3, processes for manufacturing nanoparticles according to Section 5.4, pharmaceutical compositions according to Section 5.5, and methods of treating according to Section 5.6. Without wishing to be bound by theory, the nanoparticles are conjugated to peptides according to Section 5.2.5 comprising a T cell epitope. Also without wishing to be bound by theory, the nanoparticles conjugated to peptides comprising a T cell epitope are suitable for administration to a subject, and are capable of tolerizing the subject to the peptides associated with or conjugated to the nanoparticle. Also without wishing to be bound by theory, the nanoparticles conjugated to peptides comprising a T cell epitope are suitable for administration to a subject, and are capable of suppressing a specific immune response in the subject. Also without wishing to be bound by theory, the nanoparticles conjugated to peptides comprising a T cell epitope are suitable for administration to a subject, and are capable of treating or preventing a disease or disorder in the subject. 5.1 Definitions

[00115] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art. All patents, applications, published applications and other publications are incorporated by reference in their entirety. In the event that there is a plurality of definitions for a term herein, those in this section prevail unless stated otherwise.

[00116] As used herein and unless otherwise specified, the term “about” means within plus or minus 10% of a given value or range.

[00117] As used herein, and unless otherwise specified, the term “hydrocarbyl” refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, which may be saturated or unsaturated. In one embodiment, the hydrocarbyl group is, for example, an alkyl group, an alkenyl group, or an alkynyl group. In one embodiment, the hydrocarbyl group has, for example, from one to twenty-four carbon atoms (C1-C24), four to twenty carbon atoms (C4-C20), six to sixteen carbon atoms (Ce-Cie), six to nine carbon atoms (C6-C9), one to fifteen carbon atoms (Ci-Ci 5), one to twelve carbon atoms (C1-C12), one to eight carbon atoms (Ci-Cs) or one to six carbon atoms (Ci-Ce) and which is attached to the rest of the molecule by a single bond. Unless otherwise specified, a hydrocarbyl group is optionally substituted.

[00118] As used herein, and unless otherwise specified, the term “alkyl” refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, which is saturated. In one embodiment, the alkyl group has, for example, from one to twenty-four carbon atoms (C1-C24 alkyl), four to twenty carbon atoms (C4-C20 alkyl), six to sixteen carbon atoms (Ce-Ci6 alkyl), six to nine carbon atoms (C6-C9 alkyl), one to fifteen carbon atoms (C1-C15 alkyl), one to twelve carbon atoms (C1-C12 alkyl), one to eight carbon atoms (Ci-Cs alkyl) or one to six carbon atoms (Ci-Ce alkyl) and which is attached to the rest of the molecule by a single bond. Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, 1 -methylethyl (isopropyl), n-butyl, n-pentyl, 1,1-dimethylethyl (t-butyl), 3-methylhexyl, 2-methylhexyl, and the like. Unless otherwise specified, an alkyl group is optionally substituted.

[00119] As used herein, and unless otherwise specified, the term “alkenyl” refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, which comprises one or one carbon-carbon double bonds. In one embodiment, the alkenyl group has, for example, from one to twenty-four carbon atoms (C1-C24 alkenyl), four to twenty carbon atoms (C4-C20 alkenyl), six to sixteen carbon atoms (Gs-Cie alkenyl), six to nine carbon atoms (C6-C9 alkenyl), one to fifteen carbon atoms (C1-C15 alkenyl), one to twelve carbon atoms (C1-C12 alkenyl), one to eight carbon atoms (Ci-Cs alkenyl) or one to six carbon atoms (Ci-Ce alkenyl) and which is attached to the rest of the molecule by a single bond. Examples of alkenyl groups include, but are not limited to, vinyl, propenyl, isoprenyl, crotyl, and the like. Unless otherwise specified, an alkenyl group is optionally substituted.

[00120] When the groups described herein are said to be “substituted,” they may be substituted with any appropriate substituent or substituents. Illustrative examples of substituents include, but are not limited to, those found in the exemplary compounds and embodiments disclosed herein, as well as halogen (chloro, iodo, bromo, or fluoro); alkyl; alkenyl; alkynyl; hydroxyl; alkoxy; alkoxyalkyl; amino; alkylamino; carboxy; nitro; cyano; thiol; thioether; imine; imide; amidine; guanidine; enamine; aminocarbonyl; acylamino; phosphonate; phosphine; thiocarbonyl; sulfinyl; sulfone; sulfonamide; ketone; aldehyde; ester; urea; urethane; oxime; hydroxyl amine; alkoxyamine; aryloxyamine, aralkoxyamine; N-oxide; hydrazine; hydrazide; hydrazone; azide; isocyanate; isothiocyanate; cyanate; thiocyanate; oxo (=0); B(0H)2, O(alkyl)aminocarbonyl; cycloalkyl, which may be monocyclic or fused or non-fused polycyclic (e.g., cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl), or a heterocyclyl, which may be monocyclic or fused or non-fused polycyclic (e.g., pyrrolidyl, piperidyl, piperazinyl, morpholinyl, or thiazinyl); monocyclic or fused or non-fused polycyclic aryl or heteroaryl (e.g., phenyl, naphthyl, pyrrolyl, indolyl, furanyl, thiophenyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, tetrazolyl, pyrazolyl, pyridinyl, quinolinyl, isoquinolinyl, acridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, benzimidazolyl, benzothiophenyl, or benzofuranyl) aryloxy; aralkyloxy; heterocyclyloxy; and heterocyclyl alkoxy.

[00121] As used herein, and unless otherwise specified, the term “stereoisomer” refers to the various stereoisomeric forms of a compound that comprises one or more asymmetric centers or stereohindrance in the structure. In some embodiments, a stereoisomer is an enantiomer, a mixture of enantiomers, an atropisomer, or a tautomer thereof. For example, a lipid described herein can be in the form of an individual enantiomer, diastereomer or geometric isomer (e.g. an atropisomer), or can be in the form of a mixture of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomer. Stereoisomers can be isolated from mixtures by methods known to those skilled in the art, including chiral high pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or preferred isomers can be prepared by asymmetric syntheses. See, for example, Jacques et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen etal., Tetrahedron 33:2725 (1977); Eliel, E.L. Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); and Wilen, S.H. Tables of Resolving Agents and Optical Resolutions p. 268 (E.L. Eliel, Ed., Univ, of Notre Dame Press, Notre Dame, IN 1972). The invention additionally encompasses lipids as individual isomers substantially free of other isomers, and alternatively, as mixtures of various isomers.

[00122] In certain embodiments, the lipids provided herein may be racemic. In certain embodiments, the lipids provided herein may be enriched in one enantiomer. For example, a lipid provided herein may have greater than about 30% ee, about 40% ee, about 50% ee, about 60% ee, about 70% ee, about 80% ee, about 90% ee, or even about 95% or greater ee. In certain embodiments, the lipids provided herein may have more than one stereocenter. In certain such embodiments, the lipids provided herein may be enriched in one or more diastereomer. For example, a lipid provided herein may have greater than about 30% de, about 40% de, about 50% de, about 60% de, about 70% de, about 80% de, about 90% de, or even about 95% or greater de.

[00123] In certain embodiments, the nanoparticle comprises predominantly one enantiomer of a given lipid. An enantiomerically enriched nanoparticle may comprise, for example, at least about 60 mol percent of one enantiomer, or more particularly at least about 75, about 90, about 95, or even about 99 mol percent of one enantiomer of a given lipid. In certain embodiments, the nanoparticle enriched in one enantiomer of a given lipid is substantially free of the other enantiomers of that lipid, wherein substantially free means that other enantiomers of the lipid in question make up less than about 10%, or less than about 5%, or less than about 4%, or less than about 3%, or less than about 2%, or less than about 1% as compared to the amount of the predominant enantiomer of the lipid, e.g., in the nanoparticle or a population of nanoparticles. For example, if a nanoparticle or population of nanoparticles comprises about 98 grams of a first enantiomer of a given lipid and about 2 grams of a second enantiomer of the given lipid, it would be said to contain about 98 mol percent of the first enantiomer and only about 2% of the second enantiomer.

[00124] In certain embodiments, the nanoparticle may be enriched to provide predominantly one diastereomer of a given lipid. A diastereomerically enriched nanoparticle or population of nanoparticles may comprise, for example, at least about 60 mol percent of one diastereomer, or more particularly at least about 75, about 90, about 95, or even about 99 mol percent of a given lipid.

[00125] In some embodiments, a moiety in a compound exists as a mixture of tautomers. A “tautomer” is a structural isomer of a moiety or a compound that readily interconverts with another structural isomer. For example, a pyrazole ring has two tautomers: which differ in the positions of the pi-bonds and a hydrogen atom. Unless explicitly stated otherwise, a drawing of one tautomer of a moiety or a compound encompasses all of the possible tautomers of that compound.

[00126] As used herein, and unless otherwise specified, the term “T cell epitope” refers to an agonistic peptide sequence capable of activating or inducing T cells.

[00127] As used herein, and unless otherwise specified, the term “treat” or “treating” refers to the alleviation of symptoms of a particular disease in a subject, and / or improvement of an ascertainable measurement associated with a particular disorder.

[00128] As used herein, and unless otherwise specified, the term “autoimmune disease” is defined as in Hayter et. al. (Autoimmunity Reviews 11 (2012) 754-765). 5.2 Nanoparticles

[00129] Without wishing to be bound by theory, the nanoparticles provided herein are suitable for transferring peptides to liver sinusoidal endothelial cells of a subject in vivo. In some embodiments, the nanoparticles comprise a moiety, e.g., a carbohydrate or a protein, targeting them or enhancing targeting of them to specific cells, such as liver sinusoidal endothelial cells and / or Kupffer cells. In some embodiments, the moiety, e.g. a carbohydrate or oligosaccharide, enhances or accelerates uptake of the nanoparticle from circulation via receptor mediated endocytosis.

[00130] In one embodiment, provided herein is a nanoparticle comprising: (a) an amphiphilic polymer according to Section 5.2.1; (b) a first lipid according to Section 5.2.2 comprising a polar head group and a non-polar tail group; and (c) a peptide according to Section 5.2.5 comprising a T cell epitope. In one embodiment, the composition of the nanoparticle is described in Section 5.2.7. In one embodiment, the physical properties of the nanoparticle are described in Section 5.2.8. In one embodiment, the biological properties of the nanoparticle are described in Section 5.2.9. In one embodiment, the composition, the physical properties, and / or the biological properties of the nanoparticle is determined according to an assay described in Section 5.7.

[00131] In one embodiment, provided herein is a nanoparticle comprising: (a) an amphiphilic polymer according to Section 5.2.1; (b) a first lipid according to Section 5.2.2 comprising a polar head group and a non-polar tail group; (c) a second lipid according to Section 5.2.3 capable of enhancing the stability of the nanoparticle; and (d) a peptide according to Section 5.2.5 comprising a T cell epitope. In one embodiment, the composition of the nanoparticle is described in Section 5.2.7. In one embodiment, the physical properties of the nanoparticle are described in Section 5.2.8. In one embodiment, the biological properties of the nanoparticle are described in Section 5.2.9. In one embodiment, the composition, the physical properties, and / or the biological properties of the nanoparticle is determined according to an assay described in Section 5.7.

[00132] In one embodiment, provided herein is a nanoparticle comprising: (a) an amphiphilic polymer according to Section 5.2.1; (b) a first lipid according to Section 5.2.2 comprising a polar head group and a non-polar tail group; (c) a third lipid according to Section 5.2.4 capable of being conjugated to a peptide comprising a T cell epitope; and (d) a peptide according to Section 5.2.5 comprising a T cell epitope. In one embodiment, the composition of the nanoparticle is described in Section 5.2.7. In one embodiment, the physical properties of the nanoparticle are described in Section 5.2.8. In one embodiment, the biological properties of the nanoparticle are described in Section 5.2.9. In one embodiment, the composition, the physical properties, and / or the biological properties of the nanoparticle is determined according to an assay described in Section 5.7.

[00133] In one embodiment, provided herein is a nanoparticle comprising: (a) an amphiphilic polymer according to Section 5.2.1; (b) a first lipid according to Section 5.2.2 comprising a polar head group and a non-polar tail group; (c) a second lipid according to Section 5.2.3 capable of enhancing the stability of the nanoparticle; (d) a third lipid according to Section 5.2.4 capable of being conjugated to a peptide comprising a T cell epitope; and (e) a peptide according to Section 5.2.5 comprising a T cell epitope. In one embodiment, the composition of the nanoparticle is described in Section 5.2.7. In one embodiment, the physical properties of the nanoparticle are described in Section 5.2.8. In one embodiment, the biological properties of the nanoparticle are described in Section 5.2.9. In one embodiment, the composition, the physical properties, and / or the biological properties of the nanoparticle is determined according to an assay described in Section 5.7.

[00134] In one embodiment, provided herein is a nanoparticle comprising: (a) an amphiphilic polymer according to Section 5.2.1; (b) a first lipid according to Section 5.2.2 comprising a polar head group and a non-polar tail group; and (c) a lipid-peptide conjugate according to 5.2.6, wherein the peptide is covalently linked the lipid, and the peptide comprises a T cell epitope. In one embodiment, the composition of the nanoparticle is described in Section 5.2.7. In one embodiment, the physical properties of the nanoparticle are described in Section 5.2.8. In one embodiment, the biological properties of the nanoparticle are described in Section 5.2.9. In one embodiment, the composition, the physical properties, and / or the biological properties of the nanoparticle is determined according to an assay described in Section 5.7.

[00135] In one embodiment, provided herein is a nanoparticle comprising: (a) an amphiphilic polymer according to Section 5.2.1; (b) a first lipid according to Section 5.2.2 comprising a polar head group and a non-polar tail group; (c) a second lipid according to Section 5.2.3 capable of enhancing the stability of the nanoparticle; and (d) a lipid-peptide conjugate according to Section 5.2.6, wherein the peptide is covalently linked the lipid, and the peptide comprises a T cell epitope. In one embodiment, the composition of the nanoparticle is described in Section 5.2.7. In one embodiment, the physical properties of the nanoparticle are described in Section 5.2.8. In one embodiment, the biological properties of the nanoparticle are described in Section 5.2.9. In one embodiment, the composition, the physical properties, and / or the biological properties of the nanoparticle is determined according to an assay described in Section 5.7.

[00136] In one embodiment, provided herein is a nanoparticle comprising: (a) an amphiphilic polymer according to Section 5.2.1; (b) a first lipid according to Section 5.2.2 comprising a polar head group and a non-polar tail group; and (c) a second lipid according to Section 5.2.3 capable of enhancing the stability of the nanoparticle. In one embodiment, the composition of the nanoparticle is described in Section 5.2.7. In one embodiment, the physical properties of the nanoparticle are described in Section 5.2.8. In one embodiment, the biological properties of the nanoparticle are described in Section 5.2.9. In one embodiment, the composition, the physical properties, and / or the biological properties of the nanoparticle is determined according to an assay described in Section 5.7. In one embodiment, the nanoparticle is a precursor particle used in a process of manufacturing according to Section 5.4.

[00137] In one embodiment, provided herein is a nanoparticle comprising: (a) an amphiphilic polymer according to Section 5.2.1; (b) a first lipid according to Section 5.2.2 comprising a polar head group and a non-polar tail group; (c) a second lipid according to Section 5.2.3 capable of enhancing the stability of the nanoparticle; and (d) third lipid according to Section 5.2.4 capable of being conjugated to a peptide comprising a T cell epitope. In one embodiment, the composition of the nanoparticle is described in Section 5.2.7. In one embodiment, the physical properties of the nanoparticle are described in Section 5.2.8. In one embodiment, the biological properties of the nanoparticle are described in Section 5.2.9. In one embodiment, the composition, the physical properties, and / or the biological properties of the nanoparticle is determined according to an assay described in Section 5.7. In one embodiment, the nanoparticle is a precursor particle used in a process of manufacturing according to Section 5.4.

[00138] In one embodiment, the nanoparticle is produced according to a process of manufacturing as described in Section 5.4.

[00139] In certain embodiments, the nanoparticle provided herein does not comprise a solid inorganic core. 5.2.1 Amphiphilic Polymer

[00140] Without wishing to be bound by theory, in certain embodiments, the amphiphilic polymer comprises: (a) a hydrophobic region; and (b) a hydrophilic region. In certain embodiments, the hydrophobic region comprises a hydrocarbyl chain comprising 4 to 30, or preferably 7 to 19, carbon atoms. In certain embodiments, the hydrophilic region of the amphiphilic polymer comprises a protonatable or deprotonatable moiety (e.g. -OH or -COOH) such that the amphiphilic polymer is capable of having a net charge (e.g. net negative charge) in solution. One of skill in the art will recognize that the degree of protonation or deprotonation of the moiety and, thus, the net charge of the amphiphilic polymer is an equilibrium process that depends on the p^a of the moiety and the pH of the solution.

[00141] In one embodiment, the number average molecular weight (Mn) of the amphiphilic polymer is 20,000 g / mol or less, 10,000 g / mol or less, or 6,000 g / mol or less.

[00142] In one embodiment, the number average molecular weight (Mn) of the amphiphilic polymer is between about 1,000 g / mol and 20,000 g / mol, between about 2,500 g / mol and 20,000 g / mol, between about 1,000 g / mol and 10,000 g / mol, between about 2,500 g / mol and 10,000 g / mol, between about 1,000 g / mol and 6,000 g / mol, between about 2,500 g / mol and 6,000 g / mol, between about 1,000 g / mol and 4,000 g / mol, or between about 2,500 g / mol and 4,000 g / mol.

[00143] In one embodiment, the number average molecular weight (Mn) of the amphiphilic polymer is between about 1,000 g / mol and 6,000 g / mol.

[00144] In one embodiment, the number average molecular weight (Mn) of the amphiphilic polymer is between about 3,000 g / mol and 6,000 g / mol.

[00145] In one embodiment, the number average molecular weight (Mn) of the amphiphilic polymer is between about 2,500 g / mol and 4,000 g / mol.

[00146] In one embodiment, the number average molecular weight (Mn) of the amphiphilic polymer is determined using gel permeation chromatography (GPC). In one embodiment, polystyrene is used as a calibration standard. In one embodiment the number average molecular weight (Mn) of the amphiphilic polymer is determined using a PL-gel mixed D column at a temperature of 40°C, a mobile phase consisting of tetrahydrofuran / acetic acid 90 / 10% (v / v), a flow rate of 1.0 ml / min, in combination with a refractive index detector at a temperature of 35°C and polystyrene as calibration standard. In one embodiment, the number average molecular weight (Mn) of the amphiphilic polymer is determined using GPC and the following measurement conditions: Parameter Condition Reference standards Polystyrene standard (MW (nominal Mp); 1000 g / mol to 130000 g / mol Column Agilent PL-gel mixed-D, 300 x 7.5 mm ID, 5 pm Column Temperature 40°C Detector Refractive index detector at 3 5 °C Flow rate 1.0 ml / min Injection volume 20 pL Autosampler temperature Ambient Run time 15 min Parameter Condition Mobile phase Tetrahydrofuran / Acetic acid [90 / 10]%(v / v) Mobile phase program Isocratic

[00147] In one embodiment, the amphiphilic polymer is a copolymer. In one embodiment, the amphiphilic polymer is an alternating copolymer. Without wishing to be bound by theory, an alternating copolymer is a copolymer comprising two species of monomeric units in alternating sequence. In one embodiment, the amphiphilic polymer is a copolymer of maleic anhydride and at least one alkene. In one embodiment, the amphiphilic polymer is an alternating copolymer of maleic anhydride and at least one alkene. In one embodiment, the at least one alkene is selected from the group consisting of 1-decene, 1-undecene, 1-dodecene, 1-tridecene, 1-tetradecene, 1-pentadecene, 1-hexadecene, 1-heptadecene, 1-octadecene, 1-nonadecene and 1-eicosene. In one embodiment, the alkene is 1-octadecene. In one embodiment, the amphiphilic polymer is a copolymer of maleic anhydride and 1-octadecene. In one embodiment, the amphiphilic polymer is an alternating copolymer of maleic anhydride and 1 -octadecene.

[00148] In one embodiment, the amphiphilic polymer comprises a hydrophilic poly-maleic anhydride backbone and hydrophobic hydrocarbyl side chains. In one embodiment, the side chain is a linear alkyl chain. In one embodiment, the side chain comprises 5 to 31 carbon atoms. In one embodiment, the side chain comprises 8 to 20 carbon atoms. In one embodiment, the side chain comprises 10 to 18 carbon atoms. In one embodiment, the side chain comprises 16 carbon atoms.

[00149] In one embodiment, the amphiphilic polymer comprises the following building block: wherein R is a hydrocarbyl group or a substituted hydrocarbyl group. In one embodiment, R is a linear, unsubstituted hydrocarbyl group. In one embodiment, R is a C4 to C30 alkyl group. In one embodiment, R is a linear, unsubstituted C4 to C30 alkyl group. In one embodiment, R is a C7 to C19 alkyl group. In one embodiment, R is a linear, unsubstituted C?to C19 alkyl group. In one embodiment, R is a Cgto C17 alkyl group. In one embodiment, R is a linear, unsubstituted Cyto C17 alkyl group. In one embodiment, R is a C15 alkyl group. In one embodiment, R is a C15 linear, unsubstituted alkyl group. In one embodiment, the amphiphilic polymer comprises repeating units of the building block. In one embodiment, the amphiphilic polymer comprises n repeating units of the building block, wherein n a number between about 6 and about 11. In one embodiment, the amphiphilic polymer consists of repeating units of the building block. In one embodiment, the amphiphilic polymer consists of n repeating units of the building block, wherein n a number between about 6 and about 11.

[00150] In one embodiment, the amphiphilic polymer is selected from the group consisting of poly (maleic acid-a / z-l-octadecene), poly(maleic acid-a / t-1-tetradecene) and poly(maleic acid-a / / -l-dodecene). In one embodiment, the amphiphilic polymer is poly(maleic acid-a / t-1-octadecene). In one embodiment, the amphiphilic polymer is poly(maleic acid-1-octadecene) and the number average molecular weight of the polymer is from about 1,000 to 6,000 g / mol. 5.2.2 First Lipid

[00151] In certain embodiments, the nanoparticle comprises a first lipid comprising a polar head group and a non-polar tail group. Without wishing to be bound by theory, in certain embodiments, the first lipid is a structural lipid.

[00152] In one embodiment, the non-polar tail group is an alkyl tail group. In one embodiment, the non-polar tail group is an alkenyl tail group. In one embodiment, the non-polar tail group is a C10 to C26 tail group. In one embodiment, the non-polar tail group is a C10 to C26 alkyl tail group. In one embodiment, the non-polar tail group is a C10 to C26 alkenyl tail group. In one embodiment, the non-polar tail group is a Ci6 to C20 tail group. In one embodiment, the non-polar tail group is a Ci6 to C20 alkyl tail group. In one embodiment, the non-polar tail group is a Ci6 to C20 alkenyl tail group. In one embodiment, the non-polar tail group is a Cis tail group. In one embodiment, the non-polar tail group is a Cis alkyl tail group. In one embodiment, the non-polar tail group is a octadecanoyloxy tail group. In one embodiment, the non-polar tail group is a Cis alkenyl tail group.

[00153] In one embodiment, the first lipid comprises an alkyl tail group. In one embodiment, the first lipid comprises an alkenyl tail group. In one embodiment, the first lipid comprises a C10 to C26 tail group. In one embodiment, the first lipid comprises a C10 to C26 alkyl tail group. In one embodiment, the first lipid comprises a C10 to C26 alkenyl tail group. In one embodiment, the first lipid comprises a Ci6 to C20 tail group. In one embodiment, the first lipid comprises a Ci6 to C20 alkyl tail group. In one embodiment, the first lipid comprises a Ci6 to C20 alkenyl tail group. In one embodiment, the first lipid comprises a Cis tail group. In one embodiment, the first lipid comprises a Ci s alkyl tail group. In one embodiment, the first lipid comprises an octadecanoyloxy tail group. In one embodiment, the first lipid comprises a Cis alkenyl tail group.

[00154] In one embodiment, the first lipid is a tetraalkylammonium compound. In one embodiment, the tetraalkylammonium compound comprises one or two Cio to C26 alkyl or alkenyl tail groups. In one embodiment, the tetraalkylammonium compound comprises one or two Cie to C20 alkyl or alkenyl tail groups. In one embodiment, the first lipid is l,2-dioleoyl-3-trimethylammonium propane (DOTAP) or dimethyldioctadecylammonium (DDAB).

[00155] In one embodiment, the first lipid is a phospholipid comprising a polar head group and a non-polar tail group. In one embodiment, the first lipid comprises a polar head group lacking an -COOH, -OH, -NH2, -NH3+, or -SH moiety capable of being conjugated to the peptide. In one embodiment, the first lipid comprises a polar head group lacking -NH2, -NH3+, or -SH moiety capable of being conjugated to the peptide. In one embodiment, the first lipid is a phospholipid comprising a polar head group lacking an -COOH, -OH, -NH2, -NH3+, or -SH moiety capable of being conjugated to the peptide. In one embodiment, the first lipid is a phospholipid comprising a polar head group lacking an -NH2, -NH3+, or -SH moiety capable of being conjugated to the peptide. In one embodiment, the polar head group of the first lipid comprises a tetraalkylammonium moiety.

[00156] In one embodiment, the phospholipid is a phospholipid of Formula (I): (I), wherein, R1 is a group that lacks an -COOH, -OH, -NH2, -NH3+, or -SH moiety capable of being conjugated to the peptide; and R2 and R3 are each independently a hydrocarbyl group. In one embodiment, R1 comprises a tetraalkylammonium moiety. In one embodiment, R2 and R3 are each independently a Cio to C26 hydrocarbyl group. In one embodiment, R2 and R3 are each independently an alkyl group. In one embodiment, R2 and R3 are each independently a Cio to C26 alkyl group. In one embodiment, R2 and R3 are each independently an alkenyl group. In one embodiment, R2 and R3 are each independently a Cio to C26 alkenyl group. In one embodiment, R2 and R3 are the same. In one embodiment, R2 and R3 are different.

[00157] In one embodiment, the phospholipid is a phospholipid of Formula (I): (I), wherein, R1 is a group that lacks an -NH2, -NH3+, or -SH moiety capable of being conjugated to the peptide; and R2 and R3 are each independently a hydrocarbyl group. In one embodiment, R1 comprises a tetraalkylammonium moiety. In one embodiment, R2 and R3 are each independently a C10 to C26 hydrocarbyl group. In one embodiment, R2 and R3 are each independently an alkyl group. In one embodiment, R2 and R3 are each independently a C10 to C26 alkyl group. In one embodiment, R2 and R3 are each independently an alkenyl group. In one embodiment, R2 and R3 are each independently a C10 to C26 alkenyl group. In one embodiment, R2 and R3 are the same. In one embodiment, R2 and R3 are different.

[00158] In one embodiment, R1 is choline, or a group derived from choline, ethanolamine, serine or inositol, such that the group lacks an -COOH, -OH, -NH2, -NHs+, or -SH moiety. In one embodiment, R1 is choline, ethanolamine, serine, inositol or glycerol, or a group derived therefrom lacking an -NH2, -NH3 , or -SH moiety. In one embodiment, the group derived from choline, ethanolamine, serine and inositol comprises modifications, substitutions, branching, oxidation, and / or cyclization of choline, ethanolamine, serine or inositol. In one embodiment, R1 is choline. In one embodiment, R1 is serine. In one embodiment, R1 is glycerol. In one embodiment, R1 is inositol.

[00159] In one embodiment, the phospholipid is selected from the group consisting of 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC), l,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), l,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC), l-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), l,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 Diether PC), l-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC), 1 -hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC), l,2-dilinolenoyl-sn-glycero-3-phosphocholine, 1,2-diarachidonoyl-sn-glycero-3 -phosphocholine, 1,2-didocosahexaenoyl-sn-glycero-3 -phosphocholine, 1 -stearoyl-2-oleoyl-phosphatidylcholine (SOPC), l,2-dielaidoyl-sn-glycero-3-phosphocholine (18:1 A9-Trans-PC), 1,2-dioleoyl-sn-glycero-3 -phosphocholine (DOPC), dimyristoyl phosphatidylserine (DMPS), diarachidoyl phosphatidylserine (DAPS), dipalmitoyl phosphatidylserine (DPPS), distearoylphosphatidylserine (DSPS), dioleoylphosphatidylserine (DOPS), dilauroylphosphatidylinositol (DLPI), diarachidoylphosphatidylinositol (DAPI), dimyristoylphosphatidylinositol (DMPI), dipalmitoylphosphatidylinositol (DPPI), distearoylphosphatidylinositol (DSPI), dioleoyl-phosphatidylinositol (DOPI), 1,2-dimyristoyl-sn-glycero-3-phosphoglycerol (DMPG), 1,2-dipalmitoyl-sn-glycero-3 -phosphoglycerol (DPPG), 1,2-distearoyl-sn-glycero-3-phosphoglycerol (DSPG), and 1,2-dioleoyl-sn-glycero-3-phosphoglycerol (DOPG), or mixtures thereof.

[00160] In one embodiment, the first lipid is a phosphatidylcholine, or a lipid derived from a phosphatidylinositol, a phosphatidylethanolamine, or a phosphatidylserine such that the lipid lacks an -C00H, -OH, -NH2, -NH3, or -SH moiety. In one embodiment, the first lipid is a phosphatidylcholine, phosphatidylinositol, a phosphatidylethanolamine, a phosphatidylserine, or phosphatidylglycerol lacking an -NH2, -NH3+, or -SH moiety. In one embodiment, the first lipid is a phosphatidylcholine. In one embodiment, the first lipid is l,2-distearoyl-s«-glycero-3-phosphocholine (DSPC), or Lipoid S100 (CAS-No. 97281-47-5). In one embodiment, the first lipid is l,2-distearoyl-5 / 7-glycero-3-phosphocholine (DSPC).

[00161] In one embodiment, the polar head group of the first lipid comprises a tetraalkylammonium moiety. In one embodiment, the first lipid is a phosphatidylcholine. In one embodiment, the first lipid is l,2-distearoyl-s«-glycero-3-phosphocholine (DSPC).

[00162] In one embodiment, the first lipid is a fatty acid compound. In one embodiment, the fatty acid comprises a C10 to C26 hydrocarbyl tail group. In one embodiment, the fatty acid comprises a Ci6 to C20 hydrocarbyl tail group. In one embodiment, the fatty acid is selected from the group consisting of decanoic acid (capric acid), undecanoic acid (undecylic acid), dodecanoic acid (lauric acid), tridecanoic acid (tridecylic acid), tetradecanoic acid (myristic acid), pentadecanoic acid, hexadecanoic acid (palmitic acid), heptadecanoic acid (margaric acid), octadecanoic acid (stearic acid), nonadecanoic acid (nonadecylic acid), eicosanoic acid (arachidic acid, icosanoic acid), heneicosanoic acid (heneicosylic acid), docosanoic acid (behenic acid), tricosanoic acid, tetracosanoic acid (lignoceric acid), pentacosanoic acid, pentacosanoic acid (cerotic acid), and (Z)-octadec-9-en-17-ynoic acid (oleic acid). In one embodiment, the first lipid is hexadecanoic acid (palmitic acid), heptadecanoic acid (margaric acid), octadecanoic acid (stearic acid), nonadecanoic acid (nonadecylic acid), eicosanoic acid (arachidic acid, icosanoic acid), or (Z)-octadec-9-en-17-ynoic acid (oleic acid). 5.2.3 Second Lipid

[00163] In certain embodiments, the nanoparticle comprises a second lipid capable of enhancing the stability of the nanoparticle. In one embodiment, the second lipid is a fused polycyclic hydrocarbon, optionally substituted with one or more exocyclic oxygen, nitrogen, or sulfurcontaining moieties. In one embodiment, the second lipid is a fused polycyclic hydrocarbon, optionally substituted with one or more exocyclic oxygen-containing moieties. In one embodiment, the second lipid is a fused polycyclic hydrocarbon. In one embodiment, the second lipid is a fused polycyclic hydrocarbon substituted with one or more exocyclic oxygen-containing moieties. In one embodiment, the second lipid is a sterol or a hopanoid. Without wishing to be bound by theory, in certain embodiments, the second lipid is a cohesive lipid.

[00164] In one embodiment, the second lipid is a sterol of Formula (II): (II), or a stereoisomer or mixture of stereoisomers thereof; wherein R4, R5, R6, R7, and R8 are each independently H or a C1-3 alkyl group; R9 is a hydrocarbyl group optionally substituted with an -OH moiety; and the dashed bonds are each independently single or double bonds. In one embodiment, R4, R5, R6, R7, and R8 are each independently H or a methyl group. In one embodiment, R9 is a C3-C15 hydrocarbyl group optionally substituted with an -OH moiety. In one embodiment, R9 is a C3-C15 hydrocarbyl group. In one embodiment, R9 is a C7-C11 hydrocarbyl group. In one embodiment, R9 is an alkyl or alkenyl group optionally substituted with an -OH moiety. In one embodiment, R9 is an alkyl or alkenyl group. In one embodiment, R9 is a C3-C15 alkyl or alkenyl group optionally substituted with an -OH moiety. In one embodiment, R9 is a C3-C15 alkyl or alkenyl group. In one embodiment, R9 is a C7-C11 alkyl or alkenyl group. In one embodiment, R9 is a branched alkyl or alkenyl group optionally substituted with an -OH moiety. In one embodiment, R9 is a branched alkyl or alkenyl group. In one embodiment, R9 is a branched C3-C15 alkyl or alkenyl group optionally substituted with an -OH moiety. In one embodiment, R9 is a branched C3-C15 alkyl or alkenyl group. In one embodiment, R9 is a branched C7-C11 alkyl or alkenyl group. In one embodiment, the B ring comprises six endocyclic single bonds and no endocyclic double bonds. In one embodiment, the B ring comprises five endocyclic single bonds and one endocyclic double bond. In one embodiment, the B ring comprises four endocyclic single bonds and two endocyclic double bonds.

[00165] In one embodiment, the second lipid is a sterol of Formula (Ila): (Ha), or a stereoisomer or mixture of stereoisomers thereof; wherein R6 and R8 are each independently H or a Ci-3 alkyl group; R9 is a hydrocarbyl group optionally substituted with an -OH moiety; and the dashed bonds are each independently single or double bonds. In one embodiment, R6 and R8 are each independently H or a methyl group. In one embodiment, R6 and R8 are each a methyl group. In one embodiment, R9 is a C3-C15 hydrocarbyl group optionally substituted with an -OH moiety. In one embodiment, R9 is a C3-C15 hydrocarbyl group. In one embodiment, R9 is a C7-C11 hydrocarbyl group. In one embodiment, R9 is an alkyl or alkenyl group optionally substituted with an -OH moiety. In one embodiment, R9 is an alkyl or alkenyl group. In one embodiment, R9 is a C3-C15 alkyl or alkenyl group optionally substituted with an -OH moiety. In one embodiment, R9 is a C3-C15 alkyl or alkenyl group. In one embodiment, R9 is a C7-C11 alkyl or alkenyl group. In one embodiment, R9 is a branched alkyl or alkenyl group optionally substituted with an -OH moiety. In one embodiment, R9 is a branched alkyl or alkenyl group. In one embodiment, R9 is a branched C3-C15 alkyl or alkenyl group optionally substituted with an -OH moiety. In one embodiment, R9 is a branched C3-C15 alkyl or alkenyl group. In one embodiment, R9 is a branched C7-C11 alkyl or alkenyl group. In one embodiment, R9 is a branched Cs alkyl or alkenyl group. In one embodiment, R9 is a branched Cs alkyl group. In one embodiment, the B ring comprises six endocyclic single bonds. In one embodiment, the B ring comprises five endocyclic single bonds and one endocyclic double bond. In one embodiment, the B ring comprises four endocyclic single bonds and two endocyclic double bonds.

[00166] In one embodiment, the second lipid is a sterol of Formula (lib): (lib), or a stereoisomer or mixture of stereoisomers thereof; wherein R6 and R8 are each independently H or a Ci-3 alkyl group; and R9 is a hydrocarbyl group optionally substituted with an -OH moiety. In one embodiment, R6 and R8 are each independently H or a methyl group. In one embodiment, R6 and R8 are each a methyl group. In one embodiment, R9 is a C3-C15 hydrocarbyl group optionally substituted with an -OH moiety. In one embodiment, R9 is a C3-C15 hydrocarbyl group. In one embodiment, R9 is a C7-C11 hydrocarbyl group. In one embodiment, R9 is an alkyl or alkenyl group optionally substituted with an -OH moiety. In one embodiment, R9 is an alkyl or alkenyl group. In one embodiment, R9 is a C3-C15 alkyl or alkenyl group optionally substituted with an -OH moiety. In one embodiment, R9 is a C3-C15 alkyl or alkenyl group. In one embodiment, R9 is a C7-C11 alkyl or alkenyl group. In one embodiment, R9 is a branched alkyl or alkenyl group optionally substituted with an -OH moiety. In one embodiment, R9 is a branched alkyl or alkenyl group. In one embodiment, R9 is a branched C3-C15 alkyl or alkenyl group optionally substituted with an -OH moiety. In one embodiment, R9 is a branched C3-C15 alkyl or alkenyl group. In one embodiment, R9 is a branched C7-C11 alkyl or alkenyl group. In one embodiment, R9 is a branched Cs alkyl or alkenyl group. In one embodiment, R9 is a branched Cs alkyl group.

[00167] In one embodiment, the second lipid is a sterol of Formula (lie): (lie), wherein R6 and R8 are each independently H or a C1-3 alkyl group; and R9 is a hydrocarbyl group optionally substituted with an -OH moiety. In one embodiment, R6 and R8 are each independently H or a methyl group. In one embodiment, R6 and R8 are each a methyl group. In one embodiment, R9 is a C3-C15 hydrocarbyl group optionally substituted with an -OH moiety. In one embodiment, R9 is a C3-C15 hydrocarbyl group. In one embodiment, R9 is a C7-C11 hydrocarbyl group. In one embodiment, R9 is an alkyl or alkenyl group optionally substituted with an -OH moiety. In one embodiment, R9 is an alkyl or alkenyl group. In one embodiment, R9 is a C3-C15 alkyl or alkenyl group optionally substituted with an -OH moiety. In one embodiment, R9 is a C3-C15 alkyl or alkenyl group. In one embodiment, R9 is a C7-C11 alkyl or alkenyl group. In one embodiment, R9 is a branched alkyl or alkenyl group optionally substituted with an -OH moiety. In one embodiment, R9 is a branched alkyl or alkenyl group. In one embodiment, R9 is a branched C3-C15 alkyl or alkenyl group optionally substituted with an -OH moiety. In one embodiment, R9 is a branched C3-C15 alkyl or alkenyl group. In one embodiment, R9 is a branched C7-C11 alkyl or alkenyl group. In one embodiment, R9 is a branched Cs alkyl or alkenyl group. In one embodiment, R9 is a branched Cs alkyl group. In one embodiment, R9 is a branched C10 alkyl group. In one embodiment, R9 is a branched Cs alkenyl group. In one embodiment, R9 is a branched C10 alkenyl group.

[00168] In one embodiment, the second lipid is a sterol selected from the group consisting of cholesterol, cycloartenol, sitosterol, stigmasterol, ergosterol, lanosterol, campesterol, fecosterol, brassicasterol, tomatidine, tomatine, ursolic acid and alpha-tocopherol. In one embodiment, the second lipid is cholesterol. In one embodiment, the second lipid is sitosterol. In one embodiment, the second lipid is stigmasterol.

[00169] In one embodiment, the second lipid is a hopanoid of Formula (III): (III), wherein R11, R12, R13, R14, R15, R16, and R17 are each independently H or a C1-3 alkyl group; R10 is a hydrocarbyl group optionally substituted with one or more oxygen, nitrogen, or sulfur-containing moieties. In one embodiment, R11, R12, R13, R14, R15, R16, and R17 are each independently H or a methyl group. In one embodiment, R17 is H. In one embodiment, R15 and R16 are each a methyl group. In one embodiment, R11, R12, R13, R14, R15, and R16 are each a methyl group. In one embodiment, R11, R12, R13, R14, R15, and R16 are each a methyl group, and R17 is H. In one embodiment, R10 is hydrocarbyl group optionally substituted with an oxygen-containing moiety. In one embodiment, R10 is hydrocarbyl group optionally substituted with one or more -OH moieties. In one embodiment, R10 is a C2-C15 hydrocarbyl group optionally substituted with one or more -OH moieties. In one embodiment, R10 is a C2-C15 alkyl group optionally substituted with one or more - OH moieties. In one embodiment, R10 is a C2 alkyl group optionally substituted with one or more - OH moieties. In one embodiment, R10 is a C3 alkyl group optionally substituted with one or more - OH moieties. In one embodiment, R10 is a Cs alkyl group optionally substituted with one or more - OH moieties. In one embodiment, R10 is a Cs alkyl group optionally substituted with one, two, three, four, or five -OH moieties.

[00170] In one embodiment, the second lipid is a hopanoid of Formula (Illa): (Hla), wherein R11, R12, R13, R14, R15, R16, and R17 are each independently H or a C1-3 alkyl group; R10 is a hydrocarbyl group optionally substituted with one or more oxygen, nitrogen, or sulfur-containing moieties. In one embodiment, R11, R12, R13, R14, R15, R16, and R17 are each independently H or a methyl group. In one embodiment, R17 is H. In one embodiment, R15 and R16 are each a methyl group. In one embodiment, R11, R12, R13, R14, R15, and R16 are each a methyl group. In one embodiment, R11, R12, R13, R14, R15, and R16 are each a methyl group, and R17 is H. In one embodiment, R10 is hydrocarbyl group optionally substituted with an oxygen-containing moiety. In one embodiment, R10 is hydrocarbyl group optionally substituted with one or more -OH moieties. In one embodiment, R10 is a C2-C15 hydrocarbyl group optionally substituted with one or more -OH moieties. In one embodiment, R10 is a C2-C15 alkyl group optionally substituted with one or more -OH moieties. In one embodiment, R10 is a C2 alkyl group optionally substituted with one or more - OH moieties. In one embodiment, R10 is a C3 alkyl group optionally substituted with one or more - OH moieties. In one embodiment, R10 is a Cs alkyl group optionally substituted with one or more - OH moieties. In one embodiment, R10 is a Cs alkyl group optionally substituted with one, two, three, four, or five -OH moieties.

[00171] In one embodiment, the second lipid is a hopanoid selected from the group consisting of diploptene, diplopterol, aminobacteriohopanetriol, bacteriohopanetriol, 2-methyl bacteriohopanetriol, aminobacteriohopanetriol, bacteriohopanetetrol, 2Me-aminobacteriohopanetriol, adenosylhopane, and 2Me-bacteriohopanetetrol. 5.2.4 Third Lipid

[00172] In certain embodiments, the nanoparticle comprises a third lipid capable of being conjugated to a peptide according to Section 5.2.5 comprising a T cell epitope. In one embodiment, the third lipid comprises an oxygen, nitrogen, or sulfur-containing moiety capable of being conjugated to the peptide. In one embodiment, the third lipid comprises a polar head group and a non-polar tail group. Without wishing to be bound by theory, in certain embodiments, the third lipid is an anchor lipid.

[00173] In one embodiment, the polar head group comprises an oxygen, nitrogen, or sulfurcontaining moiety capable of being conjugated to the peptide. In one embodiment, the polar head group comprises an -COOH, -OH, -NH2, -NH3, or -SH moiety.

[00174] In one embodiment, the non-polar tail group is a hydrocarbyl tail group. In one embodiment, the non-polar tail group is an alkyl tail group. In one embodiment, the non-polar tail group is an alkenyl tail group. In one embodiment, the non-polar tail group is a C10 to C26 tail group. In one embodiment, the non-polar tail group is a C10 to C26 alkyl tail group. In one embodiment, the non-polar tail group is a C10 to C26 alkenyl tail group. In one embodiment, the non-polar tail group is a Ci6 to C20 tail group. In one embodiment, the non-polar tail group is a Ci6 to C20 alkyl tail group. In one embodiment, the non-polar tail group is a Ci6 to C20 alkenyl tail group.

[00175] In one embodiment, the third lipid comprises a hydrocarbyl tail group. In one embodiment, the third lipid comprises an alkyl tail group. In one embodiment, the third lipid comprises an alkenyl tail group. In one embodiment, the third lipid comprises a C10 to C26 tail group. In one embodiment, the third lipid comprises a C10 to C26 alkyl tail group. In one embodiment, the third lipid comprises a C10 to C26 alkenyl tail group. In one embodiment, the third lipid comprises a Ci6 to C20 tail group. In one embodiment, the third lipid comprises a Ci6 to C20 alkyl tail group. In one embodiment, the third lipid comprises a Ci6 to C20 alkenyl tail group.

[00176] In one embodiment, the third lipid comprises an oxygen, nitrogen, or sulfur-containing moiety capable of being conjugated to the peptide. In one embodiment, the third lipid comprises an -COOH, -OH, -NH2, -NH3+, or -SH moiety.

[00177] In one embodiment, the third lipid is a phospholipid. In one embodiment, the third lipid is a fused polycyclic hydrocarbon substituted with an exocyclic oxygen, nitrogen, or sulfurcontaining moiety capable of being conjugated to the peptide. In one embodiment, the third lipid is a sterol or a hopanoid. (a) Phospholipids

[00178] In one embodiment, the third lipid is a phospholipid. In one embodiment, the third lipid is a phospholipid comprising a polar head group and a non-polar tail group. In one embodiment, the phospholipid comprises a polar head group comprising an oxygen, nitrogen, or sulfur-containing moiety capable of being conjugated to the peptide.

[00179] In one embodiment, the third lipid is a phospholipid of Formula (IV): (IV), wherein R18 is a group comprising an oxygen, nitrogen, or sulfur-containing moiety capable of being conjugated to the peptide; and R19 and R20 are each independently a hydrocarbyl group. In one embodiment, R18 is a group comprising an -COOH, -OH, -NH2, -NH3, or -SH moiety capable of being conjugated to the peptide. In one embodiment, R19 and R20 are each independently a C10 to C26 hydrocarbyl group. In one embodiment, R19 and R20 are each independently an alkyl group. In one embodiment, R19 and R20 are each independently a C10 to C26 alkyl group. In one embodiment, R19 and R20 are each independently an alkenyl group. In one embodiment, R19 and R20 are each independently a C10 to C26 alkenyl group. In one embodiment, R19 and R20 are the same. In one embodiment, R19 and R20 are different.

[00180] In one embodiment, R18 is ethanolamine, serine, inositol, or glyercol, or a group derived from ethanolamine, serine, inositol, or glycerol. In one embodiment, the group derived from ethanolamine, serine, inositol, or glycerol comprises modifications, substitutions, branching, oxidation, and / or cyclization of ethanolamine, serine, inositol, or glycerol. In one embodiment, R18 is ethanolamine, serine, inositol, or glycerol.

[00181] In one embodiment, the third lipid is a phosphatidylethanolamine, a phosphatidylglycerol, a phosphatidylserine, a phosphatidylate, or a phosphatidylinositol.

[00182] In one embodiment, the third lipid is selected from the group consisting of dimyristoylphosphatidylethanolamine (DMPE), dipalmitoylphosphatidylethanolamine (DPPE), distearoyl phosphatidyl-ethanolamine (DSPE), dioleylphosphatidylethanolamine (DOPE), diarachidoylphosphatidylethanolamine (DAPE), dilinoleylphosphatidylethanolamine (DLPE), dimyristoyl phosphatidylserine (DMPS), diarachidoyl phosphatidylserine (DAPS), dipalmitoyl phosphatidylserine (DPPS), distearoylphosphatidylserine (DSPS), dioleoylphosphatidylserine (DOPS), dilauroyl-phosphatidylinositol (DLPI), diarachidoylphosphatidylinositol (DAPI), dimyristoylphosphatidylinositol (DMPI), dipalmitoylphosphatidylinositol (DPPI), distearoylphosphatidylinositol (DSPI), dioleoyl-phosphatidylinositol (DOPI), 1,2-dimyristoyl-sn-glycero-3-phosphoglycerol (DMPG), l,2-dipalmitoyl-sn-glycero-3-phosphoglycerol (DPPG), 1,2-distearoyl-sn-glycero-3-phosphoglycerol (DSPG), and 1,2-dioleoyl-sn-glycero-3-phosphoglycerol (DOPG); or a mixture thereof.

[00183] In one embodiment, the third lipid is selected from the group consisting of 1,2-distearoyl-.s77-glycero-3-phosphoethanolamine (DSPE), l,2-distearoyl-s77-glycero-3-phospho-L-serine (DSPS), l,2-distearoyl-5 / 7-glycero-3-phosphoinositol (DSPI), and 1,2-distearoyl-sn-glycero-3-phosphoglycerol (DSPG); or a mixture thereof. (b) Polycyclic Hydrocarbon

[00184] In one embodiment, the third lipid is a fused polycyclic hydrocarbon substituted with an exocyclic oxygen, nitrogen, or sulfur-containing moiety capable of being conjugated to the peptide. In one embodiment, the third lipid is a sterol. In another embodiment, the third lipid is a hopanoid.

[00185] In one embodiment, the third lipid is a sterol of Formula (V): (V), or a stereoisomer or mixture of stereoisomers thereof; wherein R21, R22, R23, R24, and R25 are each independently H or a C1-3 alkyl group; R26 is a hydrocarbyl group optionally substituted with an -OH moiety; and the dashed bonds are each independently single or double bonds. In one embodiment, R21, R22, R23, R24, and R25 are each independently H or a methyl group. In one embodiment, R26 is a C3-C15 hydrocarbyl group optionally substituted with an -OH moiety. In one embodiment, R26 is a C3-C15 hydrocarbyl group. In one embodiment, R26 is a C7-C11 hydrocarbyl group. In one embodiment, R26 is an alkyl or alkenyl group optionally substituted with an -OH moiety. In one embodiment, R26 is an alkyl or alkenyl group. In one embodiment, R26 is a C3-C15 alkyl or alkenyl group optionally substituted with an -OH moiety. In one embodiment, R26 is a C3-C15 alkyl or alkenyl group. In one embodiment, R26 is a C7-C11 alkyl or alkenyl group. In one embodiment, R26 is a branched alkyl or alkenyl group optionally substituted with an -OH moiety. In one embodiment, R26 is a branched alkyl or alkenyl group. In one embodiment, R26 is a branched C3-C15 alkyl or alkenyl group optionally substituted with an -OH moiety. In one embodiment, R26 is a branched C3-C15 alkyl or alkenyl group. In one embodiment, R26 is a branched C7-C11 alkyl or alkenyl group. In one embodiment, the B ring comprises six endocyclic single bonds and no endocyclic double bonds. In one embodiment, the B ring comprises five endocyclic single bonds and one endocyclic double bond. In one embodiment, the B ring comprises four endocyclic single bonds and two endocyclic double bonds.

[00186] In one embodiment, the third lipid is a sterol of Formula (Va): (Va), or a stereoisomer or mixture of stereoisomers thereof; wherein R23 and R24 are each independently H or a C1-3 alkyl group; R26 is a hydrocarbyl group optionally substituted with an -OH moiety; and the dashed bonds are each independently single or double bonds. In one embodiment, R23 and R24 are each independently H or a methyl group. In one embodiment, R23 and R24 are each a methyl group. In one embodiment, R26 is a C3-C15 hydrocarbyl group optionally substituted with an -OH moiety. In one embodiment, R26 is a C3-C15 hydrocarbyl group. In one embodiment, R26 is a C7-C11 hydrocarbyl group. In one embodiment, R26 is an alkyl or alkenyl group optionally substituted with an -OH moiety. In one embodiment, R26 is an alkyl or alkenyl group. In one embodiment, R26 is a C3-C15 alkyl or alkenyl group optionally substituted with an -OH moiety. In one embodiment, R26 is a C3-C15 alkyl or alkenyl group. In one embodiment, R26 is a C7-C11 alkyl or alkenyl group. In one embodiment, R26 is a branched alkyl or alkenyl group optionally substituted with an -OH moiety. In one embodiment, R26 is a branched alkyl or alkenyl group. In one embodiment, R26 is a branched C3-C15 alkyl or alkenyl group optionally substituted with an -OH moiety. In one embodiment, R26 is a branched C3-C15 alkyl or alkenyl group. In one embodiment, R26 is a branched C7-C11 alkyl or alkenyl group. In one embodiment, R26 is a branched Cs alkyl or alkenyl group. In one embodiment, R26 is a branched Cs alkyl group. In one embodiment, the B ring comprises six endocyclic single bonds. In one embodiment, the B ring comprises five endocyclic single bonds and one endocyclic double bond. In one embodiment, the B ring comprises four endocyclic single bonds and two endocyclic double bonds.

[00187] In one embodiment, the third lipid is a sterol of Formula (Vb): (Vb), or a stereoisomer or mixture of stereoisomers thereof; wherein R23 and R24 are each independently H or a Ci-3 alkyl group; and R26 is a hydrocarbyl group optionally substituted with an -OH moiety. In one embodiment, R23 and R24 are each independently H or a methyl group. In one embodiment, R23 and R24 are each a methyl group. In one embodiment, R26 is a C3-C15 hydrocarbyl group optionally substituted with an -OH moiety. In one embodiment, R26 is a C3-C15 hydrocarbyl group. In one embodiment, R26 is a C7-C11 hydrocarbyl group. In one embodiment, R26 is an alkyl or alkenyl group optionally substituted with an -OH moiety. In one embodiment, R26 is an alkyl or alkenyl group. In one embodiment, R26 is a C3-C15 alkyl or alkenyl group optionally substituted with an -OH moiety. In one embodiment, R26 is a C3-C15 alkyl or alkenyl group. In one embodiment, R26 is a C7-C11 alkyl or alkenyl group. In one embodiment, R26 is a branched alkyl or alkenyl group optionally substituted with an -OH moiety. In one embodiment, R26 is a branched alkyl or alkenyl group. In one embodiment, R26 is a branched C3-C15 alkyl or alkenyl group optionally substituted with an -OH moiety. In one embodiment, R26 is a branched C3-C15 alkyl or alkenyl group. In one embodiment, R26 is a branched C7-C11 alkyl or alkenyl group. In one embodiment, R26 is a branched Cs alkyl or alkenyl group. In one embodiment, R26 is a branched Cs alkyl group.

[00188] In one embodiment, the third lipid is a sterol of Formula (Vc): (Vc), wherein R23 and R24 are each independently H or a C1-3 alkyl group; and R26 is a hydrocarbyl group optionally substituted with an -OH moiety. In one embodiment, R23 and R24 are each independently H or a methyl group. In one embodiment, R23 and R24 are each a methyl group. In one embodiment, R26 is a C3-C15 hydrocarbyl group optionally substituted with an -OH moiety. In one embodiment, R26 is a C3-C15 hydrocarbyl group. In one embodiment, R26 is a C7-C11 hydrocarbyl group. In one embodiment, R26 is an alkyl or alkenyl group optionally substituted with an -OH moiety. In one embodiment, R26 is an alkyl or alkenyl group. In one embodiment, R26 is a C3-C15 alkyl or alkenyl group optionally substituted with an -OH moiety. In one embodiment, R26 is a C3-C15 alkyl or alkenyl group. In one embodiment, R26 is a C7-C11 alkyl or alkenyl group. In one embodiment, R26 is a branched alkyl or alkenyl group optionally substituted with an -OH moiety. In one embodiment, R26 is a branched alkyl or alkenyl group. In one embodiment, R26 is a branched C3-C15 alkyl or alkenyl group optionally substituted with an -OH moiety. In one embodiment, R26 is a branched C3-C15 alkyl or alkenyl group. In one embodiment, R26 is a branched C7-C11 alkyl or alkenyl group. In one embodiment, R26 is a branched Cs alkyl or alkenyl group. In one embodiment, R26 is a branched Cs alkyl group. In one embodiment, R26 is a branched C10 alkyl group. In one embodiment, R26 is a branched Cs alkenyl group. In one embodiment, R26 is a branched C10 alkenyl group.

[00189] In one embodiment, the third lipid is a sterol selected from the group consisting of cholesterol, cycloartenol, sitosterol, stigmasterol, ergosterol, lanosterol, campesterol, fecosterol, brassicasterol, tomatidine, tomatine, ursolic acid and alpha-tocopherol. In one embodiment, the third lipid is cholesterol. In one embodiment, the third lipid is sitosterol. In one embodiment, the third lipid is stigmasterol.

[00190] In one embodiment, the third lipid is a hopanoid of Formula (VI): (VI), or a stereoisomer or mixture of stereoisomers thereof; wherein R27 is a group comprising an oxygen, nitrogen, or sulfur-containing moiety capable of being conjugated to the peptide; and R28, R29, R30, R31, R32, R33, and R34 are each independently H or a C1-3 alkyl group. In one embodiment, R28, R29, R30, R31, R32, R33, and R34 are each independently H or a methyl group. In one embodiment, R34 is H. In one embodiment, R32 and R33 are each a methyl group. In one embodiment, R28, R29, R30, R31, R32, and R33 are each a methyl group. In one embodiment, R28, R29, R30, R31, R32, and R33 are each a methyl group, and R34 is H. In one embodiment, R27 is a group comprising an oxygencontaining moiety capable of being conjugated to the peptide. In one embodiment, R27 is a hydrocarbyl group substituted with an oxygen-containing moiety capable of being conjugated to the peptide, and optionally further substituted with one or more -OH moieties. In one embodiment, R27 is a C2-C15 hydrocarbyl group substituted with an oxygen-containing moiety capable of being conjugated to the peptide, and optionally further substituted with one or more -OH moieties. In one embodiment, R27 is a C2-C15 alkyl group substituted with an oxygen-containing moiety capable of being conjugated to the peptide, and optionally further substituted with one or more -OH moieties. In one embodiment, R27 is a C2 alkyl group substituted with an oxygen-containing moiety capable of being conjugated to the peptide. In one embodiment, R27 is a C3 alkyl group substituted with an oxygen-containing moiety capable of being conjugated to the peptide. In one embodiment, R27 is a Cs alkyl group substituted with an oxygen-containing moiety capable of being conjugated to the peptide. In one embodiment, R27 is a Cs alkyl group substituted with an oxygen-containing moiety capable of being conjugated to the peptide, and further substituted with one, two, three, four, or five -OH moieties.

[00191] In one embodiment, the third lipid is a hopanoid of Formula (Via): (Via), wherein R27 is a group comprising an oxygen, nitrogen, or sulfur-containing moiety capable of being conjugated to the peptide; and R28, R29, R30, R31, R32, R33, and R34 are each independently H or a C1-3 alkyl group. In one embodiment, R28, R29, R30, R31, R32, R33, and R34 are each independently H or a methyl group. In one embodiment, R34 is H. In one embodiment, R32 and R33 are each a methyl group. In one embodiment, R28, R29, R30, R31, R32, and R33 are each a methyl group. In one embodiment, R28, R29, R30, R31, R32, and R33 are each a methyl group, and R34 is H. In one embodiment, R27 is a group comprising an oxygen-containing moiety capable of being conjugated to the peptide. In one embodiment, R27 is a hydrocarbyl group substituted with an oxygen-containing moiety capable of being conjugated to the peptide, and optionally further substituted with one or more -OH moieties. In one embodiment, R27 is a C2-C15 hydrocarbyl group substituted with an oxygen-containing moiety capable of being conjugated to the peptide, and optionally further substituted with one or more -OH moieties. In one embodiment, R27 is a C2-C15 alkyl group substituted with an oxygen-containing moiety capable of being conjugated to the peptide, and optionally further substituted with one or more -OH moieties. In one embodiment, R27 is a C2 alkyl group substituted with an oxygen-containing moiety capable of being conjugated to the peptide. In one embodiment, R27 is a C3 alkyl group substituted with an oxygen-containing moiety capable of being conjugated to the peptide. In one embodiment, R27 is a Cs alkyl group substituted with an oxygen-containing moiety capable of being conjugated to the peptide. In one embodiment, R27 is a Cs alkyl group substituted with an oxygen-containing moiety capable of being conjugated to the peptide, and further substituted with one, two, three, four, or five -OH moieties. In one embodiment, the third lipid is a hopanoid selected from the group consisting of diploptene, diplopterol, aminobacteriohopanetriol, bacteriohopanetriol, 2-methyl bacteriohopanetriol, aminobacteriohopanetriol, bacteriohopanetetrol, 2Me-aminobacteriohopanetriol, adenosylhopane, and 2Me-bacteriohopanetetrol. (c) Fatty Acids

[00192] In one embodiment, the third lipid is a fatty acid compound. In one embodiment, the fatty acid comprises a C10 to C26 hydrocarbyl tail group. In one embodiment, the fatty acid comprises a Ci6 to C20 hydrocarbyl tail group. In one embodiment, the fatty acid is selected from the group consisting of decanoic acid (capric acid), undecanoic acid (undecylic acid), dodecanoic acid (lauric acid), tridecanoic acid (tridecylic acid), tetradecanoic acid (myristic acid), pentadecanoic acid, hexadecanoic acid (palmitic acid), heptadecanoic acid (margaric acid), octadecanoic acid (stearic acid), nonadecanoic acid (nonadecylic acid), eicosanoic acid (arachidic acid, icosanoic acid), heneicosanoic acid (heneicosylic acid), docosanoic acid (behenic acid), tricosanoic acid, tetracosanoic acid (lignoceric acid), pentacosanoic acid, pentacosanoic acid (cerotic acid), and (Z)-octadec-9-en-17-ynoic acid (oleic acid). In one embodiment, the fatty acid is hexadecanoic acid (palmitic acid), heptadecanoic acid (margaric acid), octadecanoic acid (stearic acid), nonadecanoic acid (nonadecylic acid), eicosanoic acid (arachidic acid, icosanoic acid), or (Z)-octadec-9-en-17-ynoic acid (oleic acid).

[00193] In certain embodiments, the nanoparticle comprises a third lipid capable of being conjugated to a peptide according to Section 5.2.5 comprising a T cell epitope. Without wishing to be bound by theory, in certain embodiments, the third lipid is an anchor lipid. 5.2.5 Peptide

[00194] In certain embodiments, the nanoparticle comprises a peptide comprising a T cell epitope. Without wishing to be bound by theory, at least one epitope needs to be capable of being presented by cells of the subject to which the nanoparticles are to be administrated. In some embodiments, the peptide comprises several T cell epitopes which enable it to be presented in a plurality of Major Histocompatibility Complex (MHC) types. Methods for identifying T cell epitopes and selected T cell epitopes are well known in the art and described for example in the publications of Rammensee et al., 1999 (Immunogenetics 50 213-219) and Sanchez-Trincado et al. 2017 (J Immunol Res. 2017:2680160. doi: 10.1155 / 2017 / 2680160. Epub 2017 Dec 28). In one embodiment, the peptide comprises an MHC Class I or MHC Class II epitope and / or has an amino acid sequence comprising between 6 and 60 amino acids. In one embodiment, the peptide comprises an MHC Class I or MHC Class II epitope and / or has an amino acid sequence comprising between 9 and 60 amino acids. In one embodiment, the MHC Class I or MHC Class II epitope is a human MHC Class I or MHC Class II epitope.

[00195] Also without wishing to be bound by theory, as the regulatory T cells are predominantly CD4+, presentation on MHC class II is of particular interest. The HLA type of this subject, e.g., a human subject, can be tested as part of the selection of epitopes. Epitopes of a specific peptide which can be presented on specific MHC molecules are known and / or can routinely be selected, e.g., by appropriate software.

[00196] In some embodiments, peptides are designed based on published data to make sure that they - in association with the specified HLA restriction element - bind MHC / HLA with high affinity and profoundly stimulate and activate T cells. Without wishing to be bound by theory, peptides of choice are inferred from naturally processed peptides and characterized as immunodominant.

[00197] In some embodiments, the peptide is synthesized, recombinantly expressed, or isolated or modified from natural sources. In some embodiments, the peptide and / or the epitope against which regulatory T cells are to be generated is derived from a peptide or protein against which an inflammatory immune response is to be suppressed, e.g., in the context of treatment or prevention of an autoimmune disease or an allergy. In some embodiments, the peptide is an allergen or a known autoimmune antigen, or a fragment or derivative thereof. In some embodiments, the peptide comprises epitopes from various antigens. In one embodiment, the peptide is a peptide described in WO 2013072051, WO 2021 / 165227, WO 2022 / 253950, or WO 2023021098, each of which is incorporated herein in its entirety. In one embodiment, the peptide comprises an epitope of an antigen listed in the following table. In one embodiment, the peptide comprises an amino acid sequence listed in the following table. In one embodiment, the nanoparticle comprises one or more peptides from the following table. In one embodiment, the nanoparticle is covalently linked to one or more peptides from the following table. Disease Model / Indications Antigen Sequence Position Sequence Celiac Disease gliadin al+a2 RRQLQPFPQPELPYPQPE (SEQ ID NO: 1) Celiac Disease gliadin ol+o2 RRQQPFPQPEQPFPWQP (SEQ ID NO: 2) Celiac Disease gliadin var g5+ hordein 3 RRLPEQPIPEQPQPYPQ (SEQ ID NO: 3) Pemphigus Vulgaris Desmoglein-3 (Dsg3_b) 190-204 LNSKIAFKIVSQEPA (SEQ ID NO: 4) Pemphigus Vulgaris Desmoglein-3 (Dsg3_c) 206-220 TPMFLLSRNTGEVRT (SEQ ID NO: 5) Pemphigus Vulgaris Desmoglein-3 (Dsg3_d) 254-268 NIKVKDVNDNFPMFR (SEQ ID NO: 6) Pemphigus Vulgaris Desmoglein-3 (Dsg3_e) 379-393 REGIAFRPASKTFTV (SEQ ID NO: 6) Celiac Disease gliadin al RRSGEGSFQPSQENPQ (SEQ ID NO: 8) Celiac Disease gliadin yla RRQTEQPQQPFPQPQ (SEQ ID NO: 9) Celiac Disease gliadin ylb RRFPEQPQQPYPEQPQ (SEQ ID NO: 10) Celiac Disease glutenin RRGQQGYYPTSPQQSG (SEQ ID NO: 11) Celiac Disease gliadin a RRNPQAQGSVQPQQLPQFEEIRN (SEQ ID NO: 12) Celiac Disease DQ2.2-glut-L-l OOPPFSEOEQPVLPO (SEQ ID NO: Disease Model / Indications Antigen Sequence Position Sequence peptide 13) Celiac Disease DQ2.2-glia-al NPQAQGSVQPQELPQF (SEQ ID NO: 14) Celiac Disease DQ2.2-glia-a2 PQSQPQYSQPEQPIS (SEQ ID NO: 15) Primary Biliary Cholangitis pyruvate dehydrogenase complex (PDC-E2), CD4 163-176 GDLLAEIETDKATI (SEQ ID NO: 16) Primary Biliary Cholangitis pyruvate dehydrogenase complex (PDC-E2), CD8 159-167 IGAIICITV (SEQ ID NO: 17) Primary Bihary Cholangitis pyruvate dehydrogenase complex (PDC-E2), CD4 145-159 MAKILVAEGTRDVPI (SEQ ID NO: 18) Primary Bihary Cholangitis pyruvate dehydrogenase complex (PDC-E2), CD4 249-263 DLLAEIETDKATIG (SEQ ID NO: 19) Primary Bihary Cholangitis pyruvate dehydrogenase complex (PDC-E2), CD4 629-643 AQWLAEFRKYLEKPI (SEQ ID NO: 20) Multiple Sclerosis Myelin Basic Protein (huMBP) 13-32 EKASTNSETNRGESEKKRNL (SEQ ID NO: 21) Multiple Sclerosis Myelin Basic Protein 83-99 ADPGSRPHLIRLFSRDA (SEQ ID NO: 22) Disease Model / Indications Antigen Sequence Position Sequence (huMBP) Multiple Sclerosis Myelin Basic Protein (huMBP) 111-129 PSESDELQTIQEDSAATSE (SEQ ID NO: 23) Multiple Sclerosis Myelin Basic Protein (huMBP) 146-170 SKYLATASTMDHARHGFLPRHRDT G (SEQ ID NO: 24) Multiple Sclerosis Myelin Oligodendrocyt e Glycoprotein (huMOG) 1-20 MASLSRPSLPSCLCSFLLLL (SEQ ID NO: 25) Multiple Sclerosis Myelin Oligodendrocyt e Glycoprotein (huMOG) 35-55 IGPRHPIRALVGDEVELPCRI (SEQ ID NO: 26) Multiple Sclerosis Proteolipid protein (huPLP) 139-154 CHCLGKWLGHPDKFVG (SEQ ID NO: 27) Rheumatoid Arthritis Collagen II 259-273 GIAGFKGEQGPKGEB (SEQ ID NO: 28) Type 1 Diabetes Insulin (CD 8) 2-11 ALWMRLLPLL (SEQ ID NO: 29) Type 1 Diabetes Insulin (CD 8) 15-24 ALWGPDPAAA (SEQ ID NO: 30) Type 1 Diabetes Insulin (CD 8) 34-42 HLVEALYLV (SEQ ID NO: 31) Type 1 Diabetes GAD65 (CD4) 115-127 MNILLQYVVKSFD (SEQ ID NO: 32) Type 1 Diabetes GAD65 (CD4) 274-286 IAFTSEHSHFSLK (SEQ ID NO: 33) Type 1 Diabetes Insulin (CD4) 33-47 SHLVEALYLVCGERG (SEQ ID NO: 34) Type 1 Diabetes Pro insulin Cl 9- A3 75-92 GSLQPLALEGSLQKRGIV (SEQ ID NO: 35) Type 1 Diabetes GAD 524-543 SRLSKVAPVIKARMMEYGTT (SEQ ID NO: 36) Disease Model / Indications Antigen Sequence Position Sequence Type 1 Diabetes GAD 260-279 PEVKEKGMAALPRLIAFTSE (SEQ ID NO: 37) Type 1 Diabetes GAD 398-420 MGVPLQCSALLVREEGLMQNCNQ (SEQ ID NO: 38) Type 1 Diabetes IAPP 46-60 ANFLVHSSNNFGAIL (SEQ ID NO: 39) Type 1 Diabetes IAPP 19-33 HLKATPIESHQVEKR (SEQ ID NO: 40) Neuromyelitis Optica Aquaporin 4 61-80 GTEKPLPVDMVLISLCFGLS (SEQ ID NO: 41) Neuromyelitis Optica Aquaporin 4 156-170 AGHGLLVELIITFQL (SEQ ID NO: 42) Neuromyelitis Optica Aquaporin 4 21-40 NIMVAFKGVWTQAFWKAVTA (SEQ ID NO: 43) Uveitis human S-Ag 341-352 FLGELTSSEVATEV (SEQ ID NO: 44) Narcolepsy Hypocretin 53-67 LHGAGNHAAGILTL (SEQ ID NO: 45) Narcolepsy Hypocretin 85-97 QASGNHAAGILTM (SEQ ID NO: 46) Thrombotic Thrombocytopenic Purpura ADAMTS13 1324-1339 QGCRLFINVAPHARIA (SEQ ID NO: 47) Goodpasture's Syndrom Type IV collagen a3 chain non-collagenous domain 1 69-88 VNDVCNFASRNDYSYWLSTPA (SEQ ID NO: 48) Goodpasture's Syndrom Type IV collagen a3 chain non-collagenous 129-148 IPPCPHGWISLWKGFSFIMF (SEQ ID NO: 49) Disease Model / Indications Antigen Sequence Position Sequence domain 1 Celiac Disease gliadin al+a2 QLQPFPQPELPYPQPE (SEQ ID NO: 50) Celiac Disease gliadin ol+o2 QQPFPQPEQPFPWQP (SEQ ID NO: 51) Celiac Disease gliadin var g5+ hordein 3 LPEQPIPEQPQPYPQ (SEQ ID NO: 52) Type 1 Diabetes Proinsulin p24 33 FFYTPMSRRE (SEQ ID NO: 53) Type 1 Diabetes IGRP206-214 VYLKTNVFL (SEQ ID NO: 54) Type 1 Diabetes 2.5HIP (fused ChgA peptide) DLQTLALWSRMDQLAK (SEQ ID NO: 55) Type 1 Diabetes 6.9HIP (fused IAPP2) DLQTLALNAARDPNR (SEQ ID NO: 56) Multiple Sclerosis mMOG (35-55) MEVGWYRSPFSRVVHLYRNGK (SEQ ID NO: 57) Type 1 Diabetes INS B24-C4 FFYTPKTRREAED (SEQ ID NO: 58) Type 1 Diabetes IGRP226-238 RVLNIDLLWSVPI (SEQ ID NO: 59) Type 1 Diabetes ChgA only (not fused with C peptide) WSKMDQLAKELTAE (SEQ ID NO: 60) Type 1 Diabetes C-pep:IAPP2 GQVELGGGNAVEVLK_(SEQ ID NO: 61)

[00198] In one embodiment, the peptide is associated with the outside of the nanoparticle. In one embodiment, the peptide is encapsulated within the nanoparticle. In one embodiment, the peptide is non-covalently associated with the amphiphilic polymer, and / or the first lipid, and / or the second lipid, and / or the third lipid. In one embodiment, the peptide is non-covalently associated with the amphiphilic polymer. In one embodiment, the peptide is non-covalently associated with the first lipid. In one embodiment, the peptide is non-covalently associated with the second lipid. In one embodiment, the peptide is non-covalently associated with the third lipid.

[00199] In one embodiment, the peptide is covalently linked to the amphiphilic polymer, and / or the second lipid, and / or the third lipid. In one embodiment, the peptide is covalently linked to the amphiphilic polymer. Without wishing to be bound by theory, in one embodiment, the peptide is covalently linked to amphiphilic polymer via formation of an amide bond between the N-terminus of the peptide and a carboxylate group of the amphiphilic polymer. In one embodiment, the peptide is covalently linked to the second lipid. In one embodiment, the peptide is covalently linked to the third lipid. Without wishing to be bound by theory, in one embodiment, the peptide is covalently linked to the second lipid or the third lipid via formation of an amide or ester bond between the C-terminus of the peptide and an amine or alcohol group of the second or third lipid. In one embodiment, the peptide is covalently linked to the amphiphilic polymer, the second lipid, or the third lipid. In one embodiment, the peptide is covalently linked to the covalently linked to the amphiphilic polymer, and / or the second lipid, and / or the third lipid using a method of covalently coupling peptides known in the art. Without wishing to be bound by theory, known methods of covalently coupling peptides include carbodiimide or succinimide coupling. In one embodiment, the peptide is covalently linked to the micelles using l-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) chemistry or any other peptide coupling reagents. See, for example, Jaradat et al., Advances in solid-phase peptide synthesis in aqueous media (ASPPS) ((Critical Review) Green Chem., 2022, 24, 6360-6372); Albericio et al., Choosing the Right Coupling Reagent for Peptides: A Twenty-Five-Year Journey, Org. Process Res. Dev. 2018, 22, 7, 760-772. In one embodiment, the peptide is covalently linked to a lipid in a lipid-peptide conjugate. Without wishing to be bound by theory, in one embodiment, the peptide is covalently linked to the lipid of a lipid-peptide conjugate via formation of an amide or ester bond between the C-terminus of the peptide and an amine or alcohol group of the second or third lipid.

[00200] In one embodiment, the peptide comprises an amino acid sequence of a whole protein. In one embodiment, the peptide comprises a portion of an amino acid sequence of a whole protein. In one embodiment, the peptide comprises two or more different peptides linked to each other as a fusion polypeptide. In one embodiment, the peptide comprises between about 8 and 2,000 amino acids. In one embodiment, the peptide comprises between about 8 and 200 amino acids. In one embodiment, the peptide comprises between about 8 and 100 amino acids. In one embodiment, the peptide comprises between about 9 and 60 amino acids. In one embodiment, the peptide comprises between about 10 and 20 amino acids.

[00201] In one embodiment, the nanoparticle comprises more than one peptide. In one embodiment, the nanoparticle comprises only one type of peptide, e.g. peptides having the same amino acid sequence. In one embodiment, only one type of peptide, e.g. peptides having the same amino acid sequence, is associated with the nanoparticle. In one embodiment, only one type of peptide, e.g. peptides having the same amino acid sequence, is covalently linked to the nanoparticle. In other embodiments, the nanoparticle comprises two or more different types of peptides, e.g. peptides having different amino acid sequences. In some embodiments, two or more different types of peptides, e.g. peptides having different amino acid sequences, are associated with or covalently linked to the nanoparticle. 5.2.6 Lipid-Peptide Conjugate

[00202] In certain embodiments, the nanoparticle comprises a lipid-peptide conjugate, wherein the lipid-peptide conjugate comprises a peptide according to Section 5.2.5 covalently linked a lipid. In one embodiment, the lipid of the lipid-peptide conjugate comprises a polar head group and a nonpolar tail group. In one embodiment, the polar head group comprises an oxygen, nitrogen, or sulfur-containing moiety covalently linked to the peptide. In one embodiment, the non-polar tail group is a hydrocarbyl tail group. In one embodiment, the non-polar tail group is an alkyl tail group. In one embodiment, the non-polar tail group is an alkenyl tail group. In one embodiment, the non-polar tail group is a Cio to C26 tail group. In one embodiment, the non-polar tail group is a C10 to C26 alkyl tail group. In one embodiment, the non-polar tail group is a Cio to C26 alkenyl tail group. In one embodiment, the non-polar tail group is a Ci6 to C20 tail group. In one embodiment, the non-polar tail group is a Ci6 to C20 alkyl tail group. In one embodiment, the non-polar tail group is a Ci6 to C20 alkenyl tail group. In another embodiment, the non-polar tail group is a fused polycyclic hydrocarbon. In one embodiment, the lipid of the lipid-peptide conjugate is a phospholipid, a fatty acid, a sterol, or a hopanoid. Without wishing to be bound by theory, in certain embodiments, the lipid of the lipid-peptide conjugate is an anchor lipid according to Section 5.2.4. (a) Phospholipid-Peptide Conjugates

[00203] In one embodiment, the lipid of the lipid-peptide conjugate is a phospholipid covalently linked to a peptide according to Section 5.2.5. In one embodiment, the lipid of the lipid-peptide conjugate is a phospholipid comprising a polar head group and a non-polar tail group. In one embodiment, the lipid of the lipid-peptide conjugate comprises a polar head group comprising an oxygen, nitrogen, or sulfur-containing moiety covalently linked to the peptide.

[00204] In one embodiment, the lipid-peptide conjugate is a phospholipid-peptide conjugate of Formula (VII): (VII), wherein L is a linker comprising an oxygen, nitrogen, or sulfur-containing moiety; R35 is a peptide according to Section 5.2.5; and R36 and R37 are each independently a hydrocarbyl group. In one embodiment, the peptide is conjugated to the phospholipid at the N-terminus of the peptide. In another embodiment, the peptide is conjugated to the phospholipid at the C-terminus of the peptide. In one embodiment, R36 and R37 are each independently a Cio to C26 hydrocarbyl group. In one embodiment, R36 and R37 are each independently an alkyl group. In one embodiment, R36 and R37 are each independently an alkenyl group. In one embodiment, R36 and R37 are each independently a Cio to C26 alkyl group. In one embodiment, R36 and R37 are each independently a Cio to C26 alkenyl group. In one embodiment, R36 and R37 are each independently a Cie to C20 hydrocarbyl group. In one embodiment, R36 and R37 are each independently a Cie to C20 alkyl group. In one embodiment, R36 and R37 are each independently a Cie to C20 alkenyl group. In one embodiment, R36 and R37 are the same. In one embodiment, R36 and R37 are different.

[00205] In one embodiment, L is ethanolamine, serine, inositol, glycerol, or a group derived from ethanolamine, serine, inositol, glycerol. In one embodiment, the group derived from ethanolamine, serine inositol, or glyercol comprises modifications, substitutions, branching, oxidation, and / or cyclization of ethanolamine, serine, inositol, or glycerol. In one embodiment, L is ethanolamine, serine, inositol, or glycerol.

[00206] In one embodiment, the lipid-peptide conjugate comprises a peptide according to Section 5.2.5 covalently linked to a phospholipid selected from the group consisting of phosphatidylethanolamine, phosphatidylglycerol, phosphatidylserine, phosphatidylate, or phosphatidylinositol.

[00207] In one embodiment, the phospholipid is selected from the group consisting of dimyristoylphosphatidylethanolamine (DMPE), dipalmitoylphosphatidylethanolamine (DPPE), distearoyl phosphatidyl-ethanolamine (DSPE), dioleylphosphatidylethanolamine (DOPE), diarachidoylphosphatidylethanolamine (DAPE), dilinoleylphosphatidylethanolamine (DLPE), dimyristoyl phosphatidylserine (DMPS), diarachidoyl phosphatidylserine (DAPS), dipalmitoyl phosphatidylserine (DPPS), distearoylphosphatidylserine (DSPS), dioleoylphosphatidylserine (DOPS), dilauroyl-phosphatidylinositol (DLPI), diarachidoylphosphatidylinositol (DAPI), dimyristoylphosphatidylinositol (DMPI), dipalmitoylphosphatidylinositol (DPPI), distearoylphosphatidylinositol (DSPI), dioleoyl-phosphatidylinositol (DOPI), 1,2-dimyristoyl-sn-glycero-3-phosphoglycerol (DMPG), l,2-dipalmitoyl-sn-glycero-3-phosphoglycerol (DPPG), 1,2-distearoyl-sn-glycero-3-phosphoglycerol (DSPG), and 1,2-dioleoyl-sn-glycero-3-phosphoglycerol (DOPG); or a mixture thereof.

[00208] In one embodiment, the phospholipid is selected from the group consisting of 1,2-distearoyl-s / ?-glycero-3-phosphoethanolamine (DSPE), l,2-distearoyl-s / 7-glycero-3-phospho-L-serine (DSPS), l,2-distearoyl-s«-glycero-3-phosphoinositol (DSPI), and 1,2-distearoyl-sn-glycero-3-phosphoglycerol (DSPG); or a mixture thereof.

[00209] In one embodiment, the lipid-peptide conjugate comprises a peptide according to Section 5.2.5 covalently linked to a phosphatidylinositol, a phosphatidylethanolamine, a phosphatidylserine, or a phosphatidylglycerol, or a phospholipid derived from a phosphatidylinositol, a phosphatidylethanolamine, a phosphatidylserine, or a phosphatidylglycerol. In one embodiment, the lipid-peptide conjugate comprises a peptide according to Section 5.2.5 covalently linked to a phosphatidylinositol, a phosphatidylethanolamine, a phosphatidylserine, or a phosphatidylglycerol. In one embodiment, the lipid-peptide conjugate comprises a peptide according to Section 5.2.5 covalently linked to l,2-distearoyl-s«-glycero-3-phosphoinositol (DSPI), l,2-Distearoyl-s«-glycero-3-phosphoethanolamine (DSPE), l,2-distearoyl-5 / 7-glycero-3-phospho-L-serine (DSPS), or 1,2-distearoyl-sn-glycero-3 -phosphoglycerol (D SPG). (b) Fatty Acid-Peptide Conjugates

[00210] In one embodiment, the lipid of the lipid-peptide conjugate is a fatty acid covalently linked to a peptide according to Section 5.2.5. In one embodiment, the lipid-peptide conjugate is a fatty acid-peptide conjugate of formula R39-C(O)-R38, wherein R38 is a peptide according to Section 5.2.5 and R39 is a hydrocarbyl group. In one embodiment, the peptide is conjugated to the fatty acid at the N-terminus of the peptide. In one embodiment, R39 is a Cio to C26 hydrocarbyl group. In one embodiment, R39 is an alkyl group. In one embodiment, R39 is a Cio to C26 alkyl group. In one embodiment, R39 is an alkenyl group. In one embodiment, R39 is a Cio to C26 alkenyl group. In one embodiment, R39 is a Ci6 to C20 hydrocarbyl group. In one embodiment, R39 is a Ci6 to C20 alkyl group. In one embodiment, R39 is a Ci6 to C20 alkenyl group.

[00211] In one embodiment, the lipid-peptide conjugate comprises a peptide according to Section 5.2.5 covalently linked to a fatty acid selected from the group consisting of decanoic acid (capric acid), undecanoic acid (undecylic acid), dodecanoic acid (lauric acid), tridecanoic acid (tridecylic acid), tetradecanoic acid (myristic acid), pentadecanoic acid, hexadecanoic acid (palmitic acid), heptadecanoic acid (margaric acid), octadecanoic acid (stearic acid), nonadecanoic acid (nonadecylic acid), eicosanoic acid (arachidic acid, icosanoic acid), heneicosanoic acid (heneicosylic acid), docosanoic acid (behenic acid), tricosanoic acid, tetracosanoic acid (lignoceric acid), pentacosanoic acid, pentacosanoic acid (cerotic acid), and (Z)-octadec-9-en-17-ynoic acid (oleic acid). In one embodiment, the fatty acid is selected from the group consisting of hexadecanoic acid (palmitic acid), heptadecanoic acid (margaric acid), octadecanoic acid (stearic acid), nonadecanoic acid (nonadecylic acid), eicosanoic acid (arachidic acid, icosanoic acid), and (Z)-octadec-9-en-17-ynoic acid (oleic acid). (c) Polycyclic Hydrocarbon-Peptide Conjugates

[00212] In one embodiment, the lipid of the lipid-peptide conjugate is a fused polycyclic hydrocarbon substituted with an exocyclic oxygen, nitrogen, or sulfur-containing moiety covalently linked to a peptide according to Section 5.2.5. In one embodiment, the lipid of the lipid-peptide conjugate is a sterol. In another embodiment, the lipid of the lipid-peptide conjugate is a hopanoid.

[00213] In one embodiment, the lipid-peptide conjugate is a sterol-peptide conjugate of Formula (VIII): (VIII), or a stereoisomer or mixture of stereoisomers thereof; wherein R40 is a peptide according to Section 5.2.5; R41, R42, R43, R44, and R45 are each independently H or a C1-3 alkyl group; R46 is a hydrocarbyl group optionally substituted with an -OH moiety; and the dashed bonds are each independently single or double bonds. In one embodiment, the peptide is conjugated to the sterol at the C-terminus of the peptide. In one embodiment, R41, R42, R43, R44, and R45 are each independently H or a methyl group. In one embodiment, R46 is a C3-C15 hydrocarbyl group optionally substituted with an -OH moiety. In one embodiment, R46 is a C3-C15 hydrocarbyl group. In one embodiment, R46 is a C7-C11 hydrocarbyl group. In one embodiment, R46 is an alkyl or alkenyl group optionally substituted with an -OH moiety. In one embodiment, R46 is an alkyl or alkenyl group. In one embodiment, R46 is a C3-C15 alkyl or alkenyl group optionally substituted with an -OH moiety. In one embodiment, R46 is a C3-C15 alkyl or alkenyl group. In one embodiment, R46 is a C7-C11 alkyl or alkenyl group. In one embodiment, R46 is a branched alkyl or alkenyl group optionally substituted with an -OH moiety. In one embodiment, R46 is a branched alkyl or alkenyl group. In one embodiment, R46 is a branched C3-C15 alkyl or alkenyl group optionally substituted with an -OH moiety. In one embodiment, R46 is a branched C3-C15 alkyl or alkenyl group. In one embodiment, R46 is a branched C7-C11 alkyl or alkenyl group. In one embodiment, the B ring comprises six endocyclic single bonds and no endocyclic double bonds. In one embodiment, the B ring comprises five endocyclic single bonds and one endocyclic double bond. In one embodiment, the B ring comprises four endocyclic single bonds and two endocyclic double bonds.

[00214] In one embodiment, the lipid-peptide conjugate is a sterol-peptide conjugate of Formula (Villa): (Villa), or a stereoisomer or mixture of stereoisomers thereof; wherein R40 is a peptide according to Section 5.2.5; R43 and R44 are each independently H or a C1-3 alkyl group; R46 is a hydrocarbyl group optionally substituted with an -OH moiety; and the dashed bonds are each independently single or double bonds. In one embodiment, R43 and R44 are each independently H or a methyl group. In one embodiment, R43 and R44 are each a methyl group. In one embodiment, R46 is a C3-C15 hydrocarbyl group optionally substituted with an -OH moiety. In one embodiment, R46 is a C3-C15 hydrocarbyl group. In one embodiment, R46 is a C7-C11 hydrocarbyl group. In one embodiment, R46 is an alkyl or alkenyl group optionally substituted with an -OH moiety. In one embodiment, R46 is an alkyl or alkenyl group. In one embodiment, R46 is a C3-C15 alkyl or alkenyl group optionally substituted with an -OH moiety. In one embodiment, R46 is a C3-C15 alkyl or alkenyl group. In one embodiment, R46 is a C7-C11 alkyl or alkenyl group. In one embodiment, R46 is a branched alkyl or alkenyl group optionally substituted with an -OH moiety. In one embodiment, R46 is a branched alkyl or alkenyl group. In one embodiment, R46 is a branched C3-C15 alkyl or alkenyl group optionally substituted with an -OH moiety. In one embodiment, R46 is a branched C3-C15 alkyl or alkenyl group. In one embodiment, R46 is a branched C7-C11 alkyl or alkenyl group. In one embodiment, R46 is a branched Cs alkyl or alkenyl group. In one embodiment, R46 is a branched Cs alkyl group. In one embodiment, the B ring comprises six endocyclic single bonds. In one embodiment, the B ring comprises five endocyclic single bonds and one endocyclic double bond. In one embodiment, the B ring comprises four endocyclic single bonds and two endocyclic double bonds.

[00215] In one embodiment, the lipid-peptide conjugate is a sterol-peptide conjugate of Formula (VHIb): (VHIb), or a stereoisomer or mixture of stereoisomers thereof; wherein R40 is a peptide according to Section 5.2.5; R43 and R44 are each independently H or a C1-3 alkyl group; and R46 is a hydrocarbyl group optionally substituted with an -OH moiety. In one embodiment, R43 and R44 are each independently H or a methyl group. In one embodiment, R43 and R44 are each a methyl group. In one embodiment, R46 is a C3-C15 hydrocarbyl group optionally substituted with an -OH moiety. In one embodiment, R46 is a C3-C15 hydrocarbyl group. In one embodiment, R46 is a C7-C11 hydrocarbyl group. In one embodiment, R46 is an alkyl or alkenyl group optionally substituted with an -OH moiety. In one embodiment, R46 is an alkyl or alkenyl group. In one embodiment, R46 is a C3-C15 alkyl or alkenyl group optionally substituted with an -OH moiety. In one embodiment, R46 is a C3-C15 alkyl or alkenyl group. In one embodiment, R46 is a C7-C11 alkyl or alkenyl group. In one embodiment, R46 is a branched alkyl or alkenyl group optionally substituted with an -OH moiety. In one embodiment, R46 is a branched alkyl or alkenyl group. In one embodiment, R46 is a branched C3-C15 alkyl or alkenyl group optionally substituted with an -OH moiety. In one embodiment, R46 is a branched C3-C15 alkyl or alkenyl group. In one embodiment, R46 is a branched C7-C11 alkyl or alkenyl group. In one embodiment, R46 is a branched Cs alkyl or alkenyl group. In one embodiment, R46 is a branched Cs alkyl group.

[00216] In one embodiment, the lipid-peptide conjugate is a sterol-peptide conjugate of Formula (Vine): (VIIIc), wherein R40 is a peptide according to Section 5.2.5; R43 and R44 are each independently H or a C1-3 alkyl group; and R46 is a hydrocarbyl group optionally substituted with an -OH moiety. In one embodiment, R43 and R44 are each independently H or a methyl group. In one embodiment, R43 and R44 are each a methyl group. In one embodiment, R46 is a C3-C15 hydrocarbyl group optionally substituted with an -OH moiety. In one embodiment, R46 is a C3-C15 hydrocarbyl group. In one embodiment, R46 is a C7-C11 hydrocarbyl group. In one embodiment, R46 is an alkyl or alkenyl group optionally substituted with an -OH moiety. In one embodiment, R46 is an alkyl or alkenyl group. In one embodiment, R46 is a C3-C15 alkyl or alkenyl group optionally substituted with an -OH moiety. In one embodiment, R46 is a C3-C15 alkyl or alkenyl group. In one embodiment, R46 is a C7-C11 alkyl or alkenyl group. In one embodiment, R46 is a branched alkyl or alkenyl group optionally substituted with an -OH moiety. In one embodiment, R46 is a branched alkyl or alkenyl group. In one embodiment, R46 is a branched C3-C15 alkyl or alkenyl group optionally substituted with an -OH moiety. In one embodiment, R46 is a branched C3-C15 alkyl or alkenyl group. In one embodiment, R46 is a branched C7-C11 alkyl or alkenyl group. In one embodiment, R46 is a branched Cs alkyl or alkenyl group. In one embodiment, R46 is a branched Cs alkyl group. In one embodiment, R46 is a branched Cs alkenyl group. In one embodiment, R46 is a branched C10 alkyl group. In one embodiment, R46 is a branched C10 alkenyl group.

[00217] In one embodiment, the lipid-peptide conjugate comprises a peptide according to Section 5.2.5 covalently linked to a sterol selected from the group consisting of cholesterol, cycloartenol, sitosterol, stigmasterol, ergosterol, lanosterol, campesterol, fecosterol, brassicasterol, tomatidine, tomatine, ursolic acid and alpha-tocopherol.

[00218] In one embodiment, the lipid-peptide conjugate comprises a peptide according to Section 5.2.5 covalently linked to cholesterol. In one embodiment, the lipid-peptide conjugate comprises a peptide according to Section 5.2.5 covalently linked to sitosterol. In one embodiment, the lipid-peptide conjugate comprises a peptide according to Section 5.2.5 covalently linked to stigmasterol.

[00219] In one embodiment, the lipid-peptide conjugate is a hopanoid-peptide conjugate of Formula (IX): (IX), or a stereoisomer or mixture of stereoisomers thereof; wherein R47 is a peptide according to Section 5.2.5; R48, R49, R50, R51, R52, R53, and R54 are each independently H or a C1-3 alkyl group; L is a linker comprising an oxygen, nitrogen, or sulfur-containing moiety covalently linked to the peptide. In one embodiment, the peptide is conjugated to the hopanoid at the C-terminus of the peptide. In one embodiment, R48, R49, R50, R51, R52, R54, and R54 are each independently H or a methyl group. In one embodiment, R54 is H. In one embodiment, R52 and R53 are each a methyl group. In one embodiment, R48, R49, R50, R51, R52, and R53 are each a methyl group. In one embodiment, R48, R49, R50, R51, R52, and R53 are each a methyl group, and R34 is H. In one embodiment, L is a linker comprising an oxygen-containing moiety covalently linked to the peptide. In one embodiment, L is a hydrocarbyl linker substituted with an oxygen-containing moiety covalently linked to the peptide, and optionally further substituted with one or more -OH moieties. In one embodiment, L is a C2-C15 hydrocarbyl linker substituted with an oxygen-containing moiety covalently linked to the peptide, and optionally further substituted with one or more -OH moieties. In one embodiment, L is a C2-C15 alkyl linker substituted with an oxygen-containing moiety covalently linked to the peptide, and optionally further substituted with one or more -OH moieties. In one embodiment, L is a C2 alkyl linker substituted with an oxygen-containing moiety covalently linked to the peptide. In one embodiment, L is a C3 alkyl linker substituted with an oxygen-containing moiety covalently linked to the peptide. In one embodiment, L is a Cs alkyl linker substituted with an oxygen-containing moiety covalently linked to the peptide. In one embodiment, L is a Cs alkyl linker substituted with an oxygen-containing moiety covalently linked to the peptide, and further substituted with one, two, three, four, or five -OH moieties.

[00220] In one embodiment, the lipid-peptide conjugate is a hopanoid-peptide conjugate of Formula (IXa): (IXa), or a stereoisomer or mixture of stereoisomers thereof; wherein R47 is a peptide according to Section 5.2.5; R48, R49, R50, R51, R52, R53, and R54 are each independently H or a C1-3 alkyl group; L is a linker comprising an oxygen, nitrogen, or sulfur-containing moiety covalently linked to the peptide. In one embodiment, R48, R49, R50, R51, R52, R54, and R54 are each independently H or a methyl group. In one embodiment, R54 is H. In one embodiment, R52 and R53 are each a methyl group. In one embodiment, R48, R49, R50, R51, R52, and R53 are each a methyl group. In one embodiment, R48, r49, rso rsi R52 anj ^53 are eacj1 a jnejhyi group, and R34 is H. In one embodiment, L is a linker comprising an oxygen-containing moiety covalently linked to the peptide. In one embodiment, L is a hydrocarbyl linker substituted with an oxygen-containing moiety covalently linked to the peptide, and optionally further substituted with one or more -OH moieties. In one embodiment, L is a C2-C15 hydrocarbyl linker substituted with an oxygen-containing moiety covalently linked to the peptide, and optionally further substituted with one or more -OH moieties. In one embodiment, L is a C2-C15 alkyl linker substituted with an oxygen-containing moiety covalently linked to the peptide, and optionally further substituted with one or more -OH moieties. In one embodiment, L is a C2 alkyl linker substituted with an oxygen-containing moiety covalently linked to the peptide. In one embodiment, L is a C3 alkyl linker substituted with an oxygen-containing moiety covalently linked to the peptide. In one embodiment, L is a Cs alkyl linker substituted with an oxygen-containing moiety covalently linked to the peptide. In one embodiment, L is a Cs alkyl linker substituted with an oxygen-containing moiety covalently linked to the peptide, and further substituted with one, two, three, four, or five -OH moieties.

[00221] In one embodiment, the lipid-peptide conjugate comprises a peptide according to Section 5.2.5 covalently linked to a hopanoid selected from the group consisting of diploptene, diplopterol, aminobacteriohopanetriol, bacteriohopanetriol, 2-methyl bacteriohopanetriol, aminobacteriohopanetriol, bacteriohopanetetrol, 2Me-aminobacteriohopanetriol, adenosylhopane, and 2Me-bacteriohopanetetrol. 5.2.7 Composition of Nanoparticles

[00222] In certain embodiments, the nanoparticle comprises only one type of lipid (e.g. a first lipid described herein, such as DSPC). In certain embodiments, the total lipid content of the nanoparticle consists at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% of one type of lipid (e.g. a first lipid described herein, such as DSPC). In certain embodiments, the nanoparticle comprises only one type of a first lipid described herein (e.g. a phosphatidylcholine, such as DSPC). In certain embodiments, the total lipid content of the nanoparticle consists at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% of one type of a first lipid described herein (e.g. a phosphatidylcholine, such as DSPC). In certain embodiments, the nanoparticle comprises only two types of lipids (e.g. a first lipid described herein, such as DSPC, and a second lipid described herein, such as cholesterol). In certain embodiments, the total lipid content of the nanoparticle consists at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% of two types of lipid (e.g. a first lipid described herein, such as DSPC, and a second lipid described herein, such as cholesterol). In certain embodiments, the nanoparticle comprises only one type of a first lipid described herein (e.g. a phosphatidylcholine, such as DSPC) and only one type of a second lipid described herein (e.g. a sterol, such as cholesterol). In certain embodiments, the total lipid content of the nanoparticle consists at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% of one type of a first lipid described herein (e.g. a phosphatidylcholine, such as DSPC) and one type of a second lipid described herein (e.g. a sterol, such as cholesterol). In certain embodiments, the nanoparticle comprises only one type of a first lipid described herein and only one type of a third lipid described herein. In certain embodiments, the total lipid content of the nanoparticle consists at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% of one type of a first lipid described herein and one type of a third lipid described herein. In certain embodiments, the nanoparticle comprises only one type of a first lipid described herein and only one type of a lipid-peptide conjugate described herein. In certain embodiments, the total lipid content of the nanoparticle consists at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% of one type of a first lipid described herein and one type of a lipid-peptide conjugate described herein. In certain embodiments, the nanoparticle comprises only three types of lipids. In certain embodiments, the total lipid content of the nanoparticle consists at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% of three types of lipids. In certain embodiments, the nanoparticles comprises only one type of a first lipid described herein, only one type of a second lipid described herein, and only one type of a third lipid described herein. In certain embodiments, the total lipid content of the nanoparticle consists at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% of one type of a first lipid described herein, one type of a second lipid described herein, and one type of a third lipid described herein. In certain embodiments, the nanoparticle comprises only one type of a first lipid described herein, only one type of a second lipid described herein, and only one type of a lipid-peptide conjugate described herein. In certain embodiments, the total lipid content of the nanoparticle consists at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% of one type of a first lipid described herein, one type of a second lipid described herein, and one type of a lipid-peptide conjugate described herein. In certain embodiments, the nanoparticle comprises a phosphatidylcholine and a sterol. In certain embodiments, the nanoparticle comprises DSPC and cholesterol.

[00223] In certain embodiments, the nanoparticle provided herein comprises between about 10 and 40 mol of the building block of the amphiphilic polymer per mol of the first lipid. In one embodiment, the nanoparticle comprises between about 15 and 35 mol of the building block of the amphiphilic polymer per mol of the first lipid. In one embodiment, the nanoparticle comprises between about 20 and 25 mol of the building block of the amphiphilic polymer per mol of the first lipid. In one embodiment, the nanoparticle comprises between about 22 and 24 mol of the building block of the amphiphilic polymer per mol of the first lipid. In one embodiment, the nanoparticle comprises between about 23.0 and 23.5 mol of the building block of the amphiphilic polymer per mol of the first lipid. In one embodiment, the nanoparticle comprises about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29, about 30, about 31, about 32, about 33, about 34, or about 35 mol of the building block of the amphiphilic polymer per mol of the first lipid. In one embodiment, the nanoparticle comprises about 20, about 21, about 22, about 23, about 24, or about 25 mol of the building block of the amphiphilic polymer per mol of the first lipid. In one embodiment, the nanoparticle comprises about 20.0, about 20.1, about 20.2, about 20.3, about 20.4, about 20.5, about 20.6, about 20.7, about 20.8, about 20.9, about 21.0, about 21.1, about 21.2, about 21.3, about 21.4, about21.5, about21.6, about21.7, about21.8, about21.9, about22.0, about22.1, about22.2, about 22.3, about 22.4, about 22.5, about 22.6, about 22.7, about 22.8, about 22.9, about 23.0, about 23.1, about 23.2, about 23.3, about 23.4, about 23.5, about 23.6, about 23.7, about 23.8, about 23.9, about 24.0, about 24.1, about 24.2, about 24.3, about 24.4, about 24.5, about 24.6, about 24.7, about 24.8, about 24.9, or about 25 mol of the building block of the amphiphilic polymer per mol of the first lipid. In one embodiment, the nanoparticle comprises about 22.0, about 22.1, about 22.2, about 22.3, about 22.4, about 22.5, about 22.6, about 22.7, about 22.8, about 22.9, about 23.0, about 23.1, about 23.2, about 23.3, about 23.4, about 23.5, about 23.6, about 23.7, about 23.8, about 23.9, or about 24.0 of the building block of the amphiphilic polymer per mol of the first lipid. In one embodiment, the nanoparticle comprises about 23.0, about 23.1, about 23.2, about 23.3, about 23.4, or about 23.5 of the building block of the amphiphilic polymer per mol of the first lipid. In one embodiment, the nanoparticle comprises about 23.0 of the building block of the amphiphilic polymer per mol of the first lipid. In one embodiment, the nanoparticle comprises about 23.1 of the building block of the amphiphilic polymer per mol of the first lipid. In one embodiment, the nanoparticle comprises about 23.2 of the building block of the amphiphilic polymer per mol of the first lipid. In one embodiment, the nanoparticle comprises about 23.3 of the building block of the amphiphilic polymer per mol of the first lipid. In one embodiment, the nanoparticle comprises about 23.4 of the building block of the amphiphilic polymer per mol of the first lipid. In one embodiment, the nanoparticle comprises about 23.5 of the building block of the amphiphilic polymer per mol of the first lipid. In one embodiment, the building block is: wherein R is a hydrocarbyl group or a substituted hydrocarbyl group. In one embodiment, R is a linear, unsubstituted hydrocarbyl group. In one embodiment, R is a C4 to C30 alkyl group. In one embodiment, R is a linear, unsubstituted C4 to C30 alkyl group. In one embodiment, R is a C7 to C19 alkyl group. In one embodiment, R is a linear, unsubstituted C?to C19 alkyl group. In one embodiment, R is a Cgto C17 alkyl group. In one embodiment, R is a linear, unsubstituted Cyto C17 alkyl group. In one embodiment, R is a C15 alkyl group. In some embodiments, R is a C15 alkyl group.

[00224] In a preferred embodiment, the nanoparticle comprises about 23.2 of the building block of the amphiphilic polymer per mol of the first lipid. In a preferred embodiment, the nanoparticle comprises about 23.2 of the building block of the amphiphilic polymer per mol of the first lipid; and R is a C15 alkyl group.

[00225] In certain embodiments, the nanoparticle provided herein comprises the first lipid and the amphiphilic polymer in a ratio of between about 0.01:1 (w / w) and 1:1 (w / w), between about 0.05:1 (w / w) and 1:1 (w / w), between about 0.01:1 (w / w) and 0.5:1 (w / w), between about 0.05:1 (w / w) and 0.5:1 (w / w), between about 0.01:1 (w / w) and 0.4:1 (w / w), between about 0.05:1 (w / w) and 0.4:1 (w / w), between about 0.01:1 (w / w) and 0.3:1 (w / w), between about 0.05:1 (w / w) and 0.3:1 (w / w), between about 0.01:1 (w / w) and 0.2:1 (w / w), between about 0.05:1 (w / w) and 0.2:1 (w / w), between about 0.01:1 (w / w) and 0.15:1 (w / w), or between about 0.05:1 (w / w) and 0.15:1 (w / w) of first lipid to amphiphilic polymer. In one embodiment, the nanoparticle comprises the first lipid and the amphiphilic polymer in a ratio of between about 0.01:1 (w / w) and 0.2:1 (w / w), between about 0.05:1 (w / w) and 0.2:1 (w / w), between about 0.01:1 (w / w) and 0.15:1 (w / w), or between about 0.05:1 (w / w) and 0.15:1 (w / w) of first lipid to amphiphilic polymer. In one embodiment, the nanoparticle comprises the first lipid and the amphiphilic polymer in a ratio of between about 0.05:1 (w / w) and 0.15:1 (w / w) of first lipid to amphiphilic polymer. In one embodiment, the nanoparticle comprises the first lipid and the amphiphilic polymer in a ratio of between about 0.08:1 (w / w) and 0.10:1 (w / w) of first lipid to amphiphilic polymer. In one embodiment, the nanoparticle comprises the first lipid and the amphiphilic polymer in a ratio of about 0.01:1 (w / w), about 0.02:1 (w / w), about 0.03:1 (w / w), about 0.04:1 (w / w), about 0.05:1 (w / w), about 0.06:1 (w / w), about 0.07:1 (w / w), about 0.08:1 (w / w), about 0.09:1 (w / w), about 0.10:1 (w / w), about0.11:l (w / w), about0.12:l (w / w), about0.13:l (w / w), about0.14:l (w / w), about 0.15:1 (w / w), about 0.16:1 (w / w), about 0.17:1 (w / w), about 0.18:1 (w / w), about 0.19:1 (w / w), or about 0.20:1 (w / w) of first lipid to amphiphilic polymer. In one embodiment, the nanoparticle comprises the first lipid and the amphiphilic polymer in a ratio of about 0.08:1 (w / w), about 0.09:1 (w / w), or about 0.10:1 (w / w) of first lipid to amphiphilic polymer. In one embodiment, the nanoparticle comprises the first lipid and the amphiphilic polymer in a ratio of about 0.08:1 (w / w) of first lipid to amphiphilic polymer. In one embodiment, the nanoparticle comprises the first lipid and the amphiphilic polymer in a ratio of about 0.09:1 (w / w) of first lipid to amphiphilic polymer. In one embodiment, the nanoparticle comprises the first lipid and the amphiphilic polymer in a ratio of about 0.10:1 (w / w) of first lipid to amphiphilic polymer.

[00226] In certain embodiments, the nanoparticle provided herein comprises the first lipid and the amphiphilic polymer in a ratio of between about 0.05:1 (mol / mol) and 1:1 (mol / mol), between about 0.1:1 (mol / mol) and 1:1 (mol / mol), between about 0.05:1 (mol / mol) and 0.9:1 (mol / mol), between about 0.1:1 (mol / mol) and 0.9:1 (mol / mol), between about 0.05:1 (mol / mol) and 0.8:1 (mol / mol), between about 0.1:1 (mol / mol) and 0.8:1 (mol / mol), between about 0.05:1 (mol / mol) and 0.7:1 (mol / mol), between about 0.1:1 (mol / mol) and 0.7:1 (mol / mol), between about 0.05:1 (mol / mol) and 0.6:1 (mol / mol), between about 0.1:1 (mol / mol) and 0.6:1 (mol / mol), between about 0.05:1 (mol / mol) and 0.5:1 (mol / mol), between about 0.1:1 (mol / mol) and 0.5:1 (mol / mol), between about 0.2:1 (mol / mol) and 0.5:1 (mol / mol), between about 0.3:1 (mol / mol) and 0.5:1 (mol / mol), or between about 0.3:1 (mol / mol) and 0.4:1 (mol / mol) of first lipid to amphiphilic polymer. In one embodiment, the nanoparticle comprises the first lipid and the amphiphilic polymer in a ratio of between about 0.3:1 (mol / mol) and 0.7:1 (mol / mol) of the first lipid to amphiphilic polymer. In one embodiment, the nanoparticle comprises the first lipid and the amphiphilic polymer in a ratio of between about 0.25:1 (mol / mol) and 0.45:1 (mol / mol) of the first lipid to amphiphilic polymer. In one embodiment, the nanoparticle comprises the first lipid and the amphiphilic polymer in a ratio of between about 0.30:1 (mol / mol) and 0.40:1 (mol / mol) of first lipid to amphiphilic polymer. In one embodiment, the nanoparticle comprises the first lipid and the amphiphilic polymer in a ratio of about 0.25:1 (mol / mol), 0.26:1 (mol / mol), 0.27:1 (mol / mol), 0.28:1 (mol / mol), 0.30:1 (mol / mol), 0.31:1 (mol / mol), 0.32:1 (mol / mol), 0.33:1 (mol / mol), 0.34:1 (mol / mol), 0.35:1 (mol / mol), 0.36:1 (mol / mol), 0.37:1 (mol / mol), 0.38:1 (mol / mol), 0.39:1 (mol / mol), 0.40:1 (mol / mol), 0.41:1 (mol / mol), 0.42:1 (mol / mol), 0.43:1 (mol / mol), 0.44:1 (mol / mol), or 0.45:1 (mol / mol) of first lipid to amphiphilic polymer. In one embodiment, the nanoparticle comprises the first lipid and the amphiphilic polymer in a ratio of 0.30:1 (mol / mol), 0.31:1 (mol / mol), 0.32:1 (mol / mol), 0.33:1 (mol / mol), 0.34:1 (mol / mol), 0.35:1 (mol / mol), 0.36:1 (mol / mol), 0.37:1 (mol / mol), 0.38:1 (mol / mol), 0.39:1 (mol / mol), or 0.40:1 (mol / mol) of first lipid to amphiphilic polymer. In one embodiment, the nanoparticle comprises the first lipid and the amphiphilic polymer in a ratio of about 0.35:1 (mol / mol) of first lipid to amphiphilic polymer. In one embodiment, the nanoparticle comprises the first lipid and the amphiphilic polymer in a ratio of about 0.4:1 (mol / mol) of first lipid to amphiphilic polymer. In one embodiment, the nanoparticle comprises the first lipid and the amphiphilic polymer in a ratio of about 0.6:1 (mol / mol) of first lipid to amphiphilic polymer.

[00227] In certain embodiments, the nanoparticle provided herein comprises the amphiphilic polymer in an amount of about 50-95% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises the amphiphilic polymer in an amount of about 50-90% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises the amphiphilic polymer in an amount of about 50-85% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises the amphiphilic polymer in an amount of about 65-75% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises the amphiphilic polymer in an amount of about 75-85% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises the amphiphilic polymer in an amount of about 85-95% by weight of the total weight of the nanoparticle.

[00228] In certain embodiments, the nanoparticle provided herein comprises the amphiphilic polymer in an amount of about 50-95% by weight of the total weight of the nanoparticle and the first lipid in an amount of about 4-10% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises the amphiphilic polymer in an amount of about 50-85% by weight of the total weight of the nanoparticle and the first lipid in an amount of about 4-10% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle and the first lipid in an amount of about 4-10% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises the amphiphilic polymer in an amount of about 60-70% by weight of the total weight of the nanoparticle and the first lipid in an amount of about 6-8% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle and the first lipid in an amount of about 4-6% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises the amphiphilic polymer in an amount of about 65-75% by weight of the total weight of the nanoparticle and the first lipid in an amount of about 5-7% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises the amphiphilic polymer in an amount of about 75-85% by weight of the total weight of the nanoparticle and the first lipid in an amount of about 6-8% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises the amphiphilic polymer in an amount of about 85-95% by weight of the total weight of the nanoparticle and the first lipid in an amount of about 6-10% by weight of the total weight of the nanoparticle.

[00229] In certain embodiments, the nanoparticle provided herein comprises the second lipid in an amount of about 20-50% by weight of the total weight of the nanoparticle. In one embodiment, the nanoparticle comprises the second lipid in an amount of about 20-35% by weight of the total weight of the nanoparticle. In one embodiment, the nanoparticle comprises the second lipid in an amount of about 22-32% by weight of the total weight of the nanoparticle. In one embodiment, the nanoparticle comprises the second lipid in an amount of about 25-30% by weight of the total weight of the nanoparticle. In one embodiment, the nanoparticle comprises the second lipid in an amount of about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, or about 35% by weight of the total weight of the nanoparticle. In one embodiment, the nanoparticle comprises the second lipid in an amount of about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, or about 32% by weight of the total weight of the nanoparticle. In one embodiment, the nanoparticle comprises the second lipid in an amount of about 25%, about 26%, about 27%, about 28%, about 29%, or about 30% by weight of the total weight of the nanoparticle. In one embodiment, the nanoparticle comprises the second lipid in an amount of about 25% by weight of the total weight of the nanoparticle. In one embodiment, the nanoparticle comprises the second lipid in an amount of about 26% by weight of the total weight of the nanoparticle. In one embodiment, the nanoparticle comprises the second lipid in an amount of about 27% by weight of the total weight of the nanoparticle. In one embodiment, the nanoparticle comprises the second lipid in an amount of about 28% by weight of the total weight of the nanoparticle. In one embodiment, the nanoparticle comprises the second lipid in an amount of about 29% by weight of the total weight of the nanoparticle. In one embodiment, the nanoparticle comprises the second lipid in an amount of about 30% by weight of the total weight of the nanoparticle.

[00230] In certain embodiments, the nanoparticle provided herein comprises a combined amount of the first lipid and the amphiphilic polymer of between about 2:1 to about 3:1 by weight (w / w) relative to the amount of the second lipid. In certain embodiments, the nanoparticle provided herein comprises a combined amount of the first lipid and the amphiphilic polymer of about 2.0:1, about 2.1:1, about 2.2:1, about 2.3:1, about 2.4:1, about 2.5:1, about 2.6:1, about 2.7:1, about 2.8:1, about 2.9:1, or about 3.0:1 by weight (w / w) relative to the amount of the second lipid. In one embodiment, the nanoparticle comprises a combined amount of the first lipid and the amphiphilic polymer of about 2.3:1 or 2.4:1 by weight (w / w) to relative to the amount of the second lipid. In one embodiment, the nanoparticle comprises a combined amount of the first lipid and the amphiphilic polymer of about 7:3 by weight (w / w) to relative to the amount of the second lipid.

[00231] In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 50-85% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-10% by weight of the total weight of the nanoparticle; and (iii) the second lipid in an amount of about 22-32% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the nanoparticle; and (iii) the second lipid in an amount of about 22-32% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the nanoparticle; and (iii) the second lipid in an amount of about 22-32% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the nanoparticle; and (iii) the second lipid in an amount of about 2530% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the nanoparticle; and (iii) the second lipid in an amount of about 25-30% by weight of the total weight of the nanoparticle.

[00232] In a preferred embodiment, the nanoparticle comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the nanoparticle; and (iii) the second lipid in an amount of about 25-30% by weight of the total weight of the nanoparticle. In another preferred embodiment, the nanoparticle comprises: (i) the amphiphilic polymer in an amount of about 5565% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the nanoparticle; and (iii) the second lipid in an amount of about 2530% by weight of the total weight of the nanoparticle.

[00233] In certain embodiments, the nanoparticle provided herein comprises the third lipid in an amount of about 1 -3 mol% of all components of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises the third lipid in an amount of about 1.5-2.5 mol% of all components of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises the third lipid in an amount of about 1.5%, about 1.6%, about 1.7%, about 1.8%, about 1.9%, about 2.0%, about 2.1%, about 2.2%, about 2.3%, about 2.4%, or about 2.5 mol% of all components of the nanoparticle. In one embodiment, the nanoparticle comprises the third lipid in amount of about 2 mol% of all components of the nanoparticle.

[00234] In certain embodiments, the nanoparticle provided herein comprises the second lipid and the third lipid in amounts that combined are about 20-50% by weight of the total weight of the nanoparticle. In one embodiment, the nanoparticle comprises the second lipid and the third lipid in amounts that combined are about 20-35% by weight of the total weight of the nanoparticle.

[00235] In certain embodiments, the nanoparticle provided herein comprises the lipid-peptide conjugate in an amount of about 5-20% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises the lipid-peptide conjugate in an amount of about 8-16% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises the lipid-peptide conjugate in an amount of about 10-15% by weight of the total weight of the nanoparticle. In one embodiment, the nanoparticle comprises the lipid-peptide conjugate in an amount of about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, or about 20% by weight of the total weight of the nanoparticle. In one embodiment, the nanoparticle comprises the lipid-peptide conjugate in an amount of about 8%, about 9%, about 10%, about 11%, or about 12%, about 13%, about 14%, about 15%, or about 16% by weight of the total weight of the nanoparticle. In one embodiment, the nanoparticle comprises the lipid-peptide conjugate in an amount of about 10% by weight of the total weight of the nanoparticle. In one embodiment, the nanoparticle comprises the lipid-peptide conjugate in an amount of about 11% by weight of the total weight of the nanoparticle. In one embodiment, the nanoparticle comprises the lipid-peptide conjugate in an amount of about 12% by weight of the total weight of the nanoparticle. In one embodiment, the nanoparticle comprises the lipid-peptide conjugate in an amount of about 13% by weight of the total weight of the nanoparticle. In one embodiment, the nanoparticle comprises the lipid-peptide conjugate in an amount of about 14% by weight of the total weight of the nanoparticle. In one embodiment, the nanoparticle comprises the lipid-peptide conjugate in an amount of about 15% by weight of the total weight of the nanoparticle.

[00236] In certain embodiments, the nanoparticle provided herein comprises the lipid-peptide conjugate in an amount of about 1-3 mol% of all components of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises the lipid-peptide conjugate in an amount of about 1.5-2.5 mol% of all components of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises the lipid-peptide conjugate in an amount of about 1.5, about 1.6%, about 1.7%, about 1.8%, about 1.9%, about 2.0%, about 2.1%, about 2.2%, about 2.3%, about 2.4%, or about 2.5 mol% of all components of the nanoparticle. In one embodiment, the nanoparticle comprises the lipid-peptide conjugate in an amount of about 2 mol% of all components of the nanoparticle.

[00237] In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 50-90% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-10% by weight of the total weight of the nanoparticle; and (iii) the lipid-peptide conjugate in an amount of about 5-20% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 50-85% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-10% by weight of the total weight of the nanoparticle; and (iii) the lipid-peptide conjugate in an amount of about 5-20% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the nanoparticle; and (iii) the lipid-peptide conjugate in an amount of about 8-16% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the nanoparticle; and (iii) the lipid-peptide conjugate in an amount of about 8-16% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the nanoparticle; and (iii) the lipid-peptide conjugate in an amount of about 10-15% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the nanoparticle; and (iii) the lipid-peptide conjugate in an amount of about 10-15% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 65-75% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 5-7% by weight of the total weight of the nanoparticle; and (iii) the lipid-peptide conjugate in an amount of about 8-16% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 65-75% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 5-7% by weight of the total weight of the nanoparticle; and (iii) the lipid-peptide conjugate in an amount of about 10-15% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 75-85% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 6-8% by weight of the total weight of the nanoparticle; and (iii) the lipid-peptide conjugate in an amount of about 8-16% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 75-85% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 6-8% by weight of the total weight of the nanoparticle; and (iii) the lipid-peptide conjugate in an amount of about 10-15% by weight of the total weight of the nanoparticle.

[00238] In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 50-90% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-10% by weight of the total weight of the nanoparticle; and (iii) the lipid-peptide conjugate in an amount of about 1-3 mol% of all components of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 50-85% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-10% by weight of the total weight of the nanoparticle; and (iii) the lipid-peptide conjugate in an amount of about 1-3 mol% of all components of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the nanoparticle; and (iii) the lipid-peptide conjugate in an amount of about 1-3 mol% of all components of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the nanoparticle; and (iii) the lipid-peptide conjugate in an amount of about 1-3 mol% of all components of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the nanoparticle; and (iii) the lipid-peptide conjugate in an amount of about 1.5-2.5 mol% of all components of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the nanoparticle; and (iii) the lipid-peptide conjugate in an amount of about 1.5-2.5 mol% of all components of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 65-75% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 5-7% by weight of the total weight of the nanoparticle; and (iii) the lipid-peptide conjugate in an amount of about 1-3 mol% of all components of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 65-75% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 5-7% by weight of the total weight of the nanoparticle; and (iii) the lipid-peptide conjugate in an amount of about 1.5-2.5 mol% of all components of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 75-85% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 6-8% by weight of the total weight of the nanoparticle; and (iii) the lipid-peptide conjugate in an amount of about 1-3 mol% of all components of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 75-85% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 6-8% by weight of the total weight of the nanoparticle; and (iii) the lipid-peptide conjugate in an amount of about 1.5-2.5 mol% of all components of the nanoparticle.

[00239] In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 50-85% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-10% by weight of the total weight of the nanoparticle; (iii) the second lipid in an amount of about 22-32% by weight of the total weight of the nanoparticle; and (iv) the lipid-peptide conjugate in an amount of about 5-20% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the nanoparticle; (iii) the second lipid in an amount of about 22-32% by weight of the total weight of the nanoparticle; and (iv) the lipid-peptide conjugate in an amount of about 5-20% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the nanoparticle; (iii) the second lipid in an amount of about 22-32% by weight of the total weight of the nanoparticle; and (iv) the lipid-peptide conjugate in an amount of about 5-20% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the nanoparticle; (iii) the second lipid in an amount of about 22-32% by weight of the total weight of the nanoparticle; and (iv) the lipid-peptide conjugate in an amount of about 8-16% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the nanoparticle; (iii) the second lipid in an amount of about 22-32% by weight of the total weight of the nanoparticle; and (iv) the lipid-peptide conjugate in an amount of about 8-16% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the nanoparticle; (iii) the second lipid in an amount of about 22-32% by weight of the total weight of the nanoparticle; and (iv) the lipid-peptide conjugate in an amount of about 10-15% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the nanoparticle; (iii) the second lipid in an amount of about 22-32% by weight of the total weight of the nanoparticle; and (iv) the lipid-peptide conjugate in an amount of about 10-15% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the nanoparticle; (iii) the second lipid in an amount of about 25-30% by weight of the total weight of the nanoparticle; and (iv) the lipid-peptide conjugate in an amount of about 5-20% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the nanoparticle; (iii) the second lipid in an amount of about 25-30% by weight of the total weight of the nanoparticle; and (iv) the lipid-peptide conjugate in an amount of about 5-20% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the nanoparticle; (iii) the second lipid in an amount of about 25-30% by weight of the total weight of the nanoparticle; and (iv) the lipid-peptide conjugate in an amount of about 8-16% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the nanoparticle; (iii) the second lipid in an amount of about 25-30% by weight of the total weight of the nanoparticle; and (iv) the lipid-peptide conjugate in an amount of about 8-16% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the nanoparticle; (iii) the second lipid in an amount of about 25-30% by weight of the total weight of the nanoparticle; and (iv) the lipid-peptide conjugate in an amount of about 10-15% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the nanoparticle; (iii) the second lipid in an amount of about 25-30% by weight of the total weight of the nanoparticle; and (iv) the lipid-peptide conjugate in an amount of about 10-15% by weight of the total weight of the nanoparticle.

[00240] In one preferred embodiment, the nanoparticle comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the nanoparticle; (iii) the second lipid in an amount of about 25-30% by weight of the total weight of the nanoparticle; and (iv) the lipid-peptide conjugate in an amount of about 10-15% by weight of the total weight of the nanoparticle. In another preferred embodiment, the nanoparticle comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the nanoparticle; (iii) the second lipid in an amount of about 25-30% by weight of the total weight of the nanoparticle; and (iv) the lipid-peptide conjugate in an amount of about 10-15% by weight of the total weight of the nanoparticle.

[00241] In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 50-85% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-10% by weight of the total weight of the nanoparticle; (iii) the second lipid in an amount of about 22-32% by weight of the total weight of the nanoparticle; and (iv) the lipid-peptide conjugate in an amount of about 1-3 mol% of all components of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the nanoparticle; (iii) the second lipid in an amount of about 22-32% by weight of the total weight of the nanoparticle; and (iv) the lipid-peptide conjugate in an amount of about 1-3 mol% of all components of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the nanoparticle; (iii) the second lipid in an amount of about 22-32% by weight of the total weight of the nanoparticle; and (iv) the lipid-peptide conjugate in an amount of about 1-3 mol% of all components of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the nanoparticle; (iii) the second lipid in an amount of about 22-32% by weight of the total weight of the nanoparticle; and (iv) the lipid-peptide conjugate in an amount of about 1.5-2.5 mol% of all components of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the nanoparticle; (iii) the second lipid in an amount of about 22-32% by weight of the total weight of the nanoparticle; and (iv) the lipid-peptide conjugate in an amount of about 1.5-2.5 mol% of all components of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the nanoparticle; (iii) the second lipid in an amount of about 25-30% by weight of the total weight of the nanoparticle; and (iv) the lipid-peptide conjugate in an amount of about 1-3 mol% of all components of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the nanoparticle; (iii) the second lipid in an amount of about 25-30% by weight of the total weight of the nanoparticle; and (iv) the lipid-peptide conjugate in an amount of about 1-3 mol% of all components of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the nanoparticle; (iii) the second lipid in an amount of about 25-30% by weight of the total weight of the nanoparticle; and (iv) the lipid-peptide conjugate in an amount of about 1.5-2.5 mol% of all components of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the nanoparticle; (iii) the second lipid in an amount of about 25-30% by weight of the total weight of the nanoparticle; and (iv) the lipid-peptide conjugate in an amount of about 1.5-2.5 mol% of all components of the nanoparticle.

[00242] In one preferred embodiment, the nanoparticle comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the nanoparticle; (iii) the second lipid in an amount of about 25-30% by weight of the total weight of the nanoparticle; and (iv) the lipid-peptide conjugate in an amount of about 1.5-2.5 mol% of all components of the nanoparticle. In another preferred embodiment, the nanoparticle comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the nanoparticle; (iii) the second lipid in an amount of about 25-30% by weight of the total weight of the nanoparticle; and (iv) the lipid-peptide conjugate in an amount of about 1.5-2.5 mol% of all components of the nanoparticle.

[00243] In certain embodiments, the nanoparticle provided herein comprises the peptide in an amount of about 5-15% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises the peptide in an amount of about 8-12% by weight of the total weight of the nanoparticle. In one embodiment, the nanoparticle comprises the peptide in an amount of about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, or about 15% by weight of the total weight of the nanoparticle. In one embodiment, the nanoparticle comprises the peptide in an amount of about 8%, about 9%, about 10%, about 11%, or about 12% by weight of the total weight of the nanoparticle. In one embodiment, the nanoparticle comprises the peptide in an amount of about 8% by weight of the total weight of the nanoparticle. In one embodiment, the nanoparticle comprises the peptide in an amount of about 9% by weight of the total weight of the nanoparticle. In one embodiment, the nanoparticle comprises the peptide in an amount of about 10% by weight of the total weight of the nanoparticle. In one embodiment, the nanoparticle comprises the peptide in an amount of about 11% by weight of the total weight of the nanoparticle. In one embodiment, the nanoparticle comprises the peptide in an amount of about 12% by weight of the total weight of the nanoparticle.

[00244] In certain embodiments, the nanoparticle provided herein comprises the peptide in an amount of about 1 -3 mol% of all components of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises the peptide in an amount of about 1.5-2.5 mol% of all components of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises the peptide in an amount of about 1.5%, about 1.6%, about 1.7%, about 1.8%, about 1.9%, about 2.0%, about 2.1%, about 2.2%, about 2.3%, about 2.4%, or about 2.5 mol% of all components of the nanoparticle. In one embodiment, the nanoparticle comprises the peptide in an amount of about 2 mol% of all components of the nanoparticle.

[00245] In certain embodiments, the nanoparticle provided herein comprises the peptide and the amphiphilic polymer in a ratio of between about 0.03:1 (w / w) and 0.25:1 (w / w) of peptide to amphiphilic polymer. In certain embodiments, the nanoparticle provided herein comprises the peptide and the amphiphilic polymer in a ratio of between about 0.05:1 (w / w) and 0.20:1 (w / w) of peptide to amphiphilic polymer.

[00246] In certain embodiments, the nanoparticle provided herein comprises the peptide and the amphiphilic polymer in a ratio of between about 0.03:1 (mol / mol) and 0.25:1 (mol / mol) of peptide to amphiphilic polymer. In certain embodiments, the nanoparticle provided herein comprises the peptide and the amphiphilic polymer in a ratio of between about 0.05:1 (mol / mol) and 0.20:1 (mol / mol) of peptide to amphiphilic polymer.

[00247] In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 50-90% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-10% by weight of the total weight of the nanoparticle; and (iii) the peptide in an amount of about 5-15% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 50-85% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-10% by weight of the total weight of the nanoparticle; and (iii) the peptide in an amount of about 5-15% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 5565% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the nanoparticle; and (iii) the peptide in an amount of about 5-15% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the nanoparticle; and (iii) the peptide in an amount of about 5-15% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the nanoparticle; and (iii) the peptide in an amount of about 8-12% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the nanoparticle; and (iii) the peptide in an amount of about 8-12% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 65-75% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 5-7% by weight of the total weight of the nanoparticle; and (iii) the peptide in an amount of about 5-15% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 65-75% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 5-7% by weight of the total weight of the nanoparticle; and (iii) the peptide in an amount of about 8-12% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 75-85% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 6-8% by weight of the total weight of the nanoparticle; and (iii) the peptide in an amount of about 5-15% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 75-85% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 6-8% by weight of the total weight of the nanoparticle; and (iii) the peptide in an amount of about 8-12% by weight of the total weight of the nanoparticle.

[00248] In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 50-90% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-10% by weight of the total weight of the nanoparticle; and (iii) the peptide in an amount of about 1-3 mol% of all components of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 50-85% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-10% by weight of the total weight of the nanoparticle; and (iii) the peptide in an amount of about 1-3 mol% of all components of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the nanoparticle; and (iii) the peptide in an amount of about 1-3 mol% of all components of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the nanoparticle; and (iii) the peptide in an amount of about 1-3 mol% of all components of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the nanoparticle; and (iii) the peptide in an amount of about 1.5-2.5 mol% of all components of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the nanoparticle; and (iii) the peptide in an amount of about 1.5-2.5 mol% of all components of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 65-75% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 5-7% by weight of the total weight of the nanoparticle; and (iii) the peptide in an amount of about 1-3 mol% of all components of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 65-75% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 5-7% by weight of the total weight of the nanoparticle; and (iii) the peptide in an amount of about 1.5-2.5 mol% of all components of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 75-85% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 6-8% by weight of the total weight of the nanoparticle; and (iii) the peptide in an amount of about 1-3 mol% of all components of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 75-85% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 6-8% by weight of the total weight of the nanoparticle; and (iii) the peptide in an amount of about 1.5-2.5 mol% of all components of the nanoparticle.

[00249] In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 50-85% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-10% by weight of the total weight of the nanoparticle; (iii) the second lipid in an amount of about 22-32% by weight of the total weight of the nanoparticle; (iv) the peptide in an amount of about 5-15% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the nanoparticle; (iii) the second lipid in an amount of about 22-32% by weight of the total weight of the nanoparticle; and (iv) the peptide in an amount of about 5-15% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 5565% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the nanoparticle; (iii) the second lipid in an amount of about 2232% by weight of the total weight of the nanoparticle; and (iv) the peptide in an amount of about 515% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the nanoparticle; (iii) the second lipid in an amount of about 22-32% by weight of the total weight of the nanoparticle; and (iv) the peptide in an amount of about 8-12% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the nanoparticle; (iii) the second lipid in an amount of about 22-32% by weight of the total weight of the nanoparticle; and (iv) the peptide in an amount of about 8-12% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the nanoparticle; (iii) the second lipid in an amount of about 25-30% by weight of the total weight of the nanoparticle; and (iv) the peptide in an amount of about 5-15% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the nanoparticle; (iii) the second lipid in an amount of about 25-30% by weight of the total weight of the nanoparticle; and (iv) the peptide in an amount of about 5-15% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the nanoparticle; (iii) the second lipid in an amount of about 25-30% by weight of the total weight of the nanoparticle; and (iv) the peptide in an amount of about 8-12% by weight of the total weight of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the nanoparticle; (iii) the second lipid in an amount of about 25-30% by weight of the total weight of the nanoparticle; and (iv) the peptide in an amount of about 8-12% by weight of the total weight of the nanoparticle.

[00250] In one preferred embodiment, the nanoparticle comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the nanoparticle; (iii) the second lipid in an amount of about 25-30% by weight of the total weight of the nanoparticle; and (iv) the peptide in an amount of about 8-12% by weight of the total weight of the nanoparticle. In another preferred embodiment, the nanoparticle comprises: (i) the amphiphilic polymer in an amount of about 5565% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the nanoparticle; (iii) the second lipid in an amount of about 2530% by weight of the total weight of the nanoparticle; and (iv) the peptide in an amount of about 812% by weight of the total weight of the nanoparticle.

[00251] In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 50-85% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-10% by weight of the total weight of the nanoparticle; (iii) the second lipid in an amount of about 22-32% by weight of the total weight of the nanoparticle; (iv) the peptide in an amount of about 1-3 mol% of all components of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the nanoparticle; (iii) the second lipid in an amount of about 22-32% by weight of the total weight of the nanoparticle; and (iv) the peptide in an amount of about 1-3 mol% of all components of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the nanoparticle; (iii) the second lipid in an amount of about 22-32% by weight of the total weight of the nanoparticle; and (iv) the peptide in an amount of about 1-3 mol% of all components of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the nanoparticle; (iii) the second lipid in an amount of about 22-32% by weight of the total weight of the nanoparticle; and (iv) the peptide in an amount of about 1.5-2.5 mol% of all components of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the nanoparticle; (iii) the second lipid in an amount of about 22-32% by weight of the total weight of the nanoparticle; and (iv) the peptide in an amount of about 1.5-2.5 mol% of all components of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the nanoparticle; (iii) the second lipid in an amount of about 25-30% by weight of the total weight of the nanoparticle; and (iv) the peptide in an amount of about 1-3 mol% of all components of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the nanoparticle; (iii) the second lipid in an amount of about 25-30% by weight of the total weight of the nanoparticle; and (iv) the peptide in an amount of about 1-3 mol% of all components of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the nanoparticle; (iii) the second lipid in an amount of about 25-30% by weight of the total weight of the nanoparticle; and (iv) the peptide in an amount of about 1.5-2.5 mol% of all components of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the nanoparticle; (iii) the second lipid in an amount of about 25-30% by weight of the total weight of the nanoparticle; and (iv) the peptide in an amount of about 1.5-2.5 mol% of all components of the nanoparticle.

[00252] In one preferred embodiment, the nanoparticle comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the nanoparticle; (iii) the second lipid in an amount of about 25-30% by weight of the total weight of the nanoparticle; and (iv) the peptide in an amount of about 1.5-2.5 mol% of all components of the nanoparticle. In another preferred embodiment, the nanoparticle comprises: (i) the amphiphilic polymer in an amount of about 5565% by weight of the total weight of the nanoparticle; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the nanoparticle; (iii) the second lipid in an amount of about 2530% by weight of the total weight of the nanoparticle; and (iv) the peptide in an amount of about 1.5-2.5 mol% of all components of the nanoparticle.

[00253] In certain embodiments, the nanoparticle provided herein comprises: (i) the third lipid in an amount of about 1-3 mol% of all components of the nanoparticle; and (ii) the peptide in an amount of about 1 -3 mol% of all components of the nanoparticle. In certain embodiments, the nanoparticle provided herein comprises: (i) the third lipid in an amount of about 1.5-2.5 mol% of all components of the nanoparticle; and (ii) the nanoparticle provided herein comprises the peptide in an amount of about 1.5-2.5 mol% of all components of the nanoparticle. In one embodiment, the nanoparticle comprises: (i) the third lipid in amount of about 2 mol% of all components of the nanoparticle; and (ii) the peptide in an amount of about 2 mol% of all components of the nanoparticle.

[00254] In one embodiment, the composition of the nanoparticle provided in this Section is determined by standard analytical means known in the art, for example Nuclear Magnetic Resonance (NMR) or Mass Spectrometry, with or without complete or partial decomposition of the nanoparticle and separation of the individual components of the nanoparticle by chromatographic or other means. For example, the amount of peptides associated with and / or covalently linked to the nanoparticle may be determined following cleavage of the peptides from the nanoparticle, for example by hydrolysis of amide and / or ester linkages at the N- or C-terminus of peptide, respectively. In one embodiment, the composition of the nanoparticle corresponds to the average composition of a population of nanoparticles according to Section 5.3.1. In one embodiment, the composition of nanoparticle is taken to correspond to the relative proportion of components used to manufacture of the nanoparticle, for example a process of manufacture described in Section 5.4. 5.2.8 Physical Properties of Nanoparticles

[00255] In a preferred embodiment, the composition of the nanoparticle described in Section 5.2.7 is such that the nanoparticle has a hydrodynamic diameter, a zeta potential, and / or a stability as described in this Section.

[00256] In certain embodiments, the nanoparticle provided herein has a hydrodynamic diameter in the range of 10 to 100 nm as determined by Dynamic Light Scattering (DLS). In one embodiment, the nanoparticle has a hydrodynamic diameter in the range of 10 to 60 nm as determined by DLS. In one embodiment, the nanoparticle has a hydrodynamic diameter in the range of 10 to 50 nm as determined by DLS. In one embodiment, the nanoparticle has a hydrodynamic diameter in the range of 10 to 40 nm as determined by DLS. In one embodiment, the nanoparticle has a hydrodynamic diameter in the range of 10 to 30 nm as determined by DLS. In one embodiment, the nanoparticle has a hydrodynamic diameter in the range of 20 to 30 nm as determined by DLS. In certain embodiments, the nanoparticle is spherical in shape. In certain embodiments, the nanoparticle is discoidal in shape (i.e. a nanodisc). In certain embodiments, the hydrodynamic diameter of the nanoparticle is an effective hydrodynamic diameter determined by DLS (e.g. as described in Section 5.7.1).

[00257] In certain embodiments, the nanoparticle provided herein has a zeta potential between about -20 and -80 mV. In certain embodiments, the nanoparticle provided herein has a zeta potential between about -20 and -70 mV. In certain embodiments, the nanoparticle provided herein has a zeta potential between about -20 and -50 mV. In certain embodiments, the nanoparticle provided herein has a zeta potential between about -25 and -45 mV. In certain embodiments, the nanoparticle provided herein has a zeta potential between about -28 and -42 mV. In certain embodiments, the nanoparticle provided herein has a zeta potential which is less than or equal to -30 mV. In certain embodiments, the zeta potential of the nanoparticle is measured at a solution pH of 6 to 7. In certain embodiments, the zeta potential of the nanoparticle is measured using a Malvern Zetasizer Nano ZS instrument.

[00258] In certain embodiments, the nanoparticle provided herein is stable for at least 1 hour, at least 2 hours, at least 3 hours, at least 4 hours, at least 5 hours, at least 6 hours, at least 12 hours, at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, or at least 12 days at 25 °C in 25 mM sodium acetate buffer at pH about 5 as determined by Dynamic Light Scattering (DLS). In one embodiment, the stability of the nanoparticle is determined according to the Storage Stability Assay.

[00259] In certain embodiments, the nanoparticle provided herein is stable for at least 1 hour, at least 2 hours, at least 3 hours, at least 4 hours, at least 5 hours, at least 6 hours, at least 12 hours, at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, or at least 12 days at 25 °C in 25 mM MES buffer at pH about 6 as determined by Dynamic Light Scattering (DLS). In one embodiment, the stability of the nanoparticle is determined according to the Storage Stability Assay.

[00260] In certain embodiments, the nanoparticle provided herein is stable for at least 1 hour, at least 2 hours, at least 3 hours, at least 4 hours, at least 5 hours, at least 6 hours, at least 12 hours, at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, or at least 12 days at 25 °C in 0. lx PBS buffer at pH about 7 as determined by Dynamic Light Scattering (DLS). In one embodiment, the stability of the nanoparticle is determined according to the Storage Stability Assay.

[00261] In certain embodiments, the nanoparticle provided herein is stable for at least 1 hour, at least 2 hours, at least 3 hours, at least 4 hours, at least 5 hours, at least 6 hours, at least 12 hours, at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, or at least 12 days at 25 °C in 25 mM HEPES buffer at pH about 8 as determined by Dynamic Light Scattering (DLS). In one embodiment, the stability of the nanoparticle is determined according to the Storage Stability Assay.

[00262] In certain embodiments, the nanoparticle provided herein is stable for at least 1 hour, at least 2 hours, at least 3 hours, at least 4 hours, at least 5 hours, at least 6 hours, at least 12 hours, at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, or at least 12 days at 25 °C in 25 mM SBB buffer at pH about 9 as determined by Dynamic Light Scattering (DLS). In one embodiment, the stability of the nanoparticle is determined according to the Storage Stability Assay.

[00263] In certain embodiments, the nanoparticle provided herein is stable to Stress Test Assay as determined by DLS. 5.2.9 Biological Properties of Nanoparticles

[00264] In a preferred embodiment, the composition of the nanoparticle described in Section 5.2.7 is such that the nanoparticle has one or more biological property described in this Section. In a preferred embodiment, the composition of the nanoparticle described in Section 5.2.7 is such that the nanoparticle has (1) a hydrodynamic diameter, a zeta potential, and / or a stability as described in Section 5.2.8 and (2) one or more biological property as described in this Section.

[00265] In one embodiment, the nanoparticle is targeted to the liver when administered to a subject. In one embodiment, the targeting of the nanoparticle to the liver is determined by Magnetic Resonance Imaging (MRI), fluorescent imaging, or transmission electron microscopy (TEM). In one embodiment, nanoparticles described herein accumulate in the liver after administration to a subject. In one embodiment, the accumulation of the nanoparticles in the liver is determined by Magnetic Resonance Imaging (MRI), fluorescent imaging, or transmission electron microscopy (TEM).

[00266] In one embodiment, the nanoparticle is capable of being internalized by liver sinusoidal endothelial cells (LSECs) after administration to the subject or in an in vitro model. In one embodiment, the degree or efficiency of internalization of the nanoparticle by LSECs is determined according to the Internalization Assay. Without wishing to be bound by theory, nanoparticles having a composition according to 5.2.7 such that the hydrodynamic diameter of the nanoparticle is less than 30 nm are capable of being internalized by LSECs.

[00267] In one embodiment, the nanoparticle is capable of being processed after internalization by LSECs to release one or more of the peptides associated or covalently linked to the nanoparticle. In one embodiment, the nanoparticle is capable of being processed after internalization by LSECs via hydrolysis of the amide bonds covalently linking the N-termini of one or more peptides to the nanoparticle. In one embodiment, the nanoparticle is capable of being processed after internalization by LSECs via hydrolysis of the ester or amide bonds covalently linking the C-termini of one or more peptides to the nanoparticle.

[00268] In one embodiment, the nanoparticle is capable of suppressing a specific immune response. In one embodiment, the nanoparticle is capable of suppressing a specific immune response to a peptide described in 5.2.5, or to a protein comprising the amino acid sequence of a peptide described in 5.2.5.

[00269] In one embodiment, the nanoparticle is capable of treating or preventing a disease or disorder according to Section 5.6. 5.3 Populations of Nanoparticles

[00270] Also provided herein are populations of nanoparticles according to Section 5.3. In one embodiment, the population of nanoparticles is described in Section 5.3.1. In one embodiment, the population of nanoparticles has one or more physical property described in Section 5.3.2. In one embodiment, the population of nanoparticles has one or more biological property described in Section 5.3.3. In one embodiment, the composition, the physical properties, and / or the biological properties of the population of nanoparticles is determined according to an assay described in Section 5.7.

[00271] In certain embodiments, the population of nanoparticles is produced according to a process of manufacturing as described in Section 5.4.

[00272] In certain embodiments, the population is suitable for administration to a subject, and capable of tolerizing the subject to the peptide(s) conjugated to the nanoparticles of the population. In certain embodiments, the population is suitable for administration to a subject, and capable of suppressing a specific immune response in the subject. In certain embodiments, the population is suitable for administration to a subject, and capable of treating or preventing a disease or disorder in the subject. In certain embodiments, the population is suitable for transferring peptides to liver sinusoidal endothelial cells of a subject in vivo. 5.3.1 Composition of the Population of Nanoparticles

[00273] In certain embodiments, the population of nanoparticles provided herein comprises between about 10 and 40 mol of the building block of the amphiphilic polymer per mol of the first lipid. In one embodiment, the population of nanoparticles comprises between about 15 and 35 mol of the building block of the amphiphilic polymer per mol of the first lipid. In one embodiment, the population of nanoparticles comprises between about 20 and 25 mol of the building block of the amphiphilic polymer per mol of the first lipid. In one embodiment, the population of nanoparticles comprises between about 22 and 24 mol of the building block of the amphiphilic polymer per mol of the first lipid. In one embodiment, the population of nanoparticles comprises between about 23.0 and 23.5 mol of the building block of the amphiphilic polymer per mol of the first lipid. In one embodiment, the population of nanoparticles comprises about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29, about 30, about 31, about 32, about 33, about 34, or about 35 mol of the building block of the amphiphilic polymer per mol of the first lipid. In one embodiment, the population of nanoparticles comprises about 20, about 21, about 22, about 23, about 24, or about 25 mol of the building block of the amphiphilic polymer per mol of the first lipid. In one embodiment, the population of nanoparticles comprises about 20.0, about 20.1, about 20.2, about 20.3, about 20.4, about 20.5, about 20.6, about 20.7, about 20.8, about 20.9, about 21.0, about 21.1, about 21.2, about 21.3, about 21.4, about 21.5, about 21.6, about 21.7, about 21.8, about 21.9, about 22.0, about 22.1, about 22.2, about 22.3, about 22.4, about 22.5, about 22.6, about 22.7, about 22.8, about 22.9, about 23.0, about 23.1, about 23.2, about 23.3, about 23.4, about 23.5, about 23.6, about 23.7, about 23.8, about 23.9, about 24.0, about 24.1, about 24.2, about 24.3, about 24.4, about 24.5, about 24.6, about 24.7, about 24.8, about 24.9, or about 25 mol of the building block of the amphiphilic polymer per mol of the first lipid. In one embodiment, the population of nanoparticles comprises about 22.0, about 22.1, about 22.2, about 22.3, about 22.4, about 22.5, about 22.6, about 22.7, about 22.8, about 22.9, about 23.0, about 23.1, about 23.2, about 23.3, about 23.4, about 23.5, about 23.6, about 23.7, about 23.8, about 23.9, or about 24.0 of the building block of the amphiphilic polymer per mol of the first lipid. In one embodiment, the population of nanoparticles comprises about 23.0, about 23.1, about 23.2, about 23.3, about 23.4, or about 23.5 of the building block of the amphiphilic polymer per mol of the first lipid. In one embodiment, the population of nanoparticles comprises about 23.0 of the building block of the amphiphilic polymer per mol of the first lipid. In one embodiment, the population of nanoparticles comprises about 23.1 of the building block of the amphiphilic polymer per mol of the first lipid. In one embodiment, the population of nanoparticles comprises about 23.2 of the building block of the amphiphilic polymer per mol of the first lipid. In one embodiment, the population of nanoparticles comprises about 23.3 of the building block of the amphiphilic polymer per mol of the first lipid. In one embodiment, the population of nanoparticles comprises about 23.4 of the building block of the amphiphilic polymer per mol of the first lipid. In one embodiment, the population of nanoparticles comprises about 23.5 of the building block of the amphiphilic polymer per mol of the first lipid. In one embodiment, the building block is: wherein R is a hydrocarbyl group or a substituted hydrocarbyl group. In one embodiment, R is a linear, unsubstituted hydrocarbyl group. In one embodiment, R is a C4 to C30 alkyl group. In one embodiment, R is a linear, unsubstituted C4 to C30 alkyl group. In one embodiment, R is a C7 to C19 alkyl group. In one embodiment, R is a linear, unsubstituted C?to C19 alkyl group. In one embodiment, R is a Cgto C17 alkyl group. In one embodiment, R is a linear, unsubstituted Cyto C17 alkyl group. In one embodiment, R is a C15 alkyl group. In some embodiments, R is a C15 alkyl group.

[00274] In a preferred embodiment, the population of nanoparticles comprises about 23.2 of the building block of the amphiphilic polymer per mol of the first lipid. In a preferred embodiment, the population of nanoparticles comprises about 23.2 of the building block of the amphiphilic polymer per mol of the first lipid; and R is a C15 alkyl group.

[00275] In certain embodiments, the population of nanoparticles provided herein comprises the first lipid and the amphiphilic polymer in a ratio of between about 0.01:1 (w / w) and 1:1 (w / w), between about 0.05:1 (w / w) and 1:1 (w / w), between about 0.01:1 (w / w) and 0.5:1 (w / w), between about 0.05:1 (w / w) and 0.5:1 (w / w), between about 0.01:1 (w / w) and 0.4:1 (w / w), between about 0.05:1 (w / w) and 0.4:1 (w / w), between about 0.01:1 (w / w) and 0.3:1 (w / w), between about 0.05:1 (w / w) and 0.3:1 (w / w), between about 0.01:1 (w / w) and 0.2:1 (w / w), between about 0.05:1 (w / w) and 0.2:1 (w / w), between about 0.01:1 (w / w) and 0.15:1 (w / w), or between about 0.05:1 (w / w) and 0.15:1 (w / w) of first lipid to amphiphilic polymer. In one embodiment, the population of nanoparticles comprises the first lipid and the amphiphilic polymer in a ratio of between about 0.01:1 (w / w) and 0.2:1 (w / w), between about 0.05:1 (w / w) and 0.2:1 (w / w), between about 0.01:1 (w / w) and 0.15:1 (w / w), or between about 0.05:1 (w / w) and 0.15:1 (w / w) of first lipid to amphiphilic polymer. In one embodiment, the population of nanoparticles comprises the first lipid and the amphiphilic polymer in a ratio of between about 0.05:1 (w / w) and 0.15:1 (w / w) of first lipid to amphiphilic polymer. In one embodiment, the population of nanoparticles comprises the first lipid and the amphiphilic polymer in a ratio of between about 0.08:1 (w / w) and 0.10:1 (w / w) of first lipid to amphiphilic polymer. In one embodiment, the population of nanoparticles comprises the first lipid and the amphiphilic polymer in a ratio of about 0.01:1 (w / w), about 0.02:1 (w / w), about 0.03:1 (w / w), about 0.04:1 (w / w), about 0.05:1 (w / w), about 0.06:1 (w / w), about 0.07:1 (w / w), about 0.08:1 (w / w), about 0.09:1 (w / w), about 0.10:1 (w / w), about 0.11:1 (w / w), about 0.12:1 (w / w), about 0.13:1 (w / w), about 0.14:1 (w / w), about 0.15:1 (w / w), about 0.16:1 (w / w), about 0.17:1 (w / w), about 0.18:1 (w / w), about 0.19:1 (w / w), or about 0.20:1 (w / w) of first lipid to amphiphilic polymer. In one embodiment, the population of nanoparticles comprises the first lipid and the amphiphilic polymer in a ratio of about 0.08:1 (w / w), about 0.09:1 (w / w), or about 0.10:1 (w / w) of first lipid to amphiphilic polymer. In one embodiment, the population of nanoparticles comprises the first lipid and the amphiphilic polymer in a ratio of about 0.08:1 (w / w) of first lipid to amphiphilic polymer. In one embodiment, the population of nanoparticles comprises the first lipid and the amphiphilic polymer in a ratio of about 0.09:1 (w / w) of first lipid to amphiphilic polymer. In one embodiment, the population of nanoparticles comprises the first lipid and the amphiphilic polymer in a ratio of about 0.10:1 (w / w) of first lipid to amphiphilic polymer.

[00276] In certain embodiments, the population of nanoparticles provided herein comprises the first lipid and the amphiphilic polymer in a ratio of between about 0.05:1 (mol / mol) and 1:1 (mol / mol), between about 0.1:1 (mol / mol) and 1:1 (mol / mol), between about 0.05:1 (mol / mol) and 0.9:1 (mol / mol), between about 0.1:1 (mol / mol) and 0.9:1 (mol / mol), between about 0.05:1 (mol / mol) and 0.8:1 (mol / mol), between about 0.1:1 (mol / mol) and 0.8:1 (mol / mol), between about 0.05:1 (mol / mol) and 0.7:1 (mol / mol), between about 0.1:1 (mol / mol) and 0.7:1 (mol / mol), between about 0.05:1 (mol / mol) and 0.6:1 (mol / mol), between about 0.1:1 (mol / mol) and 0.6:1 (mol / mol), between about 0.05:1 (mol / mol) and 0.5:1 (mol / mol), between about 0.1:1 (mol / mol) and 0.5:1 (mol / mol), between about 0.2:1 (mol / mol) and 0.5:1 (mol / mol), between about 0.3:1 (mol / mol) and 0.5:1 (mol / mol), or between about 0.3:1 (mol / mol) and 0.4:1 (mol / mol) of first lipid to amphiphilic polymer. In one embodiment, the population of nanoparticles comprises the first lipid and the amphiphilic polymer in a ratio of between about 0.3:1 (mol / mol) and 0.7:1 (mol / mol) of the first lipid to amphiphilic polymer. In one embodiment, the population of nanoparticles comprises the first lipid and the amphiphilic polymer in a ratio of between about 0.25:1 (mol / mol) and 0.45:1 (mol / mol) of the first lipid to amphiphilic polymer. In one embodiment, the population of nanoparticles comprises the first lipid and the amphiphilic polymer in a ratio of between about 0.30:1 (mol / mol) and 0.40:1 (mol / mol) of first lipid to amphiphilic polymer. In one embodiment, the population of nanoparticles comprises the first lipid and the amphiphilic polymer in a ratio of about 0.25:1 (mol / mol), 0.26:1 (mol / mol), 0.27:1 (mol / mol), 0.28:1 (mol / mol), 0.30:1 (mol / mol), 0.31:1 (mol / mol), 0.32:1 (mol / mol), 0.33:1 (mol / mol), 0.34:1 (mol / mol), 0.35:1 (mol / mol), 0.36:1 (mol / mol), 0.37:1 (mol / mol), 0.38:1 (mol / mol), 0.39:1 (mol / mol), 0.40:1 (mol / mol), 0.41:1 (mol / mol), 0.42:1 (mol / mol), 0.43:1 (mol / mol), 0.44:1 (mol / mol), or 0.45:1 (mol / mol) of first lipid to amphiphilic polymer. In one embodiment, the population of nanoparticles comprises the first lipid and the amphiphilic polymer in a ratio of 0.30:1 (mol / mol), 0.31:1 (mol / mol), 0.32:1 (mol / mol), 0.33:1 (mol / mol), 0.34:1 (mol / mol), 0.35:1 (mol / mol), 0.36:1 (mol / mol), 0.37:1 (mol / mol), 0.38:1 (mol / mol), 0.39:1 (mol / mol), or 0.40:1 (mol / mol) of first lipid to amphiphilic polymer. In one embodiment, the population of nanoparticles comprises the first lipid and the amphiphilic polymer in a ratio of about 0.35:1 (mol / mol) of first lipid to amphiphilic polymer. In one embodiment, the population of nanoparticles comprises the first lipid and the amphiphilic polymer in a ratio of about 0.4:1 (mol / mol) of first lipid to amphiphilic polymer. In one embodiment, the population of nanoparticles comprises the first lipid and the amphiphilic polymer in a ratio of about 0.6:1 (mol / mol) of first lipid to amphiphilic polymer.

[00277] In certain embodiments, the population of nanoparticles provided herein comprises the amphiphilic polymer in an amount of about 50-95% by weight of the total weight of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises the amphiphilic polymer in an amount of about 50-90% by weight of the total weight of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises the amphiphilic polymer in an amount of about 50-85% by weight of the total weight of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises the amphiphilic polymer in an amount of about 65-75% by weight of the total weight of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises the amphiphilic polymer in an amount of about 75-85% by weight of the total weight of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises the amphiphilic polymer in an amount of about 85-95% by weight of the total weight of the population of nanoparticles.

[00278] In certain embodiments, the population of nanoparticles provided herein comprises the amphiphilic polymer in an amount of about 50-95% by weight of the total weight of the population of nanoparticles and the first lipid in an amount of about 4-10% by weight of the total weight of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises the amphiphilic polymer in an amount of about 50-85% by weight of the total weight of the population of nanoparticles and the first lipid in an amount of about 4-10% by weight of the total weight of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the population of nanoparticles and the first lipid in an amount of about 4-10% by weight of the total weight of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the population of nanoparticles and the first lipid in an amount of about 4-8% by weight of the total weight of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the population of nanoparticles and the first lipid in an amount of about 4-6% by weight of the total weight of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises the amphiphilic polymer in an amount of about 65-75% by weight of the total weight of the population of nanoparticles and the first lipid in an amount of about 5-7% by weight of the total weight of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises the amphiphilic polymer in an amount of about 75-85% by weight of the total weight of the population of nanoparticles and the first lipid in an amount of about 6-8% by weight of the total weight of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises the amphiphilic polymer in an amount of about 85-95% by weight of the total weight of the population of nanoparticles and the first lipid in an amount of about 6-10% by weight of the total weight of the population of nanoparticles.

[00279] In certain embodiments, the population of nanoparticles provided herein comprises the second lipid in an amount of about 20-50% by weight of the total weight of the population of nanoparticles. In one embodiment, the population of nanoparticles comprises the second lipid in an amount of about 20-35% by weight of the total weight of the population of nanoparticles. In one embodiment, the population of nanoparticles comprises the second lipid in an amount of about 2232% by weight of the total weight of the population of nanoparticles. In one embodiment, the population of nanoparticles comprises the second lipid in an amount of about 25-30% by weight of the total weight of the population of nanoparticles. In one embodiment, the population of nanoparticles comprises the second lipid in an amount of about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, or about 35% by weight of the total weight of the population of nanoparticles. In one embodiment, the population of nanoparticles comprises the second lipid in an amount of about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, or about 32% by weight of the total weight of the population of nanoparticles. In one embodiment, the population of nanoparticles comprises the second lipid in an amount of about 25%, about 26%, about 27%, about 28%, about 29%, or about 30% by weight of the total weight of the population of nanoparticles. In one embodiment, the population of nanoparticles comprises the second lipid in an amount of about 25% by weight of the total weight of the population of nanoparticles. In one embodiment, the population of nanoparticles comprises the second lipid in an amount of about 26% by weight of the total weight of the population of nanoparticles. In one embodiment, the population of nanoparticles comprises the second lipid in an amount of about 27% by weight of the total weight of the population of nanoparticles. In one embodiment, the population of nanoparticles comprises the second lipid in an amount of about 28% by weight of the total weight of the population of nanoparticles. In one embodiment, the population of nanoparticles comprises the second lipid in an amount of about 29% by weight of the total weight of the population of nanoparticles. In one embodiment, the population of nanoparticles comprises the second lipid in an amount of about 30% by weight of the total weight of the population of nanoparticles.

[00280] In certain embodiments, the population of nanoparticles provided herein comprises a combined amount of the first lipid and the amphiphilic polymer of between about 2:1 to about 3:1 by weight (w / w) relative to the amount of the second lipid. In certain embodiments, the population of nanoparticles provided herein comprises a combined amount of the first lipid and the amphiphilic polymer of about 2.0:1, about 2.1:1, about 2.2:1, about 2.3:1, about 2.4:1, about 2.5:1, about 2.6:1, about 2.7:1, about 2.8:1, about 2.9:1, or about 3.0:1 by weight (w / w) relative to the amount of the second lipid. In one embodiment, the population of nanoparticles comprises a combined amount of the first lipid and the amphiphilic polymer of about 2.3:1 or 2.4:1 by weight (w / w) to relative to the amount of the second lipid. In one embodiment, the population of nanoparticles comprises a combined amount of the first lipid and the amphiphilic polymer of about 7:3 by weight (w / w) to relative to the amount of the second lipid.

[00281] In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 50-85% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 4-10% by weight of the total weight of the population of nanoparticles; and (iii) the second lipid in an amount of about 22-32% by weight of the total weight of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the population of nanoparticles; and (iii) the second lipid in an amount of about 22-32% by weight of the total weight of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the population of nanoparticles; and (iii) the second lipid in an amount of about 22-32% by weight of the total weight of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the population of nanoparticles; and (iii) the second lipid in an amount of about 25-30% by weight of the total weight of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the population of nanoparticles; and (iii) the second lipid in an amount of about 25-30% by weight of the total weight of the population of nanoparticles.

[00282] In a preferred embodiment, the population of nanoparticles comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the population of nanoparticles; and (iii) the second lipid in an amount of about 25-30% by weight of the total weight of the population of nanoparticles. In another preferred embodiment, the population of nanoparticles comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the population of nanoparticles; and (iii) the second lipid in an amount of about 25-30% by weight of the total weight of the population of nanoparticles.

[00283] In certain embodiments, the population of nanoparticles provided herein comprises the third lipid in an amount of about 1-3 mol% of all components of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises the third lipid in an amount of about 1.5-2.5 mol% of all components of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises the third lipid in an amount of about 1.5%, about 1.6%, about 1.7%, about 1.8%, about 1.9%, about 2.0%, about 2.1%, about 2.2%, about 2.3%, about 2.4%, or about 2.5 mol% of all components of the population of nanoparticles. In one embodiment, the population of nanoparticles comprises the third lipid in amount of about 2 mol% of all components of the population of nanoparticles.

[00284] In certain embodiments, the population of nanoparticles provided herein comprises the second lipid and the third lipid in amounts that combined are about 20-50% by weight of the total weight of the population of nanoparticles. In one embodiment, the population of nanoparticles comprises the second lipid and the third lipid in amounts that combined are about 20-35% by weight of the total weight of the population of nanoparticles.

[00285] In certain embodiments, the population of nanoparticles provided herein comprises the lipid-peptide conjugate in an amount of about 5-20% by weight of the total weight of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises the lipid-peptide conjugate in an amount of about 8-16% by weight of the total weight of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises the lipid-peptide conjugate in an amount of about 10-15% by weight of the total weight of the population of nanoparticles. In one embodiment, the population of nanoparticles comprises the lipid-peptide conjugate in an amount of about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, or about 20% by weight of the total weight of the population of nanoparticles. In one embodiment, the population of nanoparticles comprises the lipid-peptide conjugate in an amount of about 8%, about 9%, about 10%, about 11%, or about 12%, about 13%, about 14%, about 15%, or about 16% by weight of the total weight of the population of nanoparticles. In one embodiment, the population of nanoparticles comprises the lipid-peptide conjugate in an amount of about 10% by weight of the total weight of the population of nanoparticles. In one embodiment, the population of nanoparticles comprises the lipid-peptide conjugate in an amount of about 11% by weight of the total weight of the population of nanoparticles. In one embodiment, the population of nanoparticles comprises the lipid-peptide conjugate in an amount of about 12% by weight of the total weight of the population of nanoparticles. In one embodiment, the population of nanoparticles comprises the lipid-peptide conjugate in an amount of about 13% by weight of the total weight of the population of nanoparticles. In one embodiment, the population of nanoparticles comprises the lipid-peptide conjugate in an amount of about 14% by weight of the total weight of the population of nanoparticles. In one embodiment, the population of nanoparticles comprises the lipid-peptide conjugate in an amount of about 15% by weight of the total weight of the population of nanoparticles.

[00286] In certain embodiments, the population of nanoparticles provided herein comprises the lipid-peptide conjugate in an amount of about 1-3 mol% of all components of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises the lipid-peptide conjugate in an amount of about 1.5-2.5 mol% of all components of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises the lipid-peptide conjugate in an amount of about 1.5, about 1.6%, about 1.7%, about 1.8%, about 1.9%, about 2.0%, about 2.1%, about 2.2%, about 2.3%, about 2.4%, or about 2.5 mol% of all components of the population of nanoparticles. In one embodiment, the population of nanoparticles comprises the lipid-peptide conjugate in an amount of about 2 mol% of all components of the population of nanoparticles.

[00287] In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 50-90% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 4-10% by weight of the total weight of the population of nanoparticles; and (iii) the lipid-peptide conjugate in an amount of about 5-20% by weight of the total weight of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 50-85% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 4-10% by weight of the total weight of the population of nanoparticles; and (iii) the lipid-peptide conjugate in an amount of about 5-20% by weight of the total weight of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the population of nanoparticles; and (iii) the lipid-peptide conjugate in an amount of about 8-16% by weight of the total weight of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the population of nanoparticles; and (iii) the lipid-peptide conjugate in an amount of about 8-16% by weight of the total weight of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the population of nanoparticles; and (iii) the lipid-peptide conjugate in an amount of about 10-15% by weight of the total weight of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the population of nanoparticles; and (iii) the lipid-peptide conjugate in an amount of about 10-15% by weight of the total weight of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 65-75% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 5-7% by weight of the total weight of the population of nanoparticles; and (iii) the lipid-peptide conjugate in an amount of about 8-16% by weight of the total weight of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 65-75% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 5-7% by weight of the total weight of the population of nanoparticles; and (iii) the lipid-peptide conjugate in an amount of about 10-15% by weight of the total weight of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 75-85% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 6-8% by weight of the total weight of the population of nanoparticles; and (iii) the lipid-peptide conjugate in an amount of about 8-16% by weight of the total weight of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 75-85% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 6-8% by weight of the total weight of the population of nanoparticles; and (iii) the lipid-peptide conjugate in an amount of about 10-15% by weight of the total weight of the population of nanoparticles.

[00288] In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 50-90% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 4-10% by weight of the total weight of the population of nanoparticles; and (iii) the lipid-peptide conjugate in an amount of about 1-3 mol% of all components of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 50-85% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 4-10% by weight of the total weight of the population of nanoparticles; and (iii) the lipid-peptide conjugate in an amount of about 1-3 mol% of all components of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the population of nanoparticles; and (iii) the lipid-peptide conjugate in an amount of about 1-3 mol% of all components of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the population of nanoparticles; and (iii) the lipid-peptide conjugate in an amount of about 1-3 mol% of all components of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the population of nanoparticles; and (iii) the lipid-peptide conjugate in an amount of about 1.5-2.5 mol% of all components of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the population of nanoparticles; and (iii) the lipid-peptide conjugate in an amount of about 1.5-2.5 mol% of all components of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 65-75% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 5-7% by weight of the total weight of the population of nanoparticles; and (iii) the lipid-peptide conjugate in an amount of about 1-3 mol% of all components of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 65-75% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 5-7% by weight of the total weight of the population of nanoparticles; and (iii) the lipid-peptide conjugate in an amount of about 1.5-2.5 mol% of all components of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 75-85% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 6-8% by weight of the total weight of the population of nanoparticles; and (iii) the lipid-peptide conjugate in an amount of about 1-3 mol% of all components of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 75-85% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 6-8% by weight of the total weight of the population of nanoparticles; and (iii) the lipid-peptide conjugate in an amount of about 1.5-2.5 mol% of all components of the population of nanoparticles.

[00289] In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 50-85% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 4-10% by weight of the total weight of the population of nanoparticles; (iii) the second lipid in an amount of about 22-32% by weight of the total weight of the population of nanoparticles; and (iv) the lipid-peptide conjugate in an amount of about 5-20% by weight of the total weight of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the population of nanoparticles; (iii) the second lipid in an amount of about 22-32% by weight of the total weight of the population of nanoparticles; and (iv) the lipid-peptide conjugate in an amount of about 5-20% by weight of the total weight of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the population of nanoparticles; (iii) the second lipid in an amount of about 22-32% by weight of the total weight of the population of nanoparticles; and (iv) the lipid-peptide conjugate in an amount of about 5-20% by weight of the total weight of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the population of nanoparticles; (iii) the second lipid in an amount of about 22-32% by weight of the total weight of the population of nanoparticles; and (iv) the lipid-peptide conjugate in an amount of about 8-16% by weight of the total weight of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the population of nanoparticles; (iii) the second lipid in an amount of about 22-32% by weight of the total weight of the population of nanoparticles; and (iv) the lipid-peptide conjugate in an amount of about 8-16% by weight of the total weight of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the population of nanoparticles; (iii) the second lipid in an amount of about 22-32% by weight of the total weight of the population of nanoparticles; and (iv) the lipid-peptide conjugate in an amount of about 10-15% by weight of the total weight of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the population of nanoparticles; (iii) the second lipid in an amount of about 22-32% by weight of the total weight of the population of nanoparticles; and (iv) the lipid-peptide conjugate in an amount of about 10-15% by weight of the total weight of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the population of nanoparticles; (iii) the second lipid in an amount of about 25-30% by weight of the total weight of the population of nanoparticles; and (iv) the lipid-peptide conjugate in an amount of about 5-20% by weight of the total weight of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the population of nanoparticles; (iii) the second lipid in an amount of about 25-30% by weight of the total weight of the population of nanoparticles; and (iv) the lipid-peptide conjugate in an amount of about 5-20% by weight of the total weight of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the population of nanoparticles; (iii) the second lipid in an amount of about 25-30% by weight of the total weight of the population of nanoparticles; and (iv) the lipid-peptide conjugate in an amount of about 8-16% by weight of the total weight of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the population of nanoparticles; (iii) the second lipid in an amount of about 25-30% by weight of the total weight of the population of nanoparticles; and (iv) the lipid-peptide conjugate in an amount of about 8-16% by weight of the total weight of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the population of nanoparticles; (iii) the second lipid in an amount of about 25-30% by weight of the total weight of the population of nanoparticles; and (iv) the lipid-peptide conjugate in an amount of about 10-15% by weight of the total weight of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the population of nanoparticles; (iii) the second lipid in an amount of about 25-30% by weight of the total weight of the population of nanoparticles; and (iv) the lipid-peptide conjugate in an amount of about 10-15% by weight of the total weight of the population of nanoparticles.

[00290] In one preferred embodiment, the population of nanoparticles comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the population of nanoparticles; (iii) the second lipid in an amount of about 25-30% by weight of the total weight of the population of nanoparticles; and (iv) the lipid-peptide conjugate in an amount of about 10-15% by weight of the total weight of the population of nanoparticles. In another preferred embodiment, the population of nanoparticles comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the population of nanoparticles; (iii) the second lipid in an amount of about 25-30% by weight of the total weight of the population of nanoparticles; and (iv) the lipid-peptide conjugate in an amount of about 10-15% by weight of the total weight of the population of nanoparticles.

[00291] In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 50-85% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 4-10% by weight of the total weight of the population of nanoparticles; (iii) the second lipid in an amount of about 22-32% by weight of the total weight of the population of nanoparticles; and (iv) the lipid-peptide conjugate in an amount of about 1-3 mol% of all components of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the population of nanoparticles; (iii) the second lipid in an amount of about 22-32% by weight of the total weight of the population of nanoparticles; and (iv) the lipid-peptide conjugate in an amount of about 1-3 mol% of all components of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the population of nanoparticles; (iii) the second lipid in an amount of about 22-32% by weight of the total weight of the population of nanoparticles; and (iv) the lipid-peptide conjugate in an amount of about 1-3 mol% of all components of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the population of nanoparticles; (iii) the second lipid in an amount of about 22-32% by weight of the total weight of the population of nanoparticles; and (iv) the lipid-peptide conjugate in an amount of about 1.5-2.5 mol% of all components of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the population of nanoparticles; (iii) the second lipid in an amount of about 22-32% by weight of the total weight of the population of nanoparticles; and (iv) the lipid-peptide conjugate in an amount of about 1.5-2.5 mol% of all components of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the population of nanoparticles; (iii) the second lipid in an amount of about 25-30% by weight of the total weight of the population of nanoparticles; and (iv) the lipid-peptide conjugate in an amount of about 1-3 mol% of all components of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the population of nanoparticles; (iii) the second lipid in an amount of about 25-30% by weight of the total weight of the population of nanoparticles; and (iv) the lipid-peptide conjugate in an amount of about 1-3 mol% of all components of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the population of nanoparticles; (iii) the second lipid in an amount of about 25-30% by weight of the total weight of the population of nanoparticles; and (iv) the lipid-peptide conjugate in an amount of about 1.5-2.5 mol% of all components of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the population of nanoparticles; (iii) the second lipid in an amount of about 25-30% by weight of the total weight of the population of nanoparticles; and (iv) the lipid-peptide conjugate in an amount of about 1.5-2.5 mol% of all components of the population of nanoparticles.

[00292] In one preferred embodiment, the population of nanoparticles comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the population of nanoparticles; (iii) the second lipid in an amount of about 25-30% by weight of the total weight of the population of nanoparticles; and (iv) the lipid-peptide conjugate in an amount of about 1.5-2.5 mol% of all components of the population of nanoparticles. In another preferred embodiment, the population of nanoparticles comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the population of nanoparticles; (iii) the second lipid in an amount of about 25-30% by weight of the total weight of the population of nanoparticles; and (iv) the lipid-peptide conjugate in an amount of about 1.5-2.5 mol% of all components of the population of nanoparticles.

[00293] In certain embodiments, the population of nanoparticles provided herein comprises the peptide in an amount of about 5-15% by weight of the total weight of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises the peptide in an amount of about 8-12% by weight of the total weight of the population of nanoparticles. In one embodiment, the population of nanoparticles comprises the peptide in an amount of about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, or about 15% by weight of the total weight of the population of nanoparticles. In one embodiment, the population of nanoparticles comprises the peptide in an amount of about 8%, about 9%, about 10%, about 11%, or about 12% by weight of the total weight of the population of nanoparticles. In one embodiment, the population of nanoparticles comprises the peptide in an amount of about 8% by weight of the total weight of the population of nanoparticles. In one embodiment, the population of nanoparticles comprises the peptide in an amount of about 9% by weight of the total weight of the population of nanoparticles. In one embodiment, the population of nanoparticles comprises the peptide in an amount of about 10% by weight of the total weight of the population of nanoparticles. In one embodiment, the population of nanoparticles comprises the peptide in an amount of about 11% by weight of the total weight of the population of nanoparticles. In one embodiment, the population of nanoparticles comprises the peptide in an amount of about 12% by weight of the total weight of the population of nanoparticles.

[00294] In certain embodiments, the population of nanoparticles provided herein comprises the peptide in an amount of about 1-3 mol% of all components of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises the peptide in an amount of about 1.5-2.5 mol% of all components of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises the peptide in an amount of about 1.5%, about 1.6%, about 1.7%, about 1.8%, about 1.9%, about 2.0%, about 2.1%, about 2.2%, about 2.3%, about 2.4%, or about 2.5 mol% of all components of the population of nanoparticles. In one embodiment, the population of nanoparticles comprises the peptide in an amount of about 2 mol% of all components of the population of nanoparticles.

[00295] In certain embodiments, the population of nanoparticles provided herein comprises the peptide and the amphiphilic polymer in a ratio of between about 0.03:1 (w / w) and 0.25:1 (w / w) of peptide to amphiphilic polymer. In certain embodiments, the population of nanoparticles provided herein comprises the peptide and the amphiphilic polymer in a ratio of between about 0.05:1 (w / w) and 0.20:1 (w / w) of peptide to amphiphilic polymer.

[00296] In certain embodiments, the population of nanoparticles provided herein comprises the peptide and the amphiphilic polymer in a ratio of between about 0.03:1 (mol / mol) and 0.25:1 (mol / mol) of peptide to amphiphilic polymer. In certain embodiments, the population of nanoparticles provided herein comprises the peptide and the amphiphilic polymer in a ratio of between about 0.05:1 (mol / mol) and 0.20:1 (mol / mol) of peptide to amphiphilic polymer.

[00297] In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 50-90% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 4-10% by weight of the total weight of the population of nanoparticles; and (iii) the peptide in an amount of about 5-15% by weight of the total weight of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 50-85% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 4-10% by weight of the total weight of the population of nanoparticles; and (iii) the peptide in an amount of about 5-15% by weight of the total weight of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the population of nanoparticles; and (iii) the peptide in an amount of about 5-15% by weight of the total weight of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the population of nanoparticles; and (iii) the peptide in an amount of about 5-15% by weight of the total weight of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the population of nanoparticles; and (iii) the peptide in an amount of about 8-12% by weight of the total weight of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 4-6% by weight of the total weight of the population of nanoparticles; and (iii) the peptide in an amount of about 8-12% by weight of the total weight of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 65-75% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 5-7% by weight of the total weight of the population of nanoparticles; and (iii) the peptide in an amount of about 5-15% by weight of the total weight of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 65-75% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 5-7% by weight of the total weight of the population of nanoparticles; and (iii) the peptide in an amount of about 8-12% by weight of the total weight of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 75-85% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 6-8% by weight of the total weight of the population of nanoparticles; and (iii) the peptide in an amount of about 5-15% by weight of the total weight of the population of nanoparticles. In certain embodiments, the population of nanoparticles provided herein comprises: (i) the amphiphilic polymer in an amount of about 75-85% by weight of the total weight of the population of nanoparticles; (ii) the first lipid in an amount of about 6-8% by weight of the total weight of ...

Claims

1. A nanoparticle comprising:a. an amphiphilic polymer;b.     a first lipid comprising a polar head group and a non-polar tail group; andc.     a peptide comprising a T cell epitope.

2. A nanoparticle comprising:a. an amphiphilic polymer;b.     a first lipid comprising a polar head group and a non-polar tail group;c.     a second lipid capable of enhancing the stability of the nanoparticle; andd. a peptide comprising a T cell epitope.

3. A nanoparticle comprising:a. an amphiphilic polymer;b. a first lipid comprising a polar head group and a non-polar tail group;c. a third lipid capable of being conjugated to a peptide comprising a T cell epitope; andd. a peptide comprising a T cell epitope.

4. A nanoparticle comprising:a. an amphiphilic polymer;b.     a first lipid comprising a polar head group and a non-polar tail group;c.     a second lipid capable of enhancing the stability of the nanoparticle;d. a third lipid capable of being conjugated to a peptide comprising a T cell epitope; ande. a peptide comprising a T cell epitope.

5. A nanoparticle comprising:a. an amphiphilic polymer;b.     a first lipid comprising a polar head group and a non-polar tail group; andc.      a lipid-peptide conjugate, wherein the peptide is covalently linked the lipid,and the peptide comprises a T cell epitope.

6. A nanoparticle comprising:a. an amphiphilic polymer;b.     a first lipid comprising a polar head group and a non-polar tail group;c.     a second lipid capable of enhancing the stability of the nanoparticle; andd.      a lipid-peptide conjugate, wherein the peptide is covalently linked the lipid,and the peptide comprises a T cell epitope.

7. A nanoparticle comprising:a. an amphiphilic polymer;b.     a first lipid comprising a polar head group and a non-polar tail group; andc.     a second lipid capable of enhancing the stability of the nanoparticle.

8. A nanoparticle comprising:a. an amphiphilic polymer;b.     a first lipid comprising a polar head group and a non-polar tail group;c.     a second lipid capable of enhancing the stability of the nanoparticle; andd. a third lipid capable of being conjugated to a peptide comprising a T cell epitope.

9. The nanoparticle of any one of claims 1-8, wherein the nanoparticle does not comprise a solid inorganic core.

10. The nanoparticle of any one of claims 1-9, wherein the first lipid comprises a Cio to C26 tail group.

11. The nanoparticle of any one of claims 1-10, wherein the first lipid comprises a Cio to C26 alkyl or alkenyl tail group.

12. The nanoparticle of any one of claims 1-11, wherein the first lipid comprises a Ci6 to C20 alkyl or alkenyl tail group.

13. The nanoparticle of any one of claims 1-12, wherein the first lipid comprises a Cis alkyl or alkenyl tail group.

14. The nanoparticle of any one of claims 1-13, wherein the first lipid comprises an octadecanoyloxy tail group.

15. The nanoparticle of any one of claims 1-14, wherein the first lipid is a phospholipid comprising a polar head group and a non-polar tail group.

16. The nanoparticle of any one of claims 1-15, wherein the first lipid comprises a polar head group lacking an -NH2, -NH3+, or -SH moiety capable of being conjugated to the peptide.

17. The nanoparticle of any one of claims 1-16, wherein the polar head group of the first lipid comprises a tetraalkylammonium moiety.

18. The nanoparticle of any one of claims 1-17, wherein the first lipid is a phospholipid of Formula (I):wherein, R1 is a group that lacks an -NH2, -NH7, or -SH moiety capable of being conjugated to the peptide; and R2 and R3 are each independently a C10 to C26 alkyl or alkenyl group.

19. The nanoparticle of claim 18, wherein R1 comprises a tetraalkylammonium moiety.

20. The nanoparticle of claim 18 or 19, wherein R1 is choline, ethanolamine, serine, inositol or glycerol, or a group derived therefrom lacking an -NH2, -NH3 , or -SH moiety.

21. The nanoparticle of any one of claims 1-20, wherein the first lipid is a phosphatidylcholine, a phosphatidylinositol, a phosphatidylethanolamine, a phosphatidylserine, or a phosphatidylglycerol lacking an -NH2, -NH3+, or -SH moiety.

22. The nanoparticle of claim 21, wherein the first lipid is a phosphatidylcholine.

23. The nanoparticle of any one of claims 1-22, wherein the first lipid is selected fromthe group consisting of l,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3 -phosphocholine (DPPC), 1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC), l-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), l,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 Diether PC), 1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC), 1 -hexadecyl-sn-glycero-3-phosphocholine (Cl6 Lyso PC), 1,2-dilinolenoyl-sn-glycero-3-phosphocholine, 1,2-diarachidonoyl-sn-glycero-3 -phosphocholine, 1,2-didocosahexaenoyl-sn-glycero-3 -phosphocholine, 1 -stearoyl-2-oleoyl-phosphatidylcholine (SOPC), 1,2-dielaidoyl-sn-glycero-3-phosphocholine (18:1 A9-Trans-PC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), dimyristoyl phosphatidylserine (DMPS), diarachidoyl phosphatidylserine (DAPS), dipalmitoyl phosphatidylserine (DPPS), distearoylphosphatidylserine (DSPS), dioleoylphosphatidylserine (DOPS), dilauroylphosphatidylinositol (DLPI), diarachidoylphosphatidylinositol (DAPI), dimyristoylphosphatidylinositol (DMPI), dipalmitoylphosphatidylinositol (DPPI), distearoylphosphatidylinositol (DSPI), dioleoyl-phosphatidylinositol (DOPI), 1,2-dimyristoyl-sn-glycero-3-phosphoglycerol (DMPG), 1,2-dipalmitoyl-sn-glycero-3 -phosphoglycerol (DPPG), 1,2-distearoyl-sn-glycero-3-phosphoglycerol (DSPG), and 1,2-dioleoyl-sn-glycero-3-phosphoglycerol (DOPG), or mixtures thereof.

24. The nanoparticle of any one of claims 1-23, wherein the first lipid is 1,2-distearoyl-5 / 7-glycero-3-phosphocholine (DSPC).

25. The nanoparticle of any one of claims 1-14, wherein the first lipid is a tetraalkylammonium compound.

26. The nanoparticle of claim 25, wherein the tetraalkylammonium compound comprises one or two Cio to C26 alkyl or alkenyl tail groups, optionally wherein the tetraalkylammonium compound comprises one or two Ci6 to C20 alkyl or alkenyl tail groups.

27. The nanoparticle of claim 25 or claim 26, wherein the first lipid is l,2-dioleoyl-3-trimethylammonium propane (DOTAP) or dimethyldioctadecylammonium (DDAB).

28. The nanoparticle of any one of claims 1-14, wherein the first lipid is a fatty acid compound.

29. The nanoparticle of claim 28, wherein the fatty acid comprises a Cio to C26 hydrocarbyl tail group, optionally wherein the fatty acid comprises a Ci6 to C20 hydrocarbyl tail group.

30. The nanoparticle of claim 28 or claim 29, wherein the fatty acid is selected from the group consisting of decanoic acid (capric acid), undecanoic acid (undecylic acid), dodecanoic acid (lauric acid), tridecanoic acid (tridecylic acid), tetradecanoic acid (myristic acid), pentadecanoic acid, hexadecanoic acid (palmitic acid), heptadecanoic acid (margaric acid), octadecanoic acid (stearic acid), nonadecanoic acid (nonadecylic acid), eicosanoic acid (arachidic acid, icosanoic acid), heneicosanoic acid (heneicosylic acid), docosanoic acid (behenic acid), tricosanoic acid, tetracosanoic acid (lignoceric acid), pentacosanoic acid, pentacosanoic acid (cerotic acid), and (Z)-octadec-9-en-17-ynoic acid (oleic acid), optionally wherein the first lipid is hexadecanoic acid (palmitic acid), heptadecanoic acid (margaric acid), octadecanoic acid (stearic acid), nonadecanoic acid (nonadecylic acid), eicosanoic acid (arachidic acid, icosanoic acid), or (Z)-octadec-9-en- 17-ynoic acid (oleic acid).

31. The nanoparticle of any one of claims 1 -30, wherein the first lipid is a structural lipid.

32. The nanoparticle of any one of claims 2, 4, and 6-31, wherein the second lipid is a fused polycyclic hydrocarbon, optionally substituted with one or more exocyclic oxygen, nitrogen, or sulfur-containing moieties.

33. The nanoparticle of any one of claims 2, 4, and 6-32, wherein the second lipid is a sterol or a hopanoid.

34. The nanoparticle of any one of claims 2, 4, and 6-33, wherein the second lipid is a sterol of Formula (II):(II),or a stereoisomer or mixture of stereoisomers thereof; wherein R4, R5, R6, R7, and R8 are each independently H or a C1-3 alkyl group; R9 is a hydrocarbyl group optionally substituted with an -OH moiety; and the dashed bonds are each independently single or double bonds.

35. The nanoparticle of any one of claims 2, 4, and 6-34, wherein the second lipid is a sterol of Formula (Ila):(Ha),or a stereoisomer or mixture of stereoisomers thereof; wherein R6 and R8 are each independently H or a C1-3 alkyl group; R9 is a hydrocarbyl group optionally substituted with an -OH moiety; and the dashed bonds are each independently single or double bonds.

36. The nanoparticle of any one of claims 2, 4, and 6-35, wherein the second lipid is a sterol of Formula (lib):(lib),or a stereoisomer or mixture or stereoisomers thereof; wherein R6 and R8 are each independently H or a C1-3 alkyl group; and R9 is a hydrocarbyl group optionally substituted with an -OH moiety.

37. The nanoparticle of any one of claims 2, 4, and 6-36, wherein the second lipid is a sterol of Formula (lie):(lie),wherein R6 and R8 are each independently H or a C1-3 alkyl group; and R9 is a hydrocarbyl group optionally substituted with an -OH moiety.

38. The nanoparticle of any one of claims 34-37, wherein R6 and R8 are each independently H or a methyl group.

39. The nanoparticle of any one of claims 34-38, wherein R9 is a C3-C15 alkyl or alkenyl group optionally substituted with an -OH moiety, optionally wherein R9 is a C7-C11 branched alkyl or alkenyl group.

40. The nanoparticle of any one of claims 2, 4, and 6-39, wherein the second lipid is cholesterol, cycloartenol, sitosterol, stigmasterol, ergosterol, lanosterol, campesterol, fecosterol, brassicasterol, tomatidine, tomatine, ursolic acid and alpha-tocopherol.

41. The nanoparticle of any one of claims 2, 4, and 6-40, wherein the second lipid is cholesterol.

42. The nanoparticle of any one of claims 2, 4, and 6-33, wherein the second lipid is a hopanoid of Formula (III):(III),or a stereoisomer or mixture of stereoisomers thereof; wherein R11, R12, R13, R14, R15, R16, and R17 are each independently H or a C1-3 alkyl group; R10 is a hydrocarbyl group optionally substituted with one or more oxygen, nitrogen, or sulfur-containing moieties.

43. The nanoparticle of any one of claims 2, 4, 6-33, and 42, wherein the second lipid is a hopanoid of Formula (Illa):(Hla),wherein R11, R12, R13, R14, R15, R16, and R17 are each independently H or a C1-3 alkyl group; R10 is a hydrocarbyl group optionally substituted with one or more oxygen, nitrogen, or sulfur-containing moieties.

44. The nanoparticle of any one of claims 2, 4, and 6-43, wherein the second lipid is a cohesive lipid.

45. The nanoparticle of any one of claims 3, 4, and 8-44, wherein the third lipid comprises an oxygen, nitrogen, or sulfur-containing moiety capable of being conjugated to the peptide.

46. The nanoparticle of any one of claims 3, 4, and 8-45, wherein the third lipid comprises an -COOH, -OH, -NH2, -NH3, or -SH moiety.

47. The nanoparticle of any one of claims 3, 4, and 8-46, wherein the third lipid comprises a polar head group and a non-polar tail group.

48. The nanoparticle of any one of claims 3, 4, and 8-47, wherein the third lipid is a phospholipid.

49. The nanoparticle of any one of claims 3, 4, and 8-48, wherein the third lipid is a phospholipid of Formula (IV):(IV),wherein R18 is a group comprising an oxygen, nitrogen, or sulfur-containing moiety capable of being conjugated to the peptide; and R19 and R20 are each independently a hydrocarbyl group.

50. The nanoparticle of claim 49, wherein R18 is a group comprising an -COOH, -OH, -NH2, -NH3+, or -SH moiety capable of being conjugated to the peptide.

51. The nanoparticle of claim 49 or 50, wherein R19 and R20 are each independently a C10 to C26 alkyl or alkenyl group, optionally wherein R19 and R20 are each independently a Ci6 to C20 alkyl or alkenyl group.

52. The nanoparticle of any one of claims 3, 4, and 8-51, wherein the third lipid is a phosphatidylinositol, a phosphatidylethanolamine, a phosphatidylserine, or a phosphatidylglycerol.

53. The nanoparticle of claim 52, wherein the third lipid is 1,2-distearoyl-s«-glycero-3 -phosphoinositol (DSPI), l,2-Distearoyl-s«-glycero-3-phosphoethanolamine (DSPE), 1,2-distearoyl-5 / 7-glycero-3-phospho-L-serine, or 1,2-distearoyl-sn-glycero-3-phosphoglycerol (DSPG).

54. The nanoparticle of any one of claims 3, 4, and 8-47, wherein the third lipid is a fused polycyclic hydrocarbon substituted with an exocyclic oxygen, nitrogen, or sulfur-containing moiety capable of being conjugated to the peptide.

55. The nanoparticle of any one of claims 3, 4, and 8-47, wherein the third lipid is a sterol.

56. The nanoparticle of any one of claims 3, 4, 8-47, and 55, wherein the third lipid is a sterol of Formula (V):(V),or a stereoisomer or mixture of stereoisomers thereof; wherein R21, R22, R23, R24, and R25 are each independently H or a C1-3 alkyl group; R26 is a hydrocarbyl group optionally substituted with an -OH moiety; and the dashed bonds are each independently single or double bonds.

57. The nanoparticle of any one of claims 3, 4, 8-47, 55, and 56, wherein the third lipidis a sterol of Formula (Va):(Va),or a stereoisomer or mixture of stereoisomers thereof; wherein R23 and R24 are each independently H or a C1-3 alkyl group; R26 is a hydrocarbyl group optionally substituted with an -OH moiety; and the dashed bonds are each independently single or double bonds.

58. The nanoparticle of any one of claims 3, 4, 8-47, and 55-57, wherein the third lipid is a sterol of Formula (Vb):(Vb),or a stereoisomer or mixture of stereoisomers thereof; wherein R23 and R24 are each independently H or a C1-3 alkyl group; and R26 is a hydrocarbyl group optionally substituted with an -OH moiety.

59. The nanoparticle of any one of claims 3, 4, 8-47, and 55-58, wherein the third lipid isa sterol of Formula (Vc):(Vc),wherein R23 and R24 are each independently H or a C1-3 alkyl group; and R26 is a hydrocarbyl group optionally substituted with an -OH moiety.

60. The nanoparticle of any one of claims 56-59, wherein R23 and R24 are each independently H or a methyl group.

61. The nanoparticle of any one of claims 56-60, wherein R26 is a C3-C15 alkyl or alkenyl group optionally substituted with an -OH moiety, optionally wherein R26 is a C7-C11 alkyl or alkenyl group.

62. The nanoparticle of any one of claims 3, 4, 8-47, and 55-61, wherein the third lipid is selected from the group consisting of cholesterol, cycloartenol, sitosterol, stigmasterol, ergosterol,lanosterol, campesterol, fecosterol, brassicasterol, tomatidine, tomatine, ursolic acid and alphatocopherol.

63. The nanoparticle of claim 62, wherein the third lipid is cholesterol.

64. The nanoparticle of any one of claims 3, 4, and 8-47, wherein the third lipid is ahopanoid.

65. The nanoparticle of any one of claims 3, 4, 8-47, and 64, wherein the third lipid is a hopanoid of Formula (VI):R31 R30R33 R32(VI),or a stereoisomer or mixture of stereoisomers thereof; wherein R27 is a group comprising an oxygen, nitrogen, or sulfur-containing moiety capable of being conjugated to the peptide; and R28, R29, R30, R31, R32, R33, and R34 are each independently H or a C1-3 alkyl group.

66. The nanoparticle of any one of claims 3, 4, 8-47, 64, and 65, wherein the third lipidis a hopanoid of Formula (Via):R33 R32R31 R30(Via),wherein R27 is a group comprising an oxygen, nitrogen, or sulfur-containing moiety capable of being conjugated to the peptide; and R28, R29, R30, R31, R32, R33, and R34 are each independently H or a C1-3 alkyl group.

67. The nanoparticle of any one of claims 3, 4, and 8-47, wherein the third lipid is a fatty acid compound.

68. The nanoparticle of claim 67, wherein the fatty acid comprises a C10 to C26 hydrocarbyl tail group, optionally wherein the fatty acid comprises a Ci6 to C20 hydrocarbyl tail group.

69. The nanoparticle of claim 67 or claim 68, wherein the fatty acid is selected from the group consisting of decanoic acid (capric acid), undecanoic acid (undecylic acid), dodecanoic acid (lauric acid), tridecanoic acid (tridecylic acid), tetradecanoic acid (myristic acid), pentadecanoic acid, hexadecanoic acid (palmitic acid), heptadecanoic acid (margaric acid), octadecanoic acid (stearic acid), nonadecanoic acid (nonadecylic acid), eicosanoic acid (arachidic acid, icosanoic acid), heneicosanoic acid (heneicosylic acid), docosanoic acid (behenic acid), tricosanoic acid, tetracosanoic acid (lignoceric acid), pentacosanoic acid, pentacosanoic acid (cerotic acid), and (Z)-octadec-9-en-17-ynoic acid (oleic acid), optionally wherein the fatty acid is hexadecanoic acid (palmitic acid), heptadecanoic acid (margaric acid), octadecanoic acid (stearic acid), nonadecanoic acid (nonadecylic acid), eicosanoic acid (arachidic acid, icosanoic acid), or (Z)-octadec-9-en- 17-ynoic acid (oleic acid).

70. The nanoparticle of any one of claims 3, 4, and 8-69, wherein the third lipid is an anchor lipid.

71. The nanoparticle of any one of claims 5, 6, and 9-44, wherein the lipid of the lipidpeptide conjugate comprises a polar head group and a non-polar tail group.

72. The nanoparticle of claim 71, wherein the polar head group comprises an oxygen, nitrogen, or sulfur-containing moiety covalently linked to the peptide.

73. The nanoparticle of any one of claims 5, 6, 9-44, 71, and 72, wherein the lipid of the lipid-peptide conjugate is a phospholipid, a fatty acid, a sterol, or a hopanoid.

74. The nanoparticle of any one of claims 5, 6, 9-44, and 71-73, wherein the lipidpeptide conjugate is a phospholipid-peptide conjugate of Formula (VII):O(VII),wherein L is a linker comprising an oxygen, nitrogen, or sulfur-containing moiety; R35 is the peptide; and R36 and R37 are each independently a hydrocarbyl group.

75. The nanoparticle of claim 74, wherein R36 and R37 are each independently a Cio to C26 alkyl or alkenyl group, optionally wherein R36 and R37 are each independently a Ci6 to C20 alkyl or alkenyl group.

76. The nanoparticle of claim 74 or 75, wherein L is ethanolamine, serine, inositol, or glycerol, or a group derived from ethanolamine, serine, inositol, or glycerol.

77. The nanoparticle of any one of claims 5, 6, 9-44, and 71-76, wherein the lipidpeptide conjugate comprises the peptide covalently linked to a phospholipid selected from the group consisting of phosphatidylethanolamine, phosphatidylglycerol, phosphatidylserine, phosphatidylate, or phosphatidylinositol.

78. The nanoparticle of any one of claims 5, 6, 9-44, and 71-73, wherein the lipidpeptide conjugate is a fatty acid-peptide conjugate of formula R39-C(O)-R38, wherein R38 is the peptide and R39 is a hydrocarbyl group.

79. The nanoparticle of claim 78, wherein R39 is a Cio to C26 alkyl or alkenyl group, optionally wherein R39 is a Ci6 to C20 alkyl or alkenyl group.

80. The nanoparticle of any one of claims 5, 6, 9-44, and 71-73, wherein the lipidpeptide conjugate is a sterol-peptide conjugate of Formula (VIII):(VIII),or a stereoisomer or mixture of stereoisomers thereof; wherein R40 is the peptide; R41, R42, r43 ^44 anj |^45 are each inciepencientiy H or a C1-3 alkyl group; R46 is a hydrocarbyl group optionally substituted with an -OH moiety; and the dashed bonds are each independently single or double bonds.

81. The nanoparticle of any one of claims 5, 6, 9-44, 71-73, and 80, wherein the lipidpeptide conjugate is a sterol-peptide conjugate of Formula (Villa):R44R46(Villa),or a stereoisomer or mixture of stereoisomers thereof; wherein R40 is the peptide; R43 and R44 are each independently H or a C1-3 alkyl group; R46 is a hydrocarbyl group optionally substituted with an -OH moiety; and the dashed bonds are each independently single or double bonds.

82. The nanoparticle of any one of claims 5, 6, 9-44, 71-73, 80, and 81, wherein the lipid-peptide conjugate is a sterol-peptide conjugate of Formula (Vlllb):(Vlllb),or a stereoisomer or mixture of stereoisomers thereof; wherein R40 is the peptide; R43 and R44 are each independently H or a C1-3 alkyl group; and R46 is a hydrocarbyl group optionally substituted with an -OH moiety.

83. The nanoparticle of any one of claims 5, 6, 9-44, 71-73, and 80-82, wherein the lipid-peptide conjugate is a sterol-peptide conjugate of Formula (VIIIc):(vine),wherein R40 is the peptide; R43 and R44 are each independently H or a C1-3 alkyl group; and R46 is a hydrocarbyl group optionally substituted with an -OH moiety.

84. The nanoparticle of any one of claims 80-83, wherein R43 and R44 are each independently H or a methyl group.

85. The nanoparticle of any one of claims 80-84, wherein R46 is a C3-C15 alkyl or alkenyl group optionally substituted with an -OH moiety, optionally wherein R46 is a C7-C11 alkyl or alkenyl group.

86. The nanoparticle of any one of claims 80-85, wherein the lipid-peptide conjugate comprises the peptide covalently linked to a sterol selected from the group consisting of cholesterol, cycloartenol, sitosterol, stigmasterol, ergosterol, lanosterol, campesterol, fecosterol, brassicasterol, tomatidine, tomatine, ursolic acid and alpha-tocopherol.

87. The nanoparticle of any one of claims 80-86, wherein the lipid-peptide conjugate comprises the peptide covalently linked to cholesterol.

88. The nanoparticle of any one of claims 5, 6, 9-44, and 71-73, wherein the lipidpeptide conjugate is a hopanoid-peptide conjugate of Formula (IX):^47R51 R50(IX),or a stereoisomer or mixture of stereoisomers thereof; wherein R47 is the peptide; R48, R49, R50, R51, R52, R53, and R54 are each independently H or a C1-3 alkyl group; L is a linker comprising an oxygen, nitrogen, or sulfur-containing moiety covalently linked to the peptide.

89. The nanoparticle of any one of claims 5, 6, 9-44, 71-73, and 88, wherein the lipidpeptide conjugate is a hopanoid-peptide conjugate of Formula (IXa):R34 R33R32 R31(IXa),or a stereoisomer or mixture of stereoisomers thereof; wherein R47 is the peptide; R48, R49, R50, R51, R52, R53, and R54 are each independently H or a C1-3 alkyl group; L is a linker comprising an oxygen, nitrogen, or sulfur-containing moiety covalently linked to the peptide.

90. The nanoparticle of any one of claims 1 -89, wherein the nanoparticle comprises only one type of lipid.

91. The nanoparticle of any one of claims 1-90, wherein the nanoparticle comprises only one type of the first lipid.

92. The nanoparticle of any one of claims 1 -89, wherein the nanoparticle comprises only two types of lipids.

93. The nanoparticle of any one of claims 2-89 and 92, wherein the nanoparticle comprises only one type of the first lipid and only one type of the second lipid.

94. The nanoparticle of any one of claims 3-89 and 92, wherein the nanoparticle comprises only one type of the first lipid and only one type of the third lipid.

95. The nanoparticle of any one of claims 5-89 and 92, wherein the nanoparticle comprises only one type of the first lipid and only one type of the lipid-peptide conjugate.

96. The nanoparticle of any one of claims 1 -89, wherein the nanoparticle comprises only three types of lipids.

97. The nanoparticle of any one of claims 4-89 and 96, wherein the nanoparticles comprises only one type of the first lipid, only one type of the second lipid, and only one type of the third lipid.

98. The nanoparticle of any one of claims 6-89 and 96, wherein the nanoparticle comprises only one type of the first lipid, only one type of the second lipid, and only one type of the lipid-peptide conjugate.

99. The nanoparticle of any one of claims 1-98, wherein the nanoparticle comprises a phosphatidylcholine and a sterol.

100. The nanoparticle of claim 99, wherein the nanoparticle comprises DSPC and cholesterol.

101. The nanoparticle of any one of claims 1-4, 9-70, and 90-100, wherein the peptide is covalently linked to the amphiphilic polymer.

102. The nanoparticle of any one of claims 1-4 and 9-101, wherein the peptide is non-covalently associated with the amphiphilic polymer, and / or the first lipid, and / or the second lipid, and / or the third lipid.

103. The nanoparticle of any one of claims 3, 4, 9-70, 90-100, and 102, wherein the peptide is covalently linked to the third lipid.

104. The nanoparticle of any one of claims 1-103, wherein the peptide comprises an MHC Class I or MHC Class II epitope.

105. The nanoparticle of claim 104, wherein the MHC Class I or MHC Class II epitope is a human MHC Class I or MHC Class II epitope.

106. The nanoparticle of any one of claims 1-105., wherein the peptide has an amino acid sequence comprising between 6 and 60 amino acids, optionally between 9 and 60 amino acids.

107. The nanoparticle of any one of claims 1-106, wherein the peptide has an amino acid sequence comprising between 10 and 20 amino acids.

108. The nanoparticle of any one of claims 1-107, wherein the nanoparticle comprises only one type of peptide (e.g. peptides having the same amino acid sequence).

109. The nanoparticle of any one of claims 1-108, wherein only one type of peptide (e.g. peptides having the same amino acid sequence) is associated with the nanoparticle.

110. The nanoparticle of any one of claims 1-109, wherein only one type of peptide (e.g. peptides having the same amino acid sequence) is covalently linked to the nanoparticle.

111. The nanoparticle of any one of claims 1-110, wherein the amphiphilic polymer is an alternating copolymer of maleic anhydride and at least one alkene.

112. The nanoparticle of any one of claims 1-111, wherein the number average molecular weight (Mn) of the amphiphilic polymer is between about 1,000 g / mol and 20,000 g / mol, between about 2,500 g / mol and 20,000 g / mol, between about 1,000 g / mol and 10,000 g / mol, between about 2,500 g / mol and 10,000 g / mol, between about 1,000 g / mol and 6,000 g / mol, between about 2,500 g / mol and 6,000 g / mol, between about 1,000 g / mol and 4,000 g / mol, or between about 2,500 g / mol and 4,000 g / mol.

113. The nanoparticle of any one of claims 1-112, wherein the number average molecular weight (Mn) of the amphiphilic polymer is between about 1,000 g / mol and 6,000 g / mol.

114. The nanoparticle of any one of claims 1-113, wherein the number average molecular weight (Mn) of the amphiphilic polymer is between about 2,500 g / mol and 4,000 g / mol.

115. The nanoparticle of any one of claims 1-114, wherein the amphiphilic polymer comprises the following building block:wherein R is a hydrocarbyl group or a substituted hydrocarbyl group.

116. The nanoparticle of claim 115, wherein R is a C4 to C30 alkyl group.

117. The nanoparticle of claim 116, wherein R is a C7 to C19 alkyl group.

118. The nanoparticle of claim 116, wherein R is a C15 alkyl group.

119. The nanoparticle of any one of claims 1-118, wherein the amphiphilic polymer isselected from the group consisting of poly(maleic acid-a / t-1-octadecene), poly(maleic acid-a / z-1-tetradecene) and poly(maleic acid-a / t-1-dodecene).

120. The nanoparticle of claim 119, wherein the amphiphilic polymer is poly (maleic acid-alt-1 -octadecene).

121. The nanoparticle of any one of claims 1-120, wherein the nanoparticle comprises between about 10 and 40 mol of the building block per mol of the first lipid.

122. The nanoparticle of any one of claims 1-120, wherein the nanoparticle comprises between about 15 and 35 mol of the building block per mol of the first lipid.

123. The nanoparticle of any one of claims 1-120, wherein the nanoparticle comprises between about 20 and 25 mol of the building block per mol of the first lipid.

124. The nanoparticle of any one of claims 1-120, wherein the nanoparticle comprises about 20, about 21, about 22, about 23, about 24, or about 25 mol of the building block per mol of the first lipid.

125. The nanoparticle of any one of claims 1-124, wherein the nanoparticle comprises the first lipid and the amphiphilic polymer in a ratio of between about 0.01:1 (w / w) and 1:1 (w / w), between about 0.05:1 (w / w) and 1:1 (w / w), between about 0.01:1 (w / w) and 0.5:1 (w / w), between about 0.05:1 (w / w) and 0.5:1 (w / w), between about 0.01:1 (w / w) and 0.4:1 (w / w), between about 0.05:1 (w / w) and 0.4:1 (w / w), between about 0.01:1 (w / w) and 0.3:1 (w / w), between about 0.05:1 (w / w) and 0.3:1 (w / w), between about 0.01:1 (w / w) and 0.2:1 (w / w), between about 0.05:1 (w / w) and 0.2:1 (w / w), between about 0.01:1 (w / w) and 0.15:1 (w / w), or between about 0.05:1 (w / w) and 0.15:1 (w / w) first lipid to amphiphilic polymer.

126. The nanoparticle of any one of claims 1-125, wherein the nanoparticle comprises the first lipid and the amphiphilic polymer in a ratio of between about 0.01:1 (w / w) and 0.2:1 (w / w), between about 0.05:1 (w / w) and 0.2:1 (w / w), between about 0.01:1 (w / w) and 0.15:1 (w / w), or between about 0.05:1 (w / w) and 0.15:1 (w / w) first lipid to amphiphilic polymer.

127. The nanoparticle of any one of claims 1-126, wherein the nanoparticle comprises the first lipid and the amphiphilic polymer in a ratio of between about 0.05:1 (w / w) and 0.15:1 (w / w) first lipid to amphiphilic polymer.

128. The nanoparticle of any one of claims 1-127, wherein the nanoparticle comprises the first lipid and the amphiphilic polymer in a ratio of about 0.01:1 (w / w), about 0.02:1 (w / w), about 0.03:1 (w / w), about 0.04:1 (w / w), about 0.05:1 (w / w), about 0.06:1 (w / w), about 0.07:1 (w / w), about 0.08:1 (w / w), about 0.09:1 (w / w), about 0.10:1 (w / w), about 0.11:1 (w / w), about 0.12:1 (w / w), about0.13:l (w / w), about0.14:l (w / w), about0.15:l (w / w), about0.16:l (w / w), about 0.17:1 (w / w), about0.18:l (w / w), about0.19:l (w / w), or about 0.20:1 (w / w) first lipid to amphiphilic polymer.

129. The nanoparticle of any one of claims 1-128, wherein the nanoparticle comprises the first lipid and the amphiphilic polymer in a ratio of about 0.09:1 (w / w) or about 0.10:1 (w / w) first lipid to amphiphilic polymer.

130. The nanoparticle of any one of claims 1-129, wherein the nanoparticle comprises the first lipid and the amphiphilic polymer in a ratio of about 0.05:1 (mol / mol) and 1:1 (mol / mol), between about 0.1:1 (mol / mol) and 1:1 (mol / mol), between about 0.05:1 (mol / mol) and 0.9:1 (mol / mol), between about 0.1:1 (mol / mol) and 0.9:1 (mol / mol), between about 0.05:1 (mol / mol) and 0.8:1 (mol / mol), between about 0.1:1 (mol / mol) and 0.8:1 (mol / mol), between about 0.05:1 (mol / mol) and 0.7:1 (mol / mol), between about 0.1:1 (mol / mol) and 0.7:1 (mol / mol), between about 0.05:1 (mol / mol) and 0.6:1 (mol / mol), between about 0.1:1 (mol / mol) and 0.6:1 (mol / mol), between about 0.05:1 (mol / mol) and 0.5:1 (mol / mol), between about 0.1:1 (mol / mol) and 0.5:1 (mol / mol), between about 0.2:1 (mol / mol) and 0.5:1 (mol / mol), between about 0.3:1 (mol / mol) and 0.5:1 (mol / mol), or between about 0.3:1 (mol / mol) and 0.4:1 (mol / mol) first lipid to amphiphilic polymer.

131. The nanoparticle of any one of claims 1-130, wherein the nanoparticle comprises the first lipid and the amphiphilic polymer in a ratio of between about 0.3:1 (mol / mol) and 0.7:1 (mol / mol) first lipid to amphiphilic polymer.

132. The nanoparticle of any one of claims 1-131, wherein the nanoparticle comprises the first lipid and the amphiphilic polymer in a ratio of about 0.25:1 (mol / mol), 0.26:1 (mol / mol), 0.27:1 (mol / mol), 0.28:1 (mol / mol), 0.30:1 (mol / mol), 0.31:1 (mol / mol), 0.32:1 (mol / mol), 0.33:1(mol / mol), 0.34:1 (mol / mol), 0.35:1 (mol / mol), 0.36:1 (mol / mol), 0.37:1 (mol / mol), 0.38:1(mol / mol), 0.39:1 (mol / mol), 0.40:1 (mol / mol), 0.41:1 (mol / mol), 0.42:1 (mol / mol), 0.43:1(mol / mol), 0.44:1 (mol / mol), or 0.45:1 (mol / mol) first lipid to amphiphilic polymer.

133. The nanoparticle of any one of claims 1-131, wherein the nanoparticle comprises the first lipid and the amphiphilic polymer in a ratio of about 0.39:1 (mol / mol) first lipid to amphiphilic polymer.

134. The nanoparticle of any one of claims 1-131, wherein the nanoparticle comprises the first lipid and the amphiphilic polymer in a ratio of about 0.42:1 (mol / mol) first lipid to amphiphilic polymer.

135. The nanoparticle of any one of claims 1-131, wherein the nanoparticle comprises the first lipid and the amphiphilic polymer in a ratio of about 0.6:1 (mol / mol) first lipid to amphiphilic polymer.

136. The nanoparticle of any one of claims 1-135, wherein the nanoparticle comprises the amphiphilic polymer in an amount of about 50-85%, about 55-65%, about 65-75%, about 75-85%, or about 85-95% by weight of the total weight of the nanoparticle.

137. The nanoparticle of any one of claims 1-136, wherein the nanoparticle comprises: (i) the amphiphilic polymer in an amount of about 50-95% by weight of the total weight of the nanoparticle; and (ii) the first lipid in an amount of about 4-10% by weight of the total weight of the nanoparticle.

138. The nanoparticle of any one of claims 1-137, wherein the nanoparticle comprises: (i) the amphiphilic polymer in an amount of about 55-65% by weight of the total weight of the nanoparticle; and (ii) the first lipid in an amount of about 4-8% by weight of the total weight of the nanoparticle.

139. The nanoparticle of any one of claims 1-137, wherein the nanoparticle comprises: (i) the amphiphilic polymer in an amount of about 65-75% by weight of the total weight of the nanoparticle; and (ii) the first lipid in an amount of about 5-7% by weight of the total weight of the nanoparticle.

140. The nanoparticle of any one of claims 1-137, wherein the nanoparticle comprises: (i) the amphiphilic polymer in an amount of about 75-85% by weight of the total weight of the nanoparticle; (ii) and the first lipid in an amount of about 6-8% by weight of the total weight of the nanoparticle.

141. The nanoparticle of any one of claims 2, 4, and 6-140, wherein the nanoparticle comprises the second lipid in an amount of about 20-50% by weight of the total weight of the nanoparticle.

142. The nanoparticle of any one of claims 2, 4, and 6-141, wherein the nanoparticle comprises the second lipid in an amount of about 20-35% by weight of the total weight of the nanoparticle.

143. The nanoparticle of any one of claims 2, 4, and 6-142, wherein the nanoparticle comprises the second lipid in an amount of about 22-32% by weight of the total weight of the nanoparticle.

144. The nanoparticle of any one of claims 2, 4, and 6-143, wherein the nanoparticle comprises the second lipid in an amount of about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, or about 32% by weight of the total weight of the nanoparticle.

145. The nanoparticle of any one of claims 2, 4, and 6-143, wherein the nanoparticle comprises a combined amount of the first lipid and the amphiphilic polymer of between about 2:1 to about 3:1 by weight (w / w) to relative to the amount of the second lipid.

146. The nanoparticle of any one of claims 2, 4, and 6-145, wherein the nanoparticle comprises a combined amount of the first lipid and the amphiphilic polymer of about 7:3 by weight (w / w) to relative to the amount of the second lipid.

147. The nanoparticle of any one of claims 3, 4, and 8-146, wherein the nanoparticle comprises the third lipid in an amount of about 1 -3 mol% of all components of the nanoparticle.

148. The nanoparticle of any one of claims 4 and 8-147, wherein the nanoparticle comprises the third lipid in amount of about 2 mol% of all components of the nanoparticle.

149. The nanoparticle of any one of claims 4 and 8-148, wherein the nanoparticle comprises the second lipid and the third lipid in amounts that combined are about 20-50% by weight of the total weight of the nanoparticle.

150. The nanoparticle of any one of claims 4 and 8-149, wherein the nanoparticle comprises the second lipid and the third lipid in amounts that combined are about 20-35% by weight of the total weight of the nanoparticle.

151. The nanoparticle of any one of claims 5, 6, and 9-146, wherein the nanoparticle comprises the lipid-peptide conjugate in an amount of about 5-20%, 8-16%, or 10-15% by weight of the total weight of the nanoparticle.

152. The nanoparticle of any one of claims 5, 6, 9-146, andl51, wherein the nanoparticle comprises the lipid-peptide conjugate in an amount of about 1-3 mol% of all components of the nanoparticle.

153. The nanoparticle of any one of claims 5, 6, and 9-152, wherein the nanoparticle comprises the lipid-peptide conjugate in an amount of about 2 mol% of all components of the nanoparticle.

154. The nanoparticle of any one of claims 1-153, wherein the nanoparticle comprises the peptide in an amount of about 5-15% or 8-12% by weight of the total weight of the nanoparticle.

155. The nanoparticle of any one of claims 1-154, wherein the nanoparticle comprises the peptide in an amount of about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15% by weight of the total weight of the nanoparticle.

156. The nanoparticle of any one of claims 1-155, wherein the nanoparticle comprises the peptide in an amount of about 10% by weight of the total weight of the nanoparticle.

157. The nanoparticle of any one of claims 1-156, wherein the nanoparticle comprises the peptide in an amount of about 1-3 mol% of all components of the nanoparticle.

158. The nanoparticle of any one of claims 1-157, wherein the nanoparticle comprises the peptide in an amount of about 2 mol% of all components of the nanoparticle.

159. The nanoparticle of any one of claims 1-158, wherein the nanoparticle comprises the peptide and the amphiphilic polymer in a ratio of between about 0.03:1 (w / w) and 0.25:1 (w / w) of peptide to amphiphilic polymer.

160. The nanoparticle of any one of claims 1-159, wherein the nanoparticle comprises the peptide and the amphiphilic polymer in a ratio of between about 0.03:1 (mol / mol) and 0.25:1 (mol / mol) of peptide to amphiphilic polymer.

161. The nanoparticle of any one of claims 1-160, wherein the nanoparticle has a hydrodynamic diameter in the range of 10 to 100 nm as determined by DLS.

162. The nanoparticle of any one of claims 1-161, wherein the nanoparticle has a hydrodynamic diameter in the range of 10 to 60 nm as determined by DLS.

163. The nanoparticle of any one of claims 1-162, wherein the nanoparticle has a hydrodynamic diameter in the range of 10 to 50 nm as determined by DLS.

164. The nanoparticle of any one of claims 1-163, wherein the nanoparticle has a hydrodynamic diameter in the range of 10 to 40 nm as determined by DLS.

165. The nanoparticle of any one of claims 1-164, wherein the nanoparticle has a hydrodynamic diameter in the range of 10 to 30 nm as determined by DLS.

166. The nanoparticle of any one of claims 1-165, wherein the nanoparticle is stable for at least 1 hour, at least 2 hours, at least 3 hours, at least 4 hours, at least 5 hours, at least 6 hours, at least 12 hours, at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, or at least 12 days at 25 °C in 25 mM sodium acetate buffer at pH about 5 as determined by Dynamic Light Scattering (DLS).

167. The nanoparticle of any one of claims 1-165, wherein the nanoparticle is stable for at least 1 hour, at least 2 hours, at least 3 hours, at least 4 hours, at least 5 hours, at least 6 hours, at least 12 hours, at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, or at least 12 days at 25 °C in 25 mM MES buffer at pH about 6 as determined by Dynamic Light Scattering (DLS).

168. The nanoparticle of any one of claims 1-165, wherein the nanoparticle is stable for at least 1 hour, at least 2 hours, at least 3 hours, at least 4 hours, at least 5 hours, at least 6 hours, at least 12 hours, at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, or at least 12 days at 25 °C in 0. lx PBS buffer at pH about 7 as determined by Dynamic Light Scattering (DLS).

169. The nanoparticle of any one of claims 1-165, wherein the nanoparticle is stable for at least 1 hour, at least 2 hours, at least 3 hours, at least 4 hours, at least 5 hours, at least 6 hours, at least 12 hours, at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, or at least 12 days at 25 °C in 25 mM HEPES buffer at pH about 8 as determined by Dynamic Light Scattering (DLS).

170. The nanoparticle of any one of claims 1-165, wherein the nanoparticle is stable for at least 1 hour, at least 2 hours, at least 3 hours, at least 4 hours, at least 5 hours, at least 6 hours, at least 12 hours, at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, or at least 12 days at 25 °C in 25 mM SBB buffer at pH about 9 as determined by Dynamic Light Scattering (DLS).

171. The nanoparticle of any one of claims 1-170, wherein the nanoparticle is stable to Stress Test Assay as determined by DLS.

172. The nanoparticle of any one of claims 1-171, wherein the nanoparticle is suitable for administration to a subject, and capable of tolerizing the subject to the peptide(s) associated with or conjugated to the nanoparticle.

173. The nanoparticle of any one of claims 1-172, wherein the nanoparticle is suitable for administration to a subject, and capable of suppressing a specific immune response in the subject.

174. The nanoparticle of any one of claims 1-173, wherein the nanoparticle is suitable for administration to a subject, and capable of treating or preventing a disease or disorder in the subject.

175. The nanoparticle of any one of claims 1-174, wherein the nanoparticle is suitable for transferring peptides to liver sinusoidal endothelial cells of a subject in vivo.

176. A population of nanoparticles as defined in any one of claims 1-175, wherein the population is characterized by a D90 of below 100 nm as determined by DLS.

177. A population of nanoparticles as defined in any one of claims 1-175, wherein at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of the nanoparticles in the population have a hydrodynamic diameter in the range of 10 to 100 nm as determined by DLS.

178. A population of nanoparticles as defined in any one of claims 1-175, wherein at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of the nanoparticles in the population have a hydrodynamic diameter in the range of 10 to 60 nm as determined by DLS.

179. A population of nanoparticles as defined in any one of claims 1-175, wherein at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of the nanoparticles in the population have a hydrodynamic diameter in the range of 10 to 50 nm as determined by DLS.

180. A population of nanoparticles as defined in any one of claims 1-175, wherein at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of the nanoparticles in the population have a hydrodynamic diameter in the range of 10 to 40 nm as determined by DLS.

181. A population of nanoparticles as defined in any one of claims 1-175, wherein at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of the nanoparticles in the population have a hydrodynamic diameter in the range of 10 to 30 nm as determined by DLS.

182. A population of nanoparticles as defined in any one of claims 1-175, wherein the population of nanoparticles has an intensity weighted mean hydrodynamic size of the ensemble collection of particles (“Z average”) of about 10 to 100 nm as determined by DLS.

183. A population of nanoparticles as defined in any one of claims 1-175, wherein the population of nanoparticles has a Z average of about 10 to 60 nm as determined by DLS.

184. A population of nanoparticles as defined in any one of claims 1-175, wherein the population of nanoparticles has a Z average of about 10 to 50 nm as determined by DLS.

185. A population of nanoparticles as defined in any one of claims 1-175, wherein the population of nanoparticles has a Z average of about 10 to 40 nm as determined by DLS.

186. A population of nanoparticles as defined in any one of claims 1-175, wherein the population of nanoparticles has a Z average of about 10 to 30 nm as determined by DLS.

187. The population of nanoparticles of any one of claims 176-186, wherein the population of nanoparticles has a polydispersity index of less than 0.40, less than 0.35, or less than 0.30, as determined by DLS.

188. The population of nanoparticles of any one of claims 176-186, wherein the population of nanoparticles has a polydispersity index of less than 0.30, as determined by DLS.

189. The population of any one of claims 176-188, wherein the average hydrodynamic diameter of the nanoparticles changes by no more than about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, or about 20% as determined by Dynamic Light Scattering (DLS) after storing the population for at least 1 hour, at least 2 hours, at least 3 hours, at least 4 hours, at least 5 hours, at least 6 hours, at least 12 hours, at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, or at least 12 days at 25 °C in 25 mM sodium acetate buffer at pH about 5.

190. The population of any one of claims 176-188, wherein the average hydrodynamic diameter of the nanoparticles changes by no more than about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, or about 20% as determined by Dynamic Light Scattering (DLS) after storing the population for at least 1 hour, at least 2 hours, at least 3 hours, at least 4 hours, at least 5 hours, at least 6 hours, at least 12 hours, at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, or at least 12 days at 25 °C in 25 mM MES buffer at pH about 6.

191. The population of any one of claims 176-188, wherein the average hydrodynamic diameter of the nanoparticles changes by no more than about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, or about 20% as determined by Dynamic Light Scattering (DLS) after storing the population for at least 1 hour, at least 2 hours, at least 3 hours, at least 4 hours, at least 5 hours, at least 6 hours, at least 12 hours, at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, or at least 12 days at 25 °C in 0. lx PBS buffer at pH about 7.

192. The population of any one of claims 176-188, wherein the average hydrodynamic diameter of the nanoparticles changes by no more than about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, or about 20% as determined by Dynamic Light Scattering (DLS) after storing the population for at least 1 hour, at least 2 hours, at least 3 hours, at least 4 hours, at least 5 hours, at least 6 hours, at least 12 hours, at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, or at least 12 days at 25 °C in 25 mM HEPES buffer at pH about 8.

193. The population of any one of claims 176-188, wherein the average hydrodynamic diameter of the nanoparticles changes by no more than about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, or about 20% as determined by Dynamic Light Scattering (DLS) after storing the population for at least 1 hour, at least 2 hours, at least 3 hours, at least 4 hours, at least 5 hours, at least 6 hours, at least 12 hours, at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, or at least 12 days at 25 °C in 25 mM SBB buffer at pH about 9.

194. The population of any one of claims 176-188, wherein the average hydrodynamic diameter of the nanoparticles changes by no more than about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, or about 20% as determined by Dynamic Light Scattering (DLS) after subjecting the population to the Stress Test Assay.

195. The population of any one of claims 176-188, wherein the polydispersity index of the population changes by no more than about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%,about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, or about 40% as determined by Dynamic Light Scattering (DLS) after storing the population for at least 1 hour, at least 2 hours, at least 3 hours, at least 4 hours, at least 5 hours, at least 6 hours, at least 12 hours, at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, or at least 12 days at 25 °C in 25 rnM sodium acetate buffer at pH about 5.

196. The population of any one of claims 176-188, wherein the polydispersity index of the population changes by no more than 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, or about 40% as determined by Dynamic Light Scattering (DLS) after storing the population for at least 1 hour, at least 2 hours, at least 3 hours, at least 4 hours, at least 5 hours, at least 6 hours, at least 12 hours, at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, or at least 12 days at 25 °C in 25 mM MES buffer at pH about 6.

197. The population of any one of claims 176-188, wherein the polydispersity index of the population changes by no more than 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, or about 40% as determined by Dynamic Light Scattering (DLS) after storing the population for at least 1 hour, at least 2 hours, at least 3 hours, at least 4 hours, at least 5 hours, at least 6 hours, at least 12 hours, at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, or at least 12 days at 25 °C in 0. lx PBS buffer at pH about 7.

198. The population of any one of claims 176-188, wherein the polydispersity index of the population changes by no more than 10%, about 11%, about 12%, about 13%, about 14%, about15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about39%, or about 40% as determined by Dynamic Light Scattering (DLS) after storing the population for at least 1 hour, at least 2 hours, at least 3 hours, at least 4 hours, at least 5 hours, at least 6 hours, at least 12 hours, at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, or at least 12 days at 25 °C in 25 mM HEPES buffer at pH about 8.

199. The population of any one of claims 176-188, wherein the polydispersity index of the population changes by no more than 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about39%, or about 40% as determined by Dynamic Light Scattering (DLS) after storing the population for at least 1 hour, at least 2 hours, at least 3 hours, at least 4 hours, at least 5 hours, at least 6 hours, at least 12 hours, at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, or at least 12 days at 25 °C in 25 mM SBB buffer at pH about 9.

200. The population of any one of claims 176-188, wherein the polydispersity index of the population changes by no more than 10%, about 11%, about 12%, about 13%, about 14%, about15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about39%, or about 40% as determined by Dynamic Light Scattering (DLS) after subjecting the population to the Stress Test Assay.

201. The population of any one of claims 176-200, wherein the population is suitable for administration to a subject, and capable of tolerizing the subject to the peptide(s) associated with or conjugated to the nanoparticles of the population.

202. The population of any one of claims 176-201, wherein the population is suitable for administration to a subject, and capable of suppressing a specific immune response in the subject.

203. The population of any one of claims 176-202, wherein the population is suitable for administration to a subject, and capable of treating or preventing a disease or disorder in the subject.

204. The population of any one of claims 176-203, wherein the population is suitable for transferring peptides to liver sinusoidal endothelial cells of a subject in vivo.

205. A process for manufacturing nanoparticles according to any one of claims 1-6 and 9171 or a population of nanoparticles according to any one of claims 176-204, said process comprising:a. combining the amphiphilic polymer and the first lipid in an organic solvent; andb. mixing the combination from step a with an aqueous solution, thereby forming precursor particles; andc. reacting the precursor particles with the peptides, thereby forming the nanoparticles.

206. The process of claim 205, wherein step a comprises combining the amphiphilic polymer, the first lipid, and the second lipid in an organic solvent.

207. The process of claim 205, wherein step a comprises combining the amphiphilic polymer, the first lipid, and the third lipid in an organic solvent.

208. The process of claim 205, wherein step a comprises combining the amphiphilic polymer, the first lipid, the second lipid, and the third lipid in an organic solvent.

209. A process for manufacturing nanoparticles according to any one of claims 5, 6, and 9-171 or a population of nanoparticles according to any one of claims 176-204, said process comprising:a. combining the amphiphilic polymer, the first lipid, and the lipid-peptide conjugate in an organic solvent; andb. mixing the combination from step a with an aqueous solution, thereby forming the nanoparticles.

210. The process of claim 209, wherein step a comprises combining the amphiphilic polymer, the first lipid, the lipid-peptide conjugate, and the second lipid in an organic solvent.

211. A process for manufacturing nanoparticles according to any one of claims 7-171 or a population of nanoparticles according to any one of claims 176-204, said process comprising:a. combining the amphiphilic polymer, the first lipid, and the second lipid in an organic solvent; andb. mixing the combination from step a with an aqueous solution, thereby forming the nanoparticles.

212. The process of claim 211, wherein step a comprises combining the amphiphilic polymer, the first lipid, the second lipid, and the third lipid in an organic solvent.

213. The process of any one of claims 205-212, wherein the organic solvent is a protic organic solvent or ethereal solvent.

214. The process of any one of claims 205-213, wherein the organic solvent is ethanol, tetrahydrofuran, or a mixture thereof.

215. The process of any one of claims 205-214, wherein the combination in step a comprises the first lipid and the amphiphilic polymer in a ratio of between about 0.05:1 (w / w) and 0.15:1 (w / w) first lipid to amphiphilic polymer.

216. The process of any one of claims 205-215, wherein the combination in step a comprises the first lipid and the amphiphilic polymer in a ratio of about 0.09:1 (w / w) or about 0.10:1 (w / w) first lipid to amphiphilic polymer.

217. The process of any one of claims 205-216, wherein the combination in step a comprises the first lipid and the amphiphilic polymer in a ratio of between about 0.3:1 (mol / mol) and 0.7:1 (mol / mol) first lipid to amphiphilic polymer.

218. The process of any one of claims 205-217, wherein the combination in step a comprises the first lipid and the amphiphilic polymer in a ratio of about 0.39:1, about 0.42:1, or about 0.6:1 (mol / mol) first lipid to amphiphilic polymer.

219. The process of any one of claims 206, 208, and 210-217, wherein the combination in step a comprises the second lipid in an amount of about 20-50% by weight of all components in step a.

220. The process of any one of claims 206, 208, and 210-217, wherein the combination in step a comprises the second lipid in an amount of about 20-35% by weight of all components in step a.

221. The process of any one of claims 206, 208, and 210-217, wherein the combination in step a comprises the second lipid in an amount of about 25-35% by weight of all components in step a.

222. The process of any one of claims 206, 208, and 210-217, wherein the combination in step a comprises the second lipid in an amount of about 30% by weight of all components in step a.

223. The process of any one of claims 205-222, wherein the aqueous solution is a buffered aqueous solution capable of maintaining the pH in step b between about pH 6 and pH 7.6.

224. The process of any one of claims 205-223, wherein the aqueous solution is a buffered aqueous solution capable of maintaining the pH in step b at about pH 7.

225. The process of any one of claims 205-224, wherein the aqueous solution is a phosphate-buffered saline (PBS) solution.

226. The process of any one of claims 205-225, wherein the combination from step a and the aqueous solution are mixed at a ratio of about 1:1 to about 1:20 (vol:vol) in step b.

227. The process of any one of claims 205-226, wherein the combination from step a and the aqueous solution are mixed at a ratio of about 1:4 to about 1:10 (vol:vol) in step b.

228. The process of any one of claims 205-227, wherein the combination from step a and the aqueous solution are mixed at a ratio of about 1:10 (vol: vol) in step b.

229. The process of any one of claims 205-228, wherein the combination from step a is not preheated prior to mixing in step b (i.e. the combination from step a is used at room temperature).

230. The process of any one of claims 205-228, wherein the combination from step a is preheated at a temperature of at least 30 °C or at least 40 °C prior to mixing in step b.

231. The process of any one of claims 205-230, wherein the combination from step a is preheated at a temperature of about 40-80 °C prior to mixing in step b.

232. The process of any one of claims 205-231, wherein the combination from step a and the aqueous solution are mixed at room temperature in step b.

233. The process of any one of claims 205-232, wherein the combination from step a and the aqueous solution are mixed at a temperature of about 40-80 °C in step b.

234. The process of any one of claims 205-233, wherein the combination from step a and the aqueous solution are mixed at a pH of between about 6 and about 7.6 in step b.

235. The process of any one of claims 205-234, wherein the combination from step a and the aqueous solution are mixed at a pH of about 7 in step b.

236. The process of any one of claims 205-208 and 213-235, wherein steps b and c are conducted in one pot.

237. The process of any one of claims 205-208 and 213-235, wherein step b further comprises purifying the precursor particles prior to step c.

238. The process of any one of claims 205-208 and 213-237, wherein the precursor particles are reacted with the peptides in O.lxPBS.

239. The process of any one of claims 205-208 and 213-238, wherein step c comprises reacting the precursor particles with the peptides at a pH of about 7 to 8.

240. The process of any one of claims 205-208 and 213-239, wherein step c comprises reacting the precursor particles with the peptides at a temperature of about 0 to 30 °C.

241. A nanoparticle or population of nanoparticles produced by the process of any one of claims 205-240.

Images